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Methylation dependent interactions of viral transcription factor Zta with DNA 
SUMMARY 
Epstein Barr Virus, a human herpes virus associated with infectious 
mononucleosis, Burkitt’s lymphoma, Nasopharyngeal Carcinoma and Hodgkin’s 
disease, can infect B cells and establish latency. Zta, a member of the bZIP 
transcription factor family, is a viral transcription and replication factor required 
for activation of lytic cycle.  
Zta is able to bind DNA, through specific Zta Response Elements (ZREs). 
Interestingly, Zta binds in a methylation dependent manner to specific CpG-
containing ZREs, known as Class III ZREs. RpZRE3 is one of the first examples 
of such a site, and can be found in the promoter of a key viral lytic gene, 
BRLF1. Through computational analysis and in vitro binding assays, it was 
found that the core 7mer sequence of RpZRE3 is sufficient for complex 
formation in vitro, and that the core sequence can be found in a variety of 
human gene promoter regions.  
As more methylation dependent ZREs emerged, a method to predict CpG-
containing ZREs was devised using position frequency matrices, coupled with in 
vitro binding verification, leading to the discovery of 12 novel CpG containing 
methylation dependent ZREs. The regulatory regions of both the EBV genome 
(type 1) and the human genome were mapped for a list of experimentally 
verified ZRE core sequences (both methylation dependent and independent). 
This analysis allowed identification of novel viral and host genes, potentially 
under the control of Zta activation, which were further analysed using existing 
transcriptome and methylome data.  
An investigation into potential host factors using the same methylation 
dependent mechanism was started, and an unknown protein was seen to bind 
in a methylation dependent manner to RpZRE3 in the absence of Zta in vitro. 
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Chapter 1: Introduction 
1.1 Oncogenic virus discovery 
It is currently thought that viruses account for 10-20% of all cancers. However, 
this association was not easily accepted for many years, due to the perception 
that cancer was not contagious. This view itself was derived from the inability to 
show a bacterial or parasitical association, which were the main infectious 
agents known in the late 19th century, and a failure to look on the sub-
microscopic level, when microscopic organisms could not be found. In 1911, 
Peyton Rous showed that transmission of malignant tumours, specifically a 
spindle cell sarcoma in chickens, could be achieved using a cell free filtered 
tumour extract, but was met with opposition from those who questioned whether 
the filtrate was completely cell free, or whether it contained particles of cells. 
Those who eventually accepted the virus:chicken tumour association did not 
accept that such a mechanism was possible in mammals. Evidence of a viral 
cause of breast cancer in mice, mouse mammary tumour virus, in the 1940s, 
and later, a mouse leukaemia virus in the early 1950s were met with derision 
and not accepted until the late 1950s and early 1960s. It was not until 1966 that 
Rous received the Nobel Prize for his work and the recognition it deserved 
(reviewed by (zur Hausen, 1999, Javier and Butel, 2008, Epstein, 2001)).  
Epstein Barr Virus (EBV, HHV-4) was the first human tumour causing virus 
identified, via the discovery of a new lymphoma. Burkitt’s lymphoma (BL) was 
first described in 1958, after being observed as a common childhood cancer of 
the jaw in East Africa by Denis Burkitt (Burkitt, 1958). When he investigated the 
distribution of the cancer, it was noted that it appeared to be dependent on 
climate and geographical conditions. This presented the possibility that a virus 
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might be responsible, and sparked the curiosity of Antony Epstein. The virus 
was first isolated from a Burkitt’s lymphoma tumour cell line in 1964 by Antony 
Epstein, Yvonne Barr and Bert Achong, and identified as a herpes virus by 
electron microscopy (Epstein et al., 1964). BL patients were observed to exhibit 
higher levels of EBV antibodies than healthy control patients. The 
epidemiological conditions observed were later attributed to the co-factor 
required for tumour formation (malarial infection) not the causative virus itself. 
Other conditions such as infectious mononucleosis, and cancers, such as 
nasopharyngeal carcinoma, are linked to EBV. The transformative properties of 
Epstein-Barr Virus were clearly shown by the ability to transform resting B cells 
in vitro, and to induce tumours in non-human primates, confirming the 
oncogenic potential of this virus (reviewed by (Rickinson and Kieff, 2001a, 
Rowe et al., 2009, Young and Murray, 2003)).   
EBV is a prevalent human herpes virus, carried by 95% of the world adult 
population (WHO). Despite the high growth transforming efficiency of EBV, the 
majority of infected individuals do not develop EBV-associated cancers. EBV 
exhibits a biphasic life cycle; upon infection, the virus establishes a latent 
phase, during which a minimum number of proteins are expressed and the 
genome is replicated once per cell cycle by the host machinery. This allows the 
virus to remain undetected by the host immune system. Upon reactivation, the 
virus switches to the lytic phase, whereupon a large number of lytic genes are 
expressed, replicating the DNA and packaging it up in virions before release 
into the blood stream or saliva (Rickinson and Kieff, 2001b). 
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1.2 Herpesviridae family 
The structure of a herpesvirus particle or virion consists of a linear double 
stranded DNA genome, encapsulated by an icosahedral capsid, made up of 
162 hexagonal capsomeres, which in turn is surrounded by tegument, a mixture 
of different viral and cellular proteins, and all enclosed within an envelope 
studded with viral glycoproteins. The virions are 180-200nm in diameter. The 
expression of genes encoding a variety of enzymes for processing both proteins 
and nucleic acids is shared or highly homologous across the family (Roizman 
and Baines, 1991). 
Herpesviruses are further classed into the sub-families alpha, beta and gamma 
on the basis of biological properties including the host range, length of 
reproductive cycle, latency mechanism and the individual properties of the viral 
genomes (Roizman et al., 1981). Alpha herpesviruses establish latency 
primarily in sensory ganglia, and include the simplexviruses (e.g. HSV1, also 
known as HHV-1 and HSV2, HHV-2) and the varicelloviruses (e.g. Varicella 
Zoster Virus (HHV-3), Pseudorabies Virus). Beta herpesviruses establish 
latency in leukocytes, replicate slowly and cause the infected cells to enlarge, 
and include cytomegalovirus (HCMV, HHV-5) and muromeglovirus (murine 
cytomegalovirus) (Roizman and Baines, 1991). 
EBV (HHV-4) is a member of the gamma sub family of herpes viruses, which 
includes Kaposi’s sarcoma-associated virus (KSHV, also known as HHV-8). 
This sub family is split into 2 further genera, the lymphocryptoviridae (LCV) or 
gamma-1 herpes virus (EBV), and the rhadinoviridae (RV) or gamma-2 herpes 
virus (HHV-8) (Rickinson and Kieff, 2001b). A major factor that differentiates the 
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behaviour of a gamma herpes virus from that of an alpha or beta herpesvirus is 
their ability to infect lymphocytes and induce lymphoproliferation (Barozzi et al., 
2007). EBV can also successfully infect and replicate in epithelial cells 
(Rickinson and Kieff, 2001b). 
1.3 EBV genome organisation 
The EBV genome consists of a double stranded DNA molecule, approximate 
172kbp in length, with 0.6 G:C content (Rickinson and Kieff, 2001b). For 
comparison, the human genome has an average G:C content of approximately 
0.4, with the average G:C content for a 100kbp fragment ranging from 0.35 to 
0.6 (Romiguier et al., 2010). There are around 86 genes, including non-coding 
RNAs, depending on the source of the DNA, as specific cell lines have 
particular deletions. There are 2 main types, known as Type 1 (de Jesus et al., 
2003), and Type 2 (Dolan et al., 2006). Type 1 was the first to be sequenced 
(Baer et al., 1984), and is the best annotated in the NCBI genome library. Type 
2 is more prevalent in people in equatorial Africa and New Guinea, whilst in 
developed countries, Type 1 is more dominant. However, both types can be 
found in immunocompromised patients. The most biologically relevant 
difference in sequence between Type 1 and Type 2 virus resides within the 
coding sequence of EBNA-2 (Epstein-Barr viral nuclear antigen 2, a latency 
protein); there is only 55% homology between the 2 types in this gene, and this 
difference affects the ability of the virus to transform B cells; Type 2 is less 
efficient than Type 1. (Rickinson and Kieff, 2001b). 
 The genome was first sequenced using a fragment library created using BamHI 
digests (Baer et al., 1984). Each BamHI fragment was named from A to Z in 
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size from largest to smallest, and most of the ORFs are named according to 
their position and direction within a particular fragment, for example BARF1 is 
the first rightward gene in the largest BamHI fragment (A) (Rickinson and Kieff, 
2001b). There is a terminal repeat region, consisting of 0.5kb direct repeats, 
which mediates circularisation of the genome (Baer et al., 1984) . During lytic 
genome replication, long concatamers of newly synthesised genome sequence 
are cut at variable positions in the terminal repeat region, and upon infection, 
the genome will circularise, which sets the number of terminal repeats. This 
number is then constant during latent infection. Therefore, the number of 
repeats can be used to determine whether a group of latently infected cells 
arose from a single infected cell or the infection of many cells; this is referred to 
as clonality (Rickinson and Kieff, 2001b). The genome is made up of unique 
regions (U1-5) divided up by internal repeats (IR1-4). IR1 makes up the W 
repeats, consisting of multiple W promoters from which latent proteins can be 
transcribed, and the BWRF1 gene, for which the function and whether a protein 
is even expressed is debatable (de Jesus et al., 2003). Two duplicate 
sequences are identified as origins of lytic replication (known as OriLyt L or DSL 
and OriLyt R or DSR).OriLyt L is adjacent to BHRF1 and BHLF1, and OriLyt R 
is adjacent to LF3. BHLF1 and LF3 contain tandem repeat regions, IR1 and 
IR4. Two origins of lytic replication are often found in herpesviruses, however 
some EBV genomes have been shown to lack one or the other of the orilyts 
(Xue and Griffin, 2007). IR3 forms part of EBNA-1, and is known as the EBNA-1 
triplet (Wendelburg and Vos, 1998) (Figure 1.1). 
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The latency genes EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and 
EBNA-LP are spliced versions of a long transcript that spreads over 90kb of the 
genome. Expression can be initiated from either the Cp or Wp, and it is then 
differentially spliced to form the mRNA of each specific gene.. EBNA-1 
expression can also be initiated from another promoter, Qp (Rickinson and 
Kieff, 2001b) (Figure 1.2). 
 
  
 
 
Viral genes are categorised with regard to what stage during the EBV life cycle 
they are expressed. This is practically tested according to when stable RNA can 
be detected by northern blot. Latent genes are expressed constitutively. 
Immediate early genes are defined as those expressed after lytic activation, 
Figure 1.2 Latent gene organisation.  
The differential splicing of the latency genes is represented here. Splices are indicated by 
deviation from the grey gridline, intended to represent the EBV genome DNA.  Exons are 
positioned where the splice line touches the grey gridline. All the latency genes can be 
expressed from Cp or any Wp, but only EBNA1 can be expressed from Qp. Data from 
Req_Seq entry NC_007605.1 (Farrell, 2005). 
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without the requirement of any new protein synthesis, as the mRNA transcripts 
can be detected in the presence of protein synthesis inhibitors. Early lytic genes 
cannot be detected in the presence of protein synthesis inhibitors, suggesting 
the requirement of the immediate early genes expression for their regulation. 
They are expressed in the presence of replication inhibitors, such as acyclovir. 
Late lytic genes can only be detected when replication is allowed to occur. 
(Rickinson and Kieff, 2001b). Immediate early genes are required for successful 
lytic activation and replication of the viral genome, activating a cascade of early 
and late lytic gene expression. The products of early genes have a variety of 
roles, arguably the most important being replication. Late genes encode 
structural proteins and those important for immune evasion (Odumade et al., 
2011). Table 1.1 summarises the information available for each ORF from the 
NCBI entry Ref_Seq NC_007605, as well as the gene counterparts that have 
been identified in Herpes Simplex Virus (HHV-1) and Rhadinovirus (HHV-8). 
gene 
start 
(bp) 
cycle 
phase gene name 
Information extracted 
from NCBI entry, 
Ref_Seq  NC_007605 
Core 
gene 
family 
HHV-1 
counter-
parts 
Rhadino-
virus 
genus 
counter-
parts 
1691 late lytic BNRF1  tegument protein, related to formylglycinamide     
6629 unknown EBER 1 small non-coding RNA     
6956 unknown EBER 2 small non-coding RNA     
9631 late lytic BCRF1 vIL-10     
11305 latent EBNA-1 
latency protein, 
maintenance of episomal 
genome 
    
11305 latent EBNA-2 latency protein, transcription factor     
11305 latent EBNA-3A latency protein     
11305 latent EBNA-3B/3C latency protein     
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12541 unknown BWRF1 
originally BCRF2, 
questionable whether a 
protein function is encoded 
    
14352 latent EBNA-LP latency protein     
40529 early lytic BHLF1 
basic (arginine/histidine-
rich) protein product, bind 
single-stranded DNA 
preferentially   
    
41471 early lytic BHRF1 
ncRNA ebv-miR-BHRF1-1, 
vbcl-2a, ncRNA ebv-miR-
BHRF1-2, ncRNA ebv-
miR-BHRF1-3 
    
44793 early lytic BFLF2 role in egress of capsids from nucleus   UL31   ORF69 
46236 unknown BFRF1A role in DNA packaging   UL33   ORF67A  
46280 early lytic BFLF1 role in nuclear localization 
of capsids and DNA   UL32   ORF68 
46544 early lytic BFRF1 
capsid docking protein on 
nuclear lamina, role in 
egress of capsids from 
nucleus 
  UL34   ORF67 
47520 early lytic BFRF2 related to HHv-5 UL49; ORF66     
49219 late lytic BFRF3 small capsid protein on hexon tips   UL35   ORF65 
50134 latent EBNA1.2 
QUK transcript, starts from 
the Q promoter (Qp) in 
latency I 
    
59904 unknown BPLF1 large tegument protein   UL36   ORF64 
62729 late lytic BORF1 capsid triplex protein   UL38   ORF62 
63034 unknown BOLF1 tegument protein  UL37   ORF63 
63881 early lytic BORF2 ribonucleotide reductase large subunit  UL39   ORF61 
66516 early lytic BaRF1 ribonucleotide reductase 
small subunit  UL40   ORF60 
67552 early lytic BMRF1 
DNA polymerase 
processivity subunit, early 
antigen D 
 UL42   ORF59 
68491 late lytic BMRF2 multiple transmembrane protein 
probable 
counter-
part of 
HHV-1 
UL43 
 ORF58 
72068 early lytic BSLF2/BMLF1 post-transcriptional 
regulator, SM; EB2; Mta    UL54  ORF57 
74593 early lytic BSLF1 primase subunit of helicase-primase complex  UL52   ORF56 
74594 late lytic BSRF1 tegument protein  UL51   ORF55 
76219 late lytic BLRF1 envelope glycoprotein gN  UL49A   ORF53 
76231 early lytic BLLF3 deoxyuridine triphosphatase UL50  ORF54 
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76575 late lytic BLRF2  p23, LR2, tegument protein   ORF52  
77763 early lytic BLLF2       
79904 late lytic BLLF1 
envelope glycoprotein 
gp350, binds to CD21, role 
in entry 
  
K8.1, 
ORF51 
89828 late lytic BZLF2 
envelope glycoprotein 
gp42, binds MHCII, role in 
entry, contains C-type 
lectin domain 
    
90943 early lytic BZLF1 
bZIP transcription factor, 
induces switch from latent 
to lytic infection, EB1, Zta 
  K8 
92728 early lytic BRRF1  Na, transcriptional 
activator    ORF49 
93925 early lytic BRLF1 
transactivator, role in 
reactivation from latency,  
Rta 
  ORF50 
93955 late lytic BRRF2 probable tegument protein    ORF48 
97617 late lytic BKRF2 virion glycoprotein gL  UL1   ORF47 
98065 unknown BKRF3 uracil-DNA glycosylase  UL2   ORF46 
98846 early lytic BKRF4 probable tegument protein    ORF45 
101588 late lytic BBRF1 portal protein  UL6   ORF43 
101971 early lytic BBLF4 helicase subunit of helicase-primase complex  UL5   ORF44 
103660 late lytic BBRF2 tegument protein  UL7   ORF42 
106693 late lytic BBRF3  envelope glycoprotein gM  UL10   ORF39 
106750 early lytic BBLF2/BBLF3 subunit of helicase-primase complex  UL8   ORF40 
109043 late lytic BBLF1 
myristylated tegument 
protein anchored in 
envelope 
 UL11   ORF38 
110053 early lytic BGLF5 deoxyribonuclease  UL12   ORF37 
111326 early lytic BGLF4 serine-threonine protein kinase  UL13   ORF36 
111829 unknown BGLF3.5 tegument protein  UL14   ORF35 
112650 late lytic BGRF1/BDRF1 putative ATPase subunit of terminase  UL15   ORF29 
112825 unknown BGLF3 related to HHV-5 UL95; ORF34    ORF34 
114641 late lytic BGLF2 tegument protein  UL16   ORF33 
116144 late lytic BGLF1 tegument protein, role in DNA packaging  UL17   ORF32 
116766 early lytic BDLF4 related to HHV-5 UL92    ORF31 
117016 unknown BDLF3.5 related to HHV-5 UL91    ORF30 
118816 late lytic BDLF3 membrane glycoprotein gp150    ORF28 
120188 late lytic BDLF2 membrane protein, interacts with BMRF2    ORF27 
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121098 late lytic BDLF1 capsid triplex protein  UL18   ORF26 
125073 early lytic BcRF1.2 related to HHV-5 UL87   ORF24  
125422 late lytic BcLF1 major capsid protein  UL19   ORF25 
127416 late lytic BTRF1 tegument protein  UL21   ORF23 
131021 late lytic BXLF2 envelope glycoprotein gH, gp85  UL22   ORF22 
132571 late lytic BXRF1 nuclear protein  UL24   ORF20 
132846 early lytic BXLF1 thymidine kinase  UL23   ORF21 
133013 early lytic BVRF1 putative portal-capping protein  UL25   ORF19 
135432 late lytic BVRF2 
capside maturational 
protease, minor capside 
scaffold protein 
 UL26   ORF17 
135627 unknown BVLF1 related to HHV-5 UL79    ORF18 
136331 late lytic BdRF1 major capside scaffold protein  UL26.5  ORF17.5 
138282 late lytic BILF2 contains Ig domain, 
membrane glycoprotein     
138352 unknown RPMS1 
BART mRNAs, of which 
RMPS1 and part of A73 
are included as 
representatives, are 
complex spliced transcripts 
whose significance is not 
understood 
    
143711 early lytic LF3 questionable whether a protein function is encoded     
150417 unknown LF2 derived from herpes virus dUTPase    ORF11 
151694 unknown LF1 derived from herpes virus dUTPase    ORF10 
152641 unknown BILF1 G protein-coupled receptor     
155549 unknown A73 
BART mRNAs, of which 
RMPS1 and part of A73 
are included as 
representatives, are 
complex spliced transcripts 
whose significance is not 
understood 
    
156288 early lytic BALF5 DNA polymerase catalytic 
subunit  UL30   ORF9 
158864 late lytic BALF4 envelope glycoprotein gB  UL27   ORF8 
159121 unknown BARF0 it is questionable whether a protein function is encoded     
160908 unknown BALF3  subunit of terminase  UL28   ORF7 
164356 early lytic BALF2 single-stranded DNA-binding protein  UL29   ORF6 
164984 early lytic BALF1 vbcl-2b, similarity to Bcl-2 family proteins     
165008 early lytic BARF1 
similarity to CSF-1 
receptor, secreted protein, 
contains Ig domain 
    
166011 latent LMP-2A  multiple transmembrane protein, role in latency and     
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B cell survival 
166836 early lytic BNLF2b       
167067 early lytic BNLF2a contains hydrophobic domain     
169088 latent LMP-1 
transmembrane protein 
expressed in latent 
infection, functional 
similarity to CD40, role in 
transformation 
    
169294 latent LMP-2B  
multiple transmembrane 
protein, role in latency and 
B cell survival, N-terminally 
truncated form of LMP-2A 
    
Table 1.1: The ORFs of EBV. 
Annotated with the position in the Type 1 Ref_Seq NC_007605, information extracted from this 
NCBI entry, counterparts of genes in HHV-1 and HHV-8 (de Jesus et al., 2003, Baer et al., 
1984), and gene expression classification (Farrell, 2005, Yuan et al., 2006). 
 
1.4 EBV life cycle 
The virus has a biphasic life cycle, with both latent and lytic phases. During 
latency, a restricted number of latent genes are expressed. These include 
EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA LP, LMP-1 (Latent 
Membrane Protein), LMP-2A, LMP-2B, EBER1 (Epstein Barr viral small RNA), 
EBER2 and BamHI A transcripts (BART). They are expressed at different times 
during the process of primary infection and the establishment of latency, to drive 
transformation and differentiation of the memory B cell. During the lytic phase, 
there is a dramatic change in expression, with new virus particles synthesised 
and shed into the saliva, where they can be transmitted to other individuals 
through close personal contact (Rickinson and Kieff, 2001b, Kutok and Wang, 
2006). In developing countries, EBV antibodies are acquired early, due to 
exposure to the virus at a young age; however in developed countries only 50-
70% of adolescents and young adults are seropositive (WHO, 2008). High 
standards of living can cause the individual to avoid contact with the virus until 
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adolescence or later life, and approximately 30 - 50% of the seronegative 
individuals will experience Infectious Mononucleosis (glandular fever) during 
primary infection (Steven, 1996). When primary infection occurs as an infant, 
the dose is relatively small and does not evoke the same aggressive response 
seen when exposure occurs as an adolescent or young adult, when the virus 
dose is believed to be higher (Crawford, 2001). The ability to establish latency 
allows the virus to evade immune responses and effectively remain hidden from 
the host immune system, resulting in a lifelong persistent infection. 
1.4.1 Primary Infection 
The infection and persistence of EBV is not yet fully understood, and 
controversy surrounds the initial mechanism of infection. Infection is 
summarised in Figure 1.3. EBV has been shown to replicate effectively in 
epithelial cells in culture and in oral hairy leukoplakia lesions, leading to the 
hypothesis that primary infection occurs via epithelial cells in the throat, where 
lytic replication amplifies the viral load, before circulating B lymphocytes in the 
bloodstream are infected. However, this has never been observed in a patient, 
perhaps due to the fleeting nature of initial infection and the delayed onset of 
symptoms. Primary infection may occur directly into circulating B cells in the 
bloodstream. The viral envelope protein gp350/220 interacts with B cell surface 
molecule CD21 (Fingeroth et al., 1984) to gain access to the B cell. Gp350 and 
gp220 are the unspliced and spliced products of the viral gene BLLF1. 
However, viruses that have been engineered not to express this protein can 
also infect B and epithelial cells, but at a reduced level, which indicates that 
other molecules mediate virus entry (Janz et al., 2000). The virus is then 
internalised via cytoplasmic vesicles (Nemerow and Cooper, 1984) and enters  
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Plasma cell 
differentiation 
Memory B cell 
A 
B 
C 
D 
Figure 1.3 Epstein-Barr Virus life cycle.  
Initial infection occurs via particles transferred from an infected individual, usually via saliva. 
The virus is thought to first infect epithelial cells, where the virus lytically produces viral 
particles, before infecting circulating B cells and establishing latency, however this is still 
subject to debate (A). EBV infected B cells behave in the same manner as antigen activated 
B cells, and differentiate in 2 different ways. Plasma cell differentiation (B) results in short 
lived plasmablasts with high antibody expresssion. This can activate EBV lytic cyle, and 
production of new virus particles. Alternatively, the B cell may migrate to germinal centres 
and become a memory B cell (C). When an antigen activates a memory B cell (D), lytic 
replication occurs, via Zta. The virus particles will then be released to infect other B cells or 
shed into the saliva to transmit to other people. 
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the latent phase, where there is no production of infectious virus particles, and a 
highly restricted number of latent genes are expressed. To achieve longevity 
within the host, as well as virus replication,, EBV exploits the normal B cell 
mechanisms. After activation by an antigen, B cells differentiate into 
plasmablasts, short-lived cells with a high expression of antibodies. This 
process has been shown to activate lytic cycle (Laichalk and Thorley Lawson, 
2004). Alternatively, infected cells gain access to the long term memory B cell 
compartment, where the virus can remain undetected by the host immune 
system. Normally, a specific antigen activates a B cell, causing it to enter a 
follicle of a lymph node and proliferate to form germinal centres. These cells 
undergo somatic hypermutation, a process which causes alterations to the 
immunoglobulin genes and isotype switching. The cells are then selected for 
those whose new immunoglobulin genes produce higher affinity antibodies to 
the antigen in question. To fully mature into either short lived, antibody secreting 
plasma cells, or re-circulating memory B cells, two survival signals must be 
received, via the B Cell Receptor (BCR) and B cell surface co-receptor 
molecules, such as CD40, which engages with CD154 on T helper cells. The 
overall effect of these signals causes a cascade of cellular signalling pathways 
which drive proliferation of the B cell. CD40 achieves this by interacting with 
members of the tumour-necrosis-factor-receptor-associated factor (TRAF) 
family, causing activation of nuclear –factor κB (NFκB), and also with Janus 
activated kinase 3 (JAK3), to activate signal transducers and activators of 
transcription (STATs). The c-jun N-terminal kinase pathway is also engaged to 
activate the activator protein 1 (AP-1) transcriptional complex. The alpha and 
beta chains of the BCR contain immunoreceptor tyrosine-based activator motifs 
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(ITAMs) which are phosphorylated by Lyn, a member of the Src family of 
tyrosine kinases, which leads to recruitment of Syk tyrosine kinase, activating 
PLC-γ2, increasing intracellular levels of inositol- 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG), which leads to an increase in calcium ions and activation 
of Protein Kinase C (PKC), resulting in survival signals.  Without these signals, 
the cell will undergo apoptosis, and the surviving cells, primed for the specific 
antigen, re-circulate as memory B cells. It is suggested that EBV infected B 
cells also reach the germinal centre in the same manner, the required 
proliferation driven by the latency III growth program of latent gene expression  
where 9 viral genes and 2 viral RNAs, EBERs, are expressed. These proteins 
provide all the required signals without the need for any external activation.  
Sometime during this process, the expression of the latency genes becomes 
restricted to a latency II program, expressing EBNA-1, LMP-1, LMP-2A and the 
EBERs, turning off EBNA-2 expression, which is known to block differentiation. 
LMP-1 and LMP-2A are operationally similar to CD40 and BCR (Caldwell et al, 
1998, Kilger et al, 1998), providing the survival signals required to save these 
cells from apoptosis, by driving immunoglobulin gene mutation and isotype 
switching. The pathways are not identical to normal B cell survival signals, but 
the end result is the same. LMP-1 interacts with different members of the TRAF 
family to CD40, but achieves the same activation of NFκB, STATs and AP1. 
LMP-2A contains ITAMs in the amino terminal, which are phosphorylated in the 
same manner as BCR signalling, leading to the same activation of PKC via Syk 
and PLC-γ2, and survival signals (Caldwell et al, 1998). LMP-1 downregulates 
the normal B cell signal for exit from the germinal centre, bcl-6, and so therefore 
must be differentially expressed to complete the germinal centre formation 
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(Kilger et al, 1998). All these factors allow the infected cells to mature into 
memory B cells, where all latent gene expression is switched off. (Reviewed by 
(Crawford, 2001, Amon and Farrell, 2005, Laichalk and Thorley-Lawson, 2005, 
Rickinson and Kieff, 2001b, Thorley-Lawson, 2005, Thorley-Lawson, 2001)) 
1.4.2 Latent cycle 
At the point of latent persistence, all viral expression is shut down, with the 
possible exception of LMP-2A. This is termed latency 0. In this latent form of 
infection, it is only when the memory B cells divide that the viral EBNA-1 protein 
is expressed, and in conjunction with the host cell DNA polymerase, will 
maintain the viral episome, via replication from a region called oriP, at the same 
time as the host chromosomes are replicated. EBNA-1 is poorly recognised by 
the host immune system, ensuring that EBV remains undetected (Yin et al, 
2003).  In addition to EBNA-1 and LMP-2A, EBER-1, EBER-2 and the BamH1 A 
rightward transcripts (BART) are expressed. This is known as latency I.  
As the growth promoting viral genes are not expressed, these cells are non-
pathogenic and are also not recognised by the immune system, so therefore will 
not be eliminated. In this way, EBV achieves a balance between requiring 
proliferating activity to gain entry to the memory B cell compartment, but 
controlling this mechanism to achieve latent, undetected infection of the 
otherwise healthy host to ensure ongoing infection and propagation of the virus. 
This explains why EBV-associated tumours do not arise in all infected 
individuals, and that something must go wrong with the normal B cell biology to 
allow uncontrolled proliferation (Thorley-Lawson, 2005, Thorley-Lawson, 2001). 
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Resting B cells can be infected with EBV in vitro and form lymphoblastoid cell 
lines or LCLs. This ability exhibits the transforming potential of the virus, 
specifically the latent proteins, and results in a latency III gene expression 
profile, in which all latency genes are expressed. This resembles EBV 
associated tumours in immunocompromised hosts, such as post transplantation 
lymphoproliferative disease (PTLD), as it is the lack of an immune response 
which allows the full cohort of latent genes to be expressed without detection. It 
is more usual to observe a more restricted latency profile in EBV associated 
tumours. Cell lines isolated from different tumours exhibit different latency 
profiles, for example, Burkitt’s lymphoma (such as the Akata cell line) expresses 
only EBNA-1 from Qp, known as latency I, whilst B-lymphoproliferative disease 
expresses EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, LMP-1, LMP-2A 
and LMP-2B initially from Wp, before switching to Cp after 24-48 hours, denoted 
latency III. A viral Bcl-2 homologue, BHRF1, is also expressed in latency III type 
infection, and is associated with anti-apoptotic pathways (Kelly et al, 2009). The 
latency II profile of gene expression is found in undifferentiated nasopharyngeal 
carcinoma, gastric carcinomas, Hodgkin’s lymphomas, and T cell lymphomas, 
and consists of LMP-1, LMP-2A and 2B, and Qp driven EBNA-1. The level of 
LMP-2 expression varies between these conditions. The differential expression 
is thought to determine the behaviour of the cancerous cell. Non-dividing cells 
do not require EBNA-1, therefore they are classified as latency 0. This is seen 
in asymptomatic carriers of EBV persistence. (Reviewed by (Thorley-Lawson, 
2001, Amon and Farrell, 2005, Young and Murray, 2003, Young and Rickinson, 
2004, Rickinson and Kieff, 2001b, Rowe et al., 2009, Israel and Kenney, 2003, 
Crawford, 2001, Thorley-Lawson and Babcock, 1999, Thorley-Lawson, 2005)). 
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1.4.3 Lytic cycle 
1.4.3.1 Activation of lytic cycle in vivo 
The differentiation of B cells into plasma cells, activated by an antigen binding 
to the B cell receptor, and also the differentiation of epithelial cells, is thought to 
be the main mechanism for lytic activation in the host environment (Laichalk 
and Thorley-Lawson, 2005). Antigen activation of the B cell receptor of normal 
resting memory B-cells causes them to migrate to the lymph nodes and 
proliferate, to form a small secondary germinal centre, with production of 
antibody secreting plasma cells and the replenishment of the memory pool. 
Therefore, from time to time, EBV-carrying memory B cells will be activated, 
migrate and proliferate. This is required for the transmission of virus to new 
individuals. 
The activation of the B cell receptor causes a cascade of processes within the 
cell that lead to immediate early viral gene expression, specifically BZLF1 and 
BRLF1, the activation of phosphatidylinositol 3-kinase (PI3K), Ras family 
GTPases, and phospholipase C gamma 2 (PLC) which leads to the activation of 
PKC and calcium dependent factors (Kenney, 2007). All of this contributes to 
the drastic changes that occur to the transcription pattern of the EBV genome, 
where up to 62 lytic promoters are activated. The EBV genome is silenced 
during latency by repressive chromatin structure, caused by specific histone 
modification and DNA methylation at CpG dinucleotides (Kenney, 2007). The 
silencing of Zp and Rp is thought to be controlled in the same manner. 
However, DNA reporter constructs of these promoters lacking any chromatin 
structure are still inactive when transfected into EBV negative cell lines, 
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suggesting the existence of a positive factor, absent in unstimulated cells, which 
is required for activation (Kenney, 2007).  
1.4.3.2 The immediate early genes 
BZLF1 and BRLF1 are classified as immediate early genes, and are the first 
viral genes expressed upon lytic cycle activation. They are required for 
complete viral reactivation and replication, and act as transcription factors, 
activating a cascade of lytic gene expression. BZLF1 (the protein product of 
which is known as Zta, BZLF1, EB1, ZEBRA or Z) encodes a DNA binding 
protein that exists as a dimer, and binds to the promoters of both viral and host 
genes, as well as to the viral origin of lytic replication, directly via sequence-
specific motifs within the DNA known as Zta Response Elements (ZREs). 
BRLF1 (the protein product of which is known as Rta, BRLF1 or R) can also 
dimerise and bind to DNA. Both also interact with proteins to modulate their 
function, activate the transcription of the other, and cooperate to induce 
approximately 25 early genes. Zta can also autoactivate its own promoter. 
(reviewed in (Sinclair, 2003, Kenney, 2007, Amon and Farrell, 2005)).  
1.4.3.3 Immediate early gene organisation 
The genes coding for the two immediate early genes, BZLF1 and BRLF1, are 
found close together in a region spanning approximately 5kb in the EBV 
genome (Figure 1.4). Another early lytic gene, BRRF1, is also found in this 
region, but is transcribed from the opposite strand of DNA to BZLF1 and 
BRLF1. The mRNA message from Rp is bicistronic, containing the regions 
required for the expression of both Rta and Zta (Manet et al., 1989), and 
translation of the BZLF1 region of this transcript has been seen in vivo. The 
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majority of BZLF1 expression is derived from the Zp (Kenney, 2007). RAZ, the 
product of a spliced mRNA initiated from Rp consisting of part of BRLF1 and 
BZLF1, is expressed later in infection (Furnari et al., 1994). It is thought to play 
a role in negative regulation of the  transcriptional function of Zta; however the 
manner in which this is achieved is not clear. Small amounts of RAZ inhibit Zta 
despite not reaching a level required for effective dimerisation, and a mutated 
version which was incapable of dimerisation resulted in equal repression of Zta 
mediated transcription (Segouffin et al., 1996).  
 
 
 
 
1.4.3.4 BRLF1 and BZLF1 promoter control 
The promoter regions of the immediate early viral genes provide response 
elements for a plethora of host DNA binding factors and transcriptional effectors 
(1.5). Through these, the host cell suppresses expression, but that suppression 
is also overturned upon lytic activation to allow expression of these gene 
Figure 1.4 Immediate early gene organisation.  
The region of the EBV genome encompassing the early immediate genes is represented 
here, to illustrate the mRNA splicing that BZLF1 and BRLF1 undergo. Coding sequence 
(CDS) is also shown below the appropriate mRNA, where data was available. BRRF1 is 
expressed from the opposite strand to BRLF1.    
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products, Zta and Rta. Five types of cis acting elements have been identified in 
the Zp, ZI – ZV; ZI and ZII-like elements have been found in the Rp, but have 
not yet been fully characterised (Kenney, 2007).  
ZI elements are AT rich and have been shown in Zp to have both positive and 
negative regulatory roles, due to the binding of MEF-2D. In the phosphorylated 
form, MEF-2D  interacts with histone deacetylating complexes, which cause 
transcriptional silencing of the surrounding area. Upon B cell receptor activation, 
MEF-2D becomes dephosphorylated via the activation of calcium dependent 
factors via PLC, which allows it to recruit histone acetyl transferase, and relieve 
any repressive chromatin environment, allowing expression (Gruffat et al., 
2002). MEF-2D has been shown to bind to ZIA, ZIB and ZID elements. Sp1 and 
Sp3, transcription factors, have been shown to bind to ZIA, C and D weakly, 
and are not thought to bind simultaneously with MEF-2D (Speck et al., 1997). 
Sp1 and Sp3 are required for Rta autoactivation of Rp (Ragoczy and Miller, 
2001). Another transcription factor, Smubp-2, can bind to ZI elements and has 
been shown to negatively regulate the associated gene expression, by 
disrupting stable transcription initiation machinery complex formation (Zhang et 
al., 1999).  
ZII elements are atypical cAMP response element binding factor (CREB) 
response elements (CRE) that allow binding of transcription factors including 
CREB, ATF-1, ATF-2, c-jun, and c-fos. These transcription factors are 
constitutively expressed in most cells, but are activated by phosphorylation. 
This can occur as a result of B cell receptor activation, activating the MAPK 
pathway, which causes the phosphorylation of CREB/ATF transcription factors, 
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allowing them to bind to CRE sequences in the promoter and activate 
expression (Westphal et al, 1999). ZIIR overlaps ZII in Zp; this sequence has 
been shown to be utilised in the repression of Zp and maintaining latency, but 
the specific factor has not been discovered (Yu et al., 2011).  
The ZIII elements (A and B) are Zta Response Elements (ZREs), and allow 
autoactivation of Zp. Activation of lytic cycle via anti-IgG treatment requires 
ZIIIA, indicating the requirement of Zta autoactivation in this process, or 
alternatively the presence of other cellular proteins binding this element before 
Zta. The importance of autoactivation in the context of the entire genome is 
debatable; exogenous expression of Zta has not been observed to lead to 
detectable levels of Zp initiated transcript (Speck et al., 1997, McDonald et al., 
2010). There are 3 ZREs in Rp, and all 3 are important for activation of the gene 
(Chiu et al., 2007). 
ZIV elements bind YY-1, a zinc finger protein associated with both positive and 
negative regulation of transcription, and are found in both Zp and Rp. A 
negative effect on expression is observed in Zp (Montalvo et al., 1995) and Rp 
(Zalani et al., 1997).  
ZV and ZV’ elements also act as negative regulators, allowing the binding of 
ZEB1 and ZEB2, cellular proteins which cause repression of BZLF1 expression, 
and lytic activation (Kraus et al., 2003). A mutated version of this sequence 
causes a viral genome that is defective in maintaining latency (Yu et al., 2007). 
Other elements are also found in the promoter regions. Binding sites for 
Smad3/Smad4 allow activation of Zp and lytic cycle via the TGFβ cytokine  
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Figure 1.5 
Promoter maps 
of the immediate 
early genes 
BZLF1 (Zp) and 
BRLF1 (Rp).  
Known binding 
sites of DNA 
binding proteins 
associated with 
transcription are 
mapped to the 
associated 
promoter, using 
data and 
positional 
coordinates from 
(McDonald et al., 
2010, Kenney, 
2007, Kraus et 
al., 2003, Yu et 
al., 2011, Yu et 
al., 2007).  
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activation pathway (Kenney, 2007). H box elements in Zp bind transcription 
factor E2-2, which plays a repressive role in B cells but contributes to increased 
lytic activation in epithelial cells (Thomas et al., 2003). Rp also contains 2 Egr1 
binding motifs, and the activation of lytic cycle via 12-0-tetradecanoyl phorbol-
13-acetate (TPA) treatment requires these sites (Kenney, 2007). An element 
further upstream in Rp for Nuclear Factor 1 (NF1) was discovered to act as a 
positive regulator in HeLa cells, but not in lymphoid cells (Glaser et al., 1998).  
1.4.3.5 Activation of lytic cycle in vitro 
B cell receptor activation can be mimicked in cell culture in vitro systems by 
treating the cells with an antibody against human IgG or IgM, causing 
crosslinking of the B cell receptors leading to successful activation of lytic cycle, 
particularly in Akata Burkitt’s lymphoma cells (Takada, 1984).  
Other treatments have also been shown to activate lytic cycle. 12-0-
tetradecanoyl phorbol-13-acetate (TPA) is a phorbol ester and activates lytic 
cycle via activation of Protein Kinase C (PKC). PKC is usually activated by 
diacylglycerol. Phorbol esters bind to PKC with a greater affinity, and also 
increase affinity for Ca2+. The activation of PKC is usually controlled by the 
degradation of the diacylglycerol, a process which is absent with phorbol esters, 
leading to extended periods of activation (Castagna et al., 1982). The PKC 
pathway activates the expression of transcription factors such as Egr1, MEF2D 
and CREB, which bind to response elements in the promoters of the early 
immediate gene BZLF1 and lead to the expression of Zta (Flemington and 
Speck, 1990b).  
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Sodium butyrate is a histone deacetylase (HDAC) inhibitor, and is thought to 
activate expression by allowing the accumulation of acetylation on lysine 
residues of histone tails, causing a decrease in the affinity for DNA and creating 
an open chromatin structure, permissive for transcription. Whether this alone is 
sufficient for full lytic activation is debatable (Countryman et al., 2008). 
Not all cell lines are activated by all of the mechanisms detailed above. For 
example, Raji cells require both TPA and sodium butyrate, and the B-95.8 cell 
line is not responsive to sodium butyrate (Gradoville et al., 2002).   
There is evidence that severe host cell stress response, such as that 
experienced during irradiation (Westphal et al., 2000) or chemotherapy (Feng et 
al., 2002) can induce EBV lytic cycle, which in conjunction with nucleoside 
analogues ganciclovir or 3’-azido-3’-deoxythymidine (AZT) promotes cell death. 
5-azacytidine is a nucleoside analogue that is incorporated into DNA but cannot 
be methylated. Treatment of EBV positive human lymphoid cell lines with 5-
azacytidine has been shown to activate lytic cycle. This led to the hypothesis 
that DNA methylation plays a role in maintaining viral latency (Ben-Sasson and 
Klein, 1981). An attempt to treat Nasopharyngeal Carcinoma (NPC) patients 
with 5-azacytidine, was not successful in activating lytic cycle, despite 
demonstrating demethylation of the Cp (Chan, Tao et al. 2004). This suggests 
that the removal of methylation marks is not sufficient for lytic activation NPC, or 
that demethylation did not occur at the appropriate region of the genome for 
lytic activation. Another explanation, suggested by recent data indicating no 
change in the methylation status of the genome by 5-azacytidine treatment, is 
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that the activation of lytic cycle is progressing in a novel mechanism (Miller et 
al., 2007), which may require cell specific factors. 
The transfection and expression of BZLF1 is also a successful method of 
inducing lytic cycle in some cell types, and has been delivered via an 
adenovirus vector in Jijoye cells, and severe combined immunodeficient (SCID) 
mice harbouring Jijoye cell tumours (Westphal et al., 1999).  
Lytic induction in vitro is rarely successful in higher than 50% of cells, despite 
the use of multiple inducing agents (Kenney, 2007). This varies between cell 
line types, and could be due to viral or cellular factors. Expression of LMP2A, 
which inhibits B cell receptor activation (Miller et al., 1994) could play a role, 
and changes to the chromatin structure of Rp and Zp could also be responsible 
(Paulson and Speck, 1999). Complete resistance can indicate an integrated 
viral genome (Kenney, 2007). Deletion of essential viral replication components 
allow activation from latency into an abortive lytic reactivation, which would 
exhibit the expression of early lytic genes but not late, and therefore no new 
virus particles are produced, for example Raji cells (Taylor et al., 1989). Cellular 
factors that affect reactivation include NF-κB (Morrison et al., 2004) and retinoic 
acid (Sista et al., 1993), the receptor of which interacts with Zta and inhibits 
transcription. Nitric oxide has been shown to inhibit activation via inhibition of 
p38 phosphorylation and c-myc activation in epithelial cells (Gao et al., 2004). 
1.4.3.6 Lytic Gene expression 
Immediate early genes (and latent genes) contain introns, which allow them to 
be processed by the host cell machinery, causing splicing and associated 
transport out of the nucleus to allow expression in the cytoplasm. However, 
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most early lytic and late lytic genes contain no introns, so are not exported out 
of the nucleus in the usual way. The early lytic gene BSLF2/BMLF1 encodes a 
protein known as SM, a nuclear RNA binding phosphoprotein. SM increases the 
stability of intronless mRNA, and exports it from the nucleus into the cytoplasm 
for translation. This function is required for lytic cycle (Swaminathan, 2005). 
1.4.4 Viral genome Replication 
In addition to Zta, there are six early lytic viral proteins required for replication of 
the EBV genome: BALF2, the single stranded DNA binding protein, BALF5, the 
catalytic subunit of DNA polymerase, BBLF4, helicase, BSLF1, primase, 
BBLF2/BBLF3, the primase associated protein, and BMRF1, the DNA 
polymerase processivity factor (Fixman et al., 1992). Homologues of the core 
six replication proteins were first identified in Herpes Simplex Virus 1 (HSV1) 
(Challberg, 1986), before the same techniques were implemented to discover 
the orthologues in EBV, and others herpesviruses, such as CMV (Pari and 
Anders, 1993, Pari et al., 1993) and KSHV (Wu et al., 2001). Many components 
of the core viral replication machinery can be swapped between members of the 
herpesvirus family; for example, EBV core replication proteins have been shown 
to replicate CMV, a beta-herpesvirus (Sarisky and Hayward, 1996), and 
herpesvirus papio DNA, a B lymphotrophic baboon virus with 40% overall 
homology to EBV (Ryon et al., 1993), and the KSHV core replication proteins 
have been shown to replicate the EBV genome (Wu et al., 2001). This ability 
highlights the similarities between these viruses in their mode of replication.  
Replication initiation of herpesvirus genomes is proposed to adhere to a theta 
model, in which replication occurs from one or more orilyts, in a bidirectional 
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manner, due to the circular nature of the genome, and therefore has similarities 
to prokaryotic DNA replication. However, the DNA replication intermediates 
associated with a theta model have not been detected, nor has anyone 
managed to replicate this in vitro, casting doubt on this theory (Boehmer and 
Nimonkar, 2003). The early initiation events of replication, leading to strand 
unwinding of the lytic origins, have yet to be fully elucidated. HSV1 has the best 
characterised model, in which the lytic origin-binding protein of the family is the 
helicase, which co-ordinates with the single stranded binding protein to 
separate the strands, and allow initiation of replication. Zta is structurally 
different to the HSV1 helicase; however it is suggested that there is sequence 
homology in the region that confers the ability to bind single stranded DNA in 
the HSV1 helicase (Rennekamp and Liberman, 2010). 
After replication has been initiated, the amplification of herpesvirus genomes is 
thought to progress via a rolling circle or sigma mechanism, generating long 
concatemers of the viral genome, which are then cleaved at terminal repeats 
and packaged into capsids (Boehmer and Nimonkar, 2003). However, viral DNA 
has been shown to accumulate exponentially, whereas the rolling circle model 
causes only linear amplification which suggests more than one mechanism of 
replication is involved (Rennekamp and Liberman, 2010).  
1.4.4.1 Inhibition of replication 
Acyclovir is a common drug used to inhibit lytic replication of EBV (and other 
herpesviruses), in both clinical settings and research. It is a nucleoside 
analogue that specifically inhibits viral DNA polymerase as a competitive 
inhibitor and a chain terminator of DNA replication. However, it must first be 
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activated by phosphorylation by the viral kinase, although it is unclear in EBV 
whether this is the protein kinase encoded by BGLF4 or the tyrosine kinase 
encoded by BXLF1 (Gershburg and Pagano, 2005). Ganciclovir and 3’-azido-3’-
deoxythymidine (AZT) are additional nucleoside analogues that specifically 
target lytically active EBV infected cells. 
1.5 EBV Associated Disease  
EBV is associated with a large number of different diseases, including 
malignancies in B cells, epithelial cells and T cells linked to the proliferative 
properties of latency, disorders caused by an over-enthusiastic immune 
response to primary infection, and even associations with autoimmune 
diseases. Understanding the role EBV plays in each of these diseases is 
necessary to aid effective management and treatment. By assessing whether a 
tumour is mono-, oligo- or polyclonal with regards to the EBV genome (which 
can be detected by analysing the number of terminal repeat regions), 
conclusions can be drawn as to whether EBV infection is an early (mono- or 
oligoclonal) or late (polyclonal) event, and thus aid discovery of pathogenic 
mechanisms. 
1.5.1 EBV and cancer 
1.5.1.1 Burkitt’s lymphoma 
Burkitt’s lymphoma is the prototypic EBV associated tumour, the most common 
childhood cancer in equatorial Africa. Fast growing tumours occur in the jaw, 
ovary, mammary gland, liver, intestine and kidneys, and are fatal if untreated. 
The disease is concentrated in this geographic area, classified as endemic BL, 
and occurs at only a low incidence worldwide, known as sporadic BL (Crawford, 
2001). EBV DNA is present in tumour cells of 98% of endemic BL and in the 
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majority of cases exhibits a latency I profile, expressing only EBNA-1 and the 
non-coding EBER RNAs (Allday, 2009). Some BL cases harbour a viral genome 
with a deletion over the EBNA-2 gene, resulting in an expression profile 
consisting of all of the EBNAs except EBNA-2 and the LMPs, but with the 
additional expression of BHRF1, a homologue of host Bcl-2, an anti-apoptotic 
factor. This is known as Wp-restricted latency, as all expression is activated 
from the Wp (Rowe et al., 2009). In contrast, EBV positive tumours account for 
only 15% of sporadic BL. This rises to 50% in individuals co-infected with HIV 
(Crawford, 2001). Both sporadic and endemic BL share a deregulation of the 
Myc oncogene on chromosome 8, as a result of a chromosomal translocation 
with one of three immunoglobulin genes (chromosomes 14, 22 or 2), which 
results in the active Ig locus activating constitutive expression of Myc. This 
causes an accumulation of Myc protein, a transcription factor with many targets 
including those that influence cell proliferation and apoptosis, and therefore 
contributes to the tumourogenic processes (Li et al., 2003). Infection with 
malaria appears to be an important cofactor for development of these tumours. 
Malaria suppresses the EBV specific T cells, causing high EBV viral loads in 
peripheral blood. It is also thought to increase germinal centre activity. This 
increase in activity increases the likelihood of the oncogenic translocation, due 
to the somatic hypermutation the cell is undergoing to rearrange the 
immunoglobulins creating an antigen specific response. As discussed in section 
1.4.1, the B cells are usually selected for those that generate higher affinity 
antibodies, and must differentiate to survive, by receiving specific survival 
signals. However, due to the increased viral load, it is more likely that the B cell 
will be infected with EBV, which provides alternative survival signals (LMP-1 
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and LMP-2A) to evade cell death, and allow proliferation of a B cell with 
oncogenic potential (Rowe et al., 2009, Chene et al., 2009).  
1.5.1.2 Hodgkin’s Disease 
Hodgkin’s Disease (HD) or Hodgkin’s lymphoma (HL) is a tumour of the lymph 
nodes that disrupts the recognised lymph node architecture (Kapatai and 
Murray, 2007). It originates from B lymphocytes. The tumour material is made 
up of mononuclear Hodgkin’s cells and multinuclear Reed-Sternberg cells, with 
a reactive, non malignant cell infiltrate that dictates the exact type of disease; 
either nodular sclerosing (NS), mixed cellularity (MC) or the rarer lymphocyte 
depleted (LD) (Rickinson and Kieff, 2001a, Kutok and Wang, 2006). MC and LD 
have the highest rate of EBV association (60% to 90%) whilst NS has a lower 
association rate (20% to 40%). Monoclonal viral genomes were detected in 
tumour biopsies, indicating EBV infection is an early event in disease 
development (Rickinson and Kieff, 2001a, Young and Murray, 2003). Previous 
IM diagnosis increases the chance of suffering from EBV positive Hodgkin’s 
Disease (Young and Murray, 2003). The cells exhibit a latency II profile of gene 
expression, with high expression of LMP1, under control of cellular transcription 
factor STAT3 (Rickinson and Kieff, 2001a, Young and Murray, 2003). LMP-1 
mimics normal CD40 B cell signalling, which is usually stimulated by interaction 
with T cells and promotes the differentiation of GC cells into memory B cells. 
This signalling causes constitutive NF-kB, JNK and p38 pathways activation, 
causing proliferation and aiding lymphomagenesis. LMP-2 is also expressed 
and can also enhance survival of GC cells by recruiting src tyrosine kinases to 
mimic the normal antigen activation of the B cell receptor, via the PI3 pathway 
(Rickinson and Kieff, 2001a, Young and Murray, 2003).    
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1.5.1.3 Post Transplant lymphoproliferative Disorders (PTLD) 
Patients that have undergone organ transplantation require heavy 
immunosuppression to ensure that the body does not reject the new organ 
(Munksgaard,2004). However, this comes with the risk of developing 
lymphomas, and these tumours are often associated with EBV (Maeda et al., 
2009). Indeed, EBV seronegative individuals have a 20 times higher incidence 
of developing post transplant lymphoproliferative disorders (PTLD) than 
seropositive recipients. In the absence of appropriate levels of 
immunosurveillance in a post transplant patient, the balance between normal B 
cell differentiation and EBV-driven proliferation may be disrupted, leading to 
malignancies (Rickinson and Kieff, 2001a).  
The PTLD tumours are of B cell origin and range from polyclonal B cell 
proliferations to aggressive monoclonal non-Hodgkin’s lymphomas (NDL). 
Hence they have been categorised into 3 broad types: (i) diffuse B cell 
hyperplasias of poly or oligoclonal B cell origin which occur within 1 year of 
transplantation, without disturbing the normal lymph node structures; these are 
usually EBV positive, (ii) polymorphic lesions, exhibiting necrosis, disruption of 
lymphoid structure, and atypical nuclei, oligo or monoclonal in origin, which are 
almost always EBV positive and can appear early or late after transplantation, 
and (iii) monomorphic lesions, which arise several years after transplantation as 
diffuse, large B cell lymphomas which can be further classified into 2 subsets, 
those of immunoblastic origin, which the majority of which are EBV positive, or 
centroblastic, expressing a germinal centre B cell marker, of which a subset are 
EBV positive (Rickinson and Kieff, 2001a, Kutok and Wang, 2006). Overall, 
early onset lymphomas are 100% EBV positive, and late onset lymphomas are 
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80% EBV positive, and usually express a latency III profile, but other forms of 
latency have been detected (Young and Murray, 2003). It appears that the early 
onset tumours arise from EBV transformed B cells in the absence of a full T cell 
response, and in this way, in vitro transformed LCLs strongly resemble the 
expression profile (Rickinson and Kieff, 2001a).  
1.5.1.4 T cell lymphoma 
EBV rarely infects T cells, despite the presence of receptors on the cell surface 
which would allow virus entry (Kutok and Wang, 2006). However, virus is 
detected in some T cell lymphomas, which usually occur outside the lymph 
nodes (“extranodal”), and are known as NK/T cell lymphomas. The clonality of 
the EBV genome within the tumour has been demonstrated, confirming that 
EBV infection is an early event of tumourogenesis (Kutok and Wang, 2006). 
Virus is generally detected in between 5 and 50% of tumour cells, suggesting 
that infection may occur as a secondary event in oncogenesis. As the tumour 
progresses, the number of EBV positive cells increases, supporting the idea 
that EBV may confer growth or survival advantages to the transformed T cells 
(Young and Murray, 2003). Full details of the role of EBV in the pathogenesis of 
these tumours have not yet been elucidated (Kutok and Wang, 2006). T cell 
lymphomas are also associated with virus-associated hemophagocytic 
syndrome (VAHS), in which rare, monoclonal proliferations occur from mature T 
cells in patients suffering from chronic active EBV infection (Kutok and Wang, 
2006). A latency I/II profile is expressed, and activation of tumour necrosis 
factor and other cytokines causes macrophage activation, leading to dangerous 
hemophagocytosis (Young and Murray, 2003, Kutok and Wang, 2006). 
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1.5.1.5 Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) has been categorised by the World Health 
Organisation (WHO) into 3 types: Type I, Keratinising squamous cell carcinoma; 
Type II, Non-keratinising squamous cell carcinoma and Type III, 
Undifferentiated carcinoma. EBV is linked to type III, which is characterised by 
undifferentiated carcinoma cells surrounded by lymphocytic infiltrate, which is 
required for the growth of tumour cells (Young and Murray, 2003). The link was 
first suggested, based upon serological studies, in 1966, and was later 
confirmed by detection of EBV DNA in tumour cells in 1970 (Zur Hausen 1970). 
Monoclonality of EBV has been demonstrated in tumour cells, an indication of 
EBV infection before malignant cell proliferation (Shah and Young, 2009, 
Rickinson and Kieff, 2001a). The disease is most common in China and South 
East Asia, and both genetic and environmental factors have been implicated. 
There is a high familial risk of disease, which has not yet been fully mapped. It 
is suggested to reside in the HLA antigen locus on chromosome 6, a 
component of the major histocompatibility complex that aids the differentiation 
in the body of self and non-self and therefore plays an important role in immune 
recognition (Rickinson and Kieff, 2001a). Nitrosamine, found in salted fish, has 
been suggested as a dietary co-factor (Young and Murray, 2003). A latency I/II 
intermediate profile has been described for NPC, with Qp driven EBNA-1 
expression, EBERs, variable levels of LMP-1 and high levels of spliced BARTs. 
Interestingly, a lytic gene product, BARF1, has also been detected, but no other 
lytic products can be reliably observed. However, antibody titers to lytic antigens 
are elevated in NPC patients, and this apparent inconsistency has not yet been 
explained (Rickinson and Kieff, 2001a). BARF1 protein is not detected in NPC 
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biopsies, due to secretion of BARF1 protein into the surrounding cell media 
(Seto et al., 2005).  
1.5.1.6 Gastric carcinoma 
The association of gastric carcinoma and EBV was first suggested due to 
similarities between gastric carcinoma and NPC (Deyrup, 2008). EBV is found 
in only a small proportion of diffuse or intestinal type gastric carcinomas (Young 
and Murray, 2003). The viral expression profile is more restricted than NPC, 
with EBERs, Qp EBNA-1, BARTs and BARF1 expressed in all EBV associated 
gastric carcinomas, LMP2A expressed in approximately half, but no LMP1 
expression (Rickinson and Kieff, 2001a). EBV associated gastric carcinomas 
are associated with a better prognosis when compared to other gastric 
carcinomas (Maeda et al., 2009). This may be due to a tumour-specific 
response directed against EBV antigens (Rickinson and Kieff, 2001a). 
1.5.1.7 Breast cancer 
The ubiquitous nature of EBV infection in the population can lead to controversy 
concerning the definition of an EBV associated cancer. Presence of the EBV 
genome or virus gene products in the tumour cell population should be 
unambiguously detected to allow such a conclusion to be drawn (Young and 
Murray, 2003). Unfortunately, this is not always easy to prove, and the debate 
over the aetiological status of EBV and breast cancer is a good example of this. 
EBV DNA (Labrecque et al., 1995, Luqmani and Shousha, 1995) and later 
EBER-2 and LMP-2 DNA (Bonnet et al., 1999) was first detected in whole 
tumour material in approximately 50% of cases. However, the presence of rare 
infiltrating lymphocytes into the tumour mass could account for this detection 
37 
 
 
(Murray, 2006), and therefore the evidence for an association required more 
specific evidence. Whole tumour tissues which were positive for EBV by PCR 
analysis were subjected to microdissection to isolate specific tumour cells from 
the surrounding non-cancerous tissue. The dissected tumour cells in this study 
were all negative for the presence of EBV (Murray et al., 2003). It has been 
demonstrated that EBV can infect breast cancer cell lines, exhibiting a latency 
II-like expression profile, with the additional detection of BZLF1, indicating 
evidence of viral replication (Huang et al 2003). However, this expression of 
BZLF1 may be evidence of the abortive lytic cycle activation, or the burst of 
BZLF1 expression seen upon primary infection (Halder et al., 2009).  
Difficulty in detecting EBER expression, present in all states of latency, in the 
cancer tissue led to immunohistochemistry attempts to detect EBNA-1 
(Grinstein et al., 2002). Unfortunately the antibody used (2B4) was shown to 
stain tissue where EBV DNA could not be detected (Murray et al., 2003), and 
later to cross react with another protein known to express in a wide variety of 
tumour types, MAGE4 (Hennard et al., 2006). Opinion remains divided on the 
EBV association with breast cancer, but it appears that even if an association is 
proven, it may be involved in only a small proportion of breast cancer.  
 1.5.2 Other EBV associated diseases 
1.5.2.1 Infectious Mononucleosis 
Infectious Mononucleosis (IM), also known as glandular fever, results from an 
aggressive CD8+ T cell response against EBV antigens and manifests as 
enlarged lymph glands, fever and malaise (Long et al., 2011). These symptoms 
can last between 1 and 6 months (Rea et al., 2001). The association with EBV 
was discovered when an EBV-seronegative technician in the Henle research 
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lab contracted IM, and was found to be EBV-seropositive after recovery, which 
led to further investigation (Rickinson and Kieff, 2001b). There is an incubation 
period of around 30 days between infection and onset of symptoms, during 
which time the EBV infected B cells circulate in the blood and infiltrate tissues 
(Crawford, 2001). IM is described as immunopathologic due to the cause of the 
symptoms residing with the activation of proinflamatory cytokines by the host 
immune system to primary infection of EBV. However, not all primary infection 
results in IM; indeed, primary infection in infants is usually asymptomatic, and it 
is usually EBV seronegative young adults who suffer from IM. A possible 
explanation for this is the difference in dose; young adults tend to contract EBV 
from kissing (hence the more familiar name, the kissing disease), with a 
potentially extended contact with the EBV carrier’s saliva (Crawford, 2001). 
Other explanations for the aggressive immune response include changes 
related to age in the immune system. Existing memory B cells may be specific 
to other antigens that are similar to those detected during infection, causing 
cross reactivities, which may not be present in younger individuals (Rickinson 
and Kieff, 2001a).  
1.5.2.2 Oral hairy leukoplakia 
Oral hairy leukoplakia is an epithelial lesion on the tongue caused by 
uncontrolled EBV lytic infection in immunocompromised patients (Slots et al., 
2006). It is seen as an early clinical indication that the immune system is failing, 
as it was initially observed in HIV patients, but has also been seen in post 
transplant patients and sometimes in healthy individuals (Rickinson and Kieff, 
2001b). It appears to be as a result of repeated primary infection of the 
epithelial cells rather than reactivation of latent infection from memory B cells 
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(Sandvej et al., 1992). It is self-limiting but can be treated with viral replication 
inhibitors such as acyclovir, although patients are prone to recurrence when 
treatment is stopped (Walling et al., 2003). 
1.5.2.3 Autoimmune diseases 
Some autoimmune diseases are associated with chronic stimulation of the B 
cell system, which suggests possible interactions or association with EBV 
(Rickinson and Kieff, 2001a). Systemic lupus erythematosus (SLE) produces 
autoantibodies, which attack antigens within the body such as DNA and 
histones.  Rheumatoid arthritis (RA) is a joint disease characterised by chronic 
inflammation, involving a number of different factors including genetics, 
hormonal, psychological, immune deregulation and environmental. Primary 
Sjögren's syndrome (pSS) consists of autoimmunity against the endocrine 
glands. Multiple sclerosis (MS) occurs when the myelin sheaths surrounding 
axons are damaged, causing a wide range of neurological symptoms (Toussirot 
and Roudier, 2008). Serological evidence has linked all these diseases to EBV, 
based upon co-occurrence, and an abnormally high EBV load has also been 
detected in autoimmune sufferers. It is difficult to say that the two are definitely 
connected; when a virus is as ubiquitous as EBV, the difference in sero-status 
between sufferers and non-sufferers is very small. For example, it was found 
that MS and IM had a similar distribution in the population; whether this 
indicates that late EBV infection causes a predisposition to MS, or if there is a 
common factor that increase susceptibility, is unclear (Pohl, 2009). Autoimmune 
patients have been documented to struggle to control EBV infection, and there 
is clinical evidence to suggest that EBV infection can aggravate the 
development of lupus (Toussirot and Roudier, 2008). Molecular mimicry may 
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also play a role in EBV associated autoimmune diseases; there are similarities 
between viral antigens and host proteins, which may cause cross-reactivities 
when an immune response is activated against the virus, causing harm to the 
host (Pohl, 2009, Toussirot and Roudier, 2008). EBV appears to possess all the 
qualities required of a candidate viral link for autoimmune disease; however the 
evidence is not yet completely convincing.  
1.5.3 Lytic cycle activation as a treatment option 
Activation of EBV lytic cycle provokes an immune response from the host. 
Where a cancer contains latent EBV, this mechanism could be exploited as a 
potential treatment. The transfection of a BZLF1 expression vector into cells via 
an adenovirus was shown to activate lytic cycle and decrease tumour growth 
when it was trialled in nude mice (Westphal et al., 1999). However, the 
possibility remains that the increase in virus production may activate a 
disproportionate immune response, or cause increased infection of additional 
tissues. Simultaneous treatment with acyclovir is potential solution to this 
problem (Amon and Farrell, 2005). Efficient gene delivery methods also need to 
be developed before this can be considered as a legitimate treatment option 
(Israel and Kenney, 2003). 
Other substances used to activate lytic cycle in vitro (as discussed in section 
1.4.3.5), such as treatment with histone deacetylase inhibitors (for example 
sodium butyrate) are potential options, but associated side effects would need 
to be considered (Amon and Farrell, 2005). Despite the effectiveness of 5-
azacytidine and sodium butyrate in Burkitt’s lymphoma cell lines in vitro, these 
substances have not been demonstrated to effectively induce lytic cycle in in 
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vivo mouse models with tumours derived from lymphoblastoid cell lines (Israel 
and Kenney, 2003). However, irradiation and chemotherapy, treatments already 
used in patients with EBV-positive tumours, have been shown to induce lytic 
viral gene expression (Westphal et al., 2000, Feng et al., 2002). Augmenting 
this treatment with a nucleoside analogue such as ganciclovir, which requires 
activation by lytic-specific gene products, could promote tumour cell death 
(Israel and Kenney, 2003). 
1.6 Epigenetics of EBV 
Upon infection, the EBV genome is packaged in chromatin in a similar manner 
to cellular chromosome, and the establishment of latency correlates with these 
epigenetic marks (Tempera and Lieberman, 2010). Chromatin has 2 elements; 
histone octamers that make up nucleosomes, around which DNA is wrapped, 
and the methylation state of the DNA. 
1.6.1 Histones 
Histones are an important element of the chromatin structure, with 2 of each of 
the core histones, H2A, H2B, H3 and H4 creating an octamer known as a 
nucleosome, around which 147 base pairs of DNA wraps. This condenses the 
DNA into a chromatin fibre of 11nm diameter, which then further condenses 
with the addition of histone H1 to a 30nm diameter structure, which can 
condense still further during cell replication. Each of the histones has an 
unstructured N terminal tail, which can be modified by acetylation, methylation, 
phosphorylation and ubiquitination; each of these modifications affects the 
histone/DNA interaction and changes the chromatin state, either towards a 
more condensed state (heterochromatin) or a more open state (euchromatin). 
42 
 
 
The modifications also provide binding sites to recruit other proteins that affect 
the transcriptional activity of DNA, for example, proteins with bromodomains 
recognise histone acetylation, and those with chromo-like and PHD domains 
recognise histone methylation. Enzymes have been identified that add these 
modifications and others that remove them, indicating the dynamic nature of the 
structure (Kouzarides, 2007). Histone marks such as methylated H3K9, H3K27 
and H4K20 are associated with silenced heterochromatin. H2K27 methylation 
recruits polycomb protein complex PC2, which associates with other 
transcription repressive proteins such as histone deacetylases and 
methyltransferases. Actively transcribed regions tend to exhibit high levels of 
acetylation, together with trimethylation of H3K4, H3K36 and H3K79 
(Kouzarides, 2007). However, the association with a particular mark does not 
always mean a specific transcriptional outcome for a region, and some histone 
modifications have been shown to be strongly dependent upon context. For 
example, when H3K36 methylation was found in the coding region of a gene, 
the effect was activation, but when it was found in the promoter region, it was 
repressive (Vakoc et al., 2005). CCCTC-binding factor (CTCF), a transcription 
factor, has been shown to aid the formation of boundaries between differently 
transcribed regions of chromatin by recruiting specific chromatin remodelling 
enzymes (Kouzarides, 2007). 
1.6.2 DNA methylation 
Methylation of DNA in mammals occurs primarily on carbon 5 of the pyrimidine 
ring of cytosine residues in the context of a CpG dinucleotide. Methylation of 
other residues has been identified in plants and in early development in stem 
cells (Lister et al., 2009). Methylation patterns, established by de novo 
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methyltransferases, are heritable mitotically, maintained by methyltransferases 
that copy the methylation pattern to the complementary strand. Methylation 
patterns have been shown to be inherited across generations (through meiosis) 
in mice and plants, but this has not yet been shown in humans (Flanagan et al., 
2010). CpG dinucleotides tend to cluster in CpG islands, first defined arbitrarily 
as regions approximately 200 basepairs in length with a G+C content of 50% 
and an observed/expected CpG ratio of 0.6 (Gardiner-Garden and Frommer, 
1987). This was recently revised so as to exclude repeat regions that are not 
necessarily involved in direct control of expression, increasing the region length 
to greater than 500 basepairs, with a G+C content of 55% and an 
observed/expected CpG ratio of 0.65. This definition returned regions that were 
more likely to be associated with the 5’ region of genes (Takai and Jones, 
2002). CpG islands are found at the 5’ end of approximately 60% of human 
genes (Wang and Leung, 2004) and usually remain unmethylated, whereas 
isolated CpG dinucleotides are more likely to be methylated. This is thought to 
be due to the high level of mutability of a methylated cytosine residue; 
spontaneous deamination of the methylated cytosine results in recognition as a 
T, leading to a reduction in the overall content of CpG during evolution. Methyl-
CpGs mutations occur at 10-50 times the rate of a C in any other context 
(Walser and Furano, 2010). Those residues that are methylated will be selected 
against in this way, unless they are required for a vital role, such as 
transcriptional control.   
Methylation causes transcriptional repression by attracting proteins with methyl 
binding sites, such as histone deacetylases and methyl transferases, which 
impose repressive chromatin structure upon the DNA (Jones and Baylin, 2007). 
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These proteins contain methyl binding domains (MBD), and crystal structures of 
the binding of these proteins to methylated CpG dinucleotides shows that they 
make multiple contacts with the methyl group, some of which are facilitated by 
water molecules in the major groove of DNA. There are also arginine residues 
that contact the G residue, confirming the CpG context required for interaction. 
Interaction only occurs on a double stranded symmetrically methylated CpG 
residue (Burkitt, 1985). The proteins containing MBDs recruit proteins that 
cause histone modifications associated with repression, for example Md2 is part 
of the Mi2/NuRD HDAC repressor complex, and plays a role in the silencing of 
Xist on the active X chromosome (Barr et al., 2007). Another MBD protein, 
MeCP2, associates with HDAC complexes and acts as a transcriptional 
repressor (Hutt and Burkitt, 1973).  
Another way in which methylation contributes to transcriptional silencing is by 
directly interfering with the binding of some transcription factors (Jones and 
Baylin, 2007). C-Myc, a helix-loop-helix (HLH) DNA binding transcription factor, 
binds to sequences in the DNA known as Enhancer Box sequences, (E boxes) 
through dimerisation with another HLH protein, Max. When the central CpG 
within the E box was methylated, the basic region of Myc was unable to bind 
(Prendergast and Ziff, 1991). As c-myc is thought to regulate 15% of human 
promoters (Li et al., 2003), the effect of aberrant methylation could have wide-
reaching effects. AP2 binding was inhibited by methylation in the promoter of 
the proenkaphalin gene, PENK (Comb and Goodman, 1990). The methylation 
of other transcription factor binding sites such as cAMP-responsive element 
(CRE) (Iguchi-Ariga and Schaffner, 1989), the binding sites for the E2F family of 
transcription factors (Kafuko and Burkitt, 1970) and those specific to Upstream 
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Binding Factor 1 (UBF1) (Burkitt, 1969) inhibit protein binding and activation of 
transcription. The effect of DNA methylation on the binding ability of the 
transcription factor Sp1, which binds to DNA through a zinc finger motif, 
displays a mixed phenotype. In some cases methylation appeared to inhibit 
binding (Douet et al., 2007, Clark et al., 1997), whilst in other cases, methylation 
had no effect on binding capabilities at all (Holler et al., 1988). The methylation 
status of surrounding CpG motifs was also shown to inhibit binding, leading to 
the suggestion that the effect was in fact due to the context in which the binding 
site was situated (Zhu et al., 2003). A similar scenario was observed in the 
promoter of TrkA, a nerve growth factor receptor, where specific methylation of 
the CpG motif within an AP1-like site did not disrupt c-jun binding (a bZIP 
transcription factor), but methylation of the entire oligonucleotide inhibited 
binding (Fujimoto et al., 2005).  
1.6.3 EBV Epigenetics 
H3 and H4 acetylation is increased around Cp in cell lines exhibiting a latency 
III profile, whereas in latency I, Qp is enriched for these marks and Cp is 
depleted. H3K9me3 is also detected at the W repeat and Wp during latency I. 
However it has not been conclusively shown that the switch between Cp and 
Qp driven EBNA-1 expression is driven by the changes in chromatin structure 
(Alazard et al., 2003, Tempera and Lieberman, 2010).The majority of the EBV 
genome is populated with histone marks associated with the euchromatic state, 
with a relatively low amount of heterochromatic, H3K9 methylation. The OriP 
falls within a region of euchromatin (Tempera and Lieberman, 2010).  
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CTCF, an 11 Zn finger nuclear phosphoprotein, acts as an insulator of 
transcriptionally active regions of the genome (Phillips and Corces, 2009). It 
binds to unmethylated cytosines, and has been observed upstream of Qp, Cp 
and EBER, as well as downstream of Wp (Chau et al., 2006). This is thought to 
protect the neighbouring lytic genes from undue activation during latency. It may 
also regulate enhancer promoter interactions, as it has been show to cause 
DNA loop formation, and therefore play a part in long range regulation (Phillips 
and Corces, 2009). CTCF binding is increased in latency I compared to latency 
III, which is thought to inhibit EBNA-1 binding to the region between OriP and 
Cp, and hence repress expression of EBNA-2 from Cp. CTCF binding was 
similar at Qp and the EBER promoter in latency I and III (Chau et al., 2006).  
The EBV genome is extensively methylated in latently infected cells. 
Interestingly, from the promoter regions of 77 transcription start sites analysed 
using bisulphite sequencing to create a DNA methylome for the EBV genome, 
only five were not methylated; EBER-1, EBER-2, Qp, LMP-2B/LMP-1 and 
BZLF1 (Fernandez et al., 2009). The rest of the promoters analysed, including 
BRLF1 promoter (Rp), was found to be methylated. The genome appeared to 
be almost completely unmethylated after viral replication has occurred, apart 
from BBRF1 and BBLF4 (Fernandez et al., 2009). Inhibition of DNA methylation 
relieves the repression of Cp in latency I, causing a shift to latency III 
expression (Tempera and Lieberman, 2010). As previously mentioned in 
section 1.5.3, 5’-azacitidine has been observed to activate lytic cycle, however 
no change in viral DNA methylation was detected, suggesting this reactivation 
occurred via a different, as yet unknown mechanism (Miller et al., 2007). 
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1.7 Zta 
Crucial to the reactivation of the virus is a gene known as BZLF1 that encodes a 
protein called Zta (also known as Z, BZLF1 and ZEBRA), a replication and 
transcription factor. This gene is silent during latency, but expressed within 30 
minutes of lytic activation, and the presence of Zta is able to disrupt EBV 
latency (Sinclair, 2003). As a transcription factor, it binds to Zta Response 
Elements (ZREs) that resemble AP1 sites, in both viral and host (human) DNA. 
Through these ZREs, Zta activates transcription of both viral and human genes. 
Zta binds to ZREs in the BZLF1 promoter (Zp) to create a positive feedback 
loop, as well as ZREs in lytic gene promoters. Rta activates expression from the 
Zp indirectly through ATF-2 and c-jun, cellular transcription factors that bind to a 
CRE motif (Adamson et al., 2000) as well as expression of other lytic genes. 
When neither BZLF1 nor BRLF1 are present, few lytic genes are subsequently 
transcribed. Zta belongs to the bZIP family of transcription factors, which 
includes other proteins such as yeast GCN4, c-Fos and c-Jun. As a replication 
factor, it interacts with the lytic origin replication, again via ZREs, to activate 
replication of the EBV genome itself (Burkitt, 1968). Zta can also influence cell 
cycle progression; enforced expression of Zta can induce cell cycle arrest in 
some cell types, via upregulation of C/EBPα (Wu et al., 2003). 
1.7.1 Structure 
Zta is 245 residues long, and exists as a dimer, containing a transactivation 
domain at the N terminus, a basic region that mediates DNA contact, the coiled-
coil dimerisation domain, where the leucine zipper forms, also known as a bZIP 
domain, and a C terminal (CT) region. The bZIP region of Zta is different to the 
rest of the family; most bZIP proteins dimerise and bind DNA through an 
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approximately 60 amino acid bZIP domain, whereas Zta has a bZIP domain of 
175 -220 amino acids long, and lacks a characteristic heptad repeat of leucine 
residues that are normally required for stable dimerisation and high affinity DNA 
binding (Farrell et al., 1989). Zta exhibits a variant of the bZIP fold, with a 
unique dimer interface and a substantial hydrophobic pocket, which allows Zta 
to recognise a wider range of DNA binding sites (Petosa et al., 2006). The 
crystal structure illustrates the dimerisation and DNA binding domain of Zta 
bound to DNA (Figure 1.7). The structure of the C terminal end is unknown, as it 
did not fully crystallise, and the N terminal transactivation domains are not 
shown, as they were not part of the protein used during crystallisation. It shows 
the protein contacting the DNA via two long bZIP helices, the basic region of 
each contacting the major groove of the DNA. At the C terminal end, an 
additional motif is formed; coiled-coil, hairpin turn, one turn helix (helix αC), then 
an extended stretch of residues, running antiparallel to the coiled-coil. This 
creates a small four helix bundle at the distal end of the homodimer. The C 
terminal region seems to stabilise the coiled-coil and enlarges the dimer 
interface, providing the extra stability required despite lack of leucine motif 
(Petosa et al., 2006). The CT region is required for lytic activation (Bailey et al., 
2009). A cysteine at residue 189 has been shown to be required for the redox 
sensitive control of lytic cycle reactivation (Wang et al., 2005), and a serine 
residue at position 186 appears to be required for DNA binding (Bhende et al., 
2005). 
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Figure 1.6 The crystal structure of Zta dimerisation and DNA binding domains.  
This image was created using RASMOL and the published crystal structure data from Petosa 
et al, 2006. The light and dark blue represent DNA, the pale green shows the basic DNA 
contact regions, the bZIP helices, and the bright green shows the 4 helix bundle at the distal 
end of the dimer, including the start of the CT region. The very end of the CT region did not 
crystallise, therefore this part of the structure is not complete, and the globular transactivation 
domains are not included.  
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1.7.2 DNA interactions 
Zta binds to ZREs in both the viral and host genome, and acts as a transcription 
factor to stabilise the complex bound to the DNA including TFIID and TFIIA (Chi 
et al., 1995). Binding has been established in the viral and human gene 
promoters detailed in table 1.2. 
ZRE Core Sequence 
Class Names References 
Forward Reverse 
TGAGCCA TGGCTCA I 
Zp ZREIIIA 
(Flemington and Speck, 1990a, 
Lieberman and Berk, 1990) 
(Urier et al., 1989)  
Rp ZRE1 (Sinclair et al., 1991) 
TTAGCAA TTGCTAA I Zp ZREIIIB (Flemington and Speck, 1990a, Lieberman and Berk, 1990) 16 
TGTGTAA TTACACA I DSL ZRE1 (Lieberman and Berk, 1990) 
TGAGCAA TTGCTCA I 
DSL ZRE2 (Lieberman and Berk, 1990) 
DSL ZRE7 (Lieberman and Berk, 1990) 
BMRF1ZRE(-
44) (Taylor et al., 1991) 
BMRF1ZRE(-
107) (Quinlivan et al., 1993) 
TGTGTCA TGACACA I 
DSL ZRE3 (Lieberman and Berk, 1990) 
DSL ZRE4 (Lieberman and Berk, 1990) 
DSL ZRE6 (Lieberman and Berk, 1990) 
DHRS9 ZRE1 (Jones et al., 2007) 
TGTGCAA TTGCACA I 
DSL ZRE5 (Lieberman and Berk, 1990) 
CIITA (221) (Li et al., 2009) 
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TGAGTCA TGACTCA I 
BSLF2+BMLF1 (Taylor et al., 1991) 
BMRF1 AP-1 (Kenney et al., 1992) (Quinlivan 
et al., 1993) 
IL8 AP1 (Hsu et al., 2008) 
DHRS9 (ZRE2) (Jones et al., 2007) 
TGACTAA TTAGTCA I Fp AP-1-Like Site (Zetterberg et al., 2002) 
TGAGTAA TTACTCA I 
CIITA (Li et al., 2009) 
IL13 (Tsai et al., 2009) 
GTTGCAA TTGCAAC I IL-8 ZRE (Hsu et al., 2008) 
GGAGCGA TCGCTCC III Egr1 (Heather et al., 2009) 
TGAGCGA TCGCTCA II Rp ZRE2 (Sinclair et al., 1991) (Bhende et 
al., 2004) 
TTCGCGA TCGCGAA III Rp ZRE3 (Bhende et al., 2004) 
TGAGCGT ACGCTCA III Nap ZRE2 (Dickerson et al., 2009) 
CGGGCGA TCGCCCG III Nap ZRE1 (Dickerson et al., 2009) 
 
Table 1.2 : ZRE sequences in the viral and host genome. CpG motifs are indicated in the 
ZREs in bold. 
ZREs have been characterised in the viral promoter of BRLF1 (Rp) (Bhende et 
al., 2004, Sinclair et al., 1991), BMRF1 (the viral polymerase processivity factor) 
(Taylor et al., 1991, Kenney et al., 1992, Quinlivan et al., 1993), and the 
promoter of BSLF2/BMLF1 (SM) (Taylor et al., 1991). These viral proteins are 
all required for successful lytic cycle activation. 2 interleukins have been shown 
to be upregulated by Zta; IL-8 (Hsu et al., 2008) and IL-13 (Tsai et al., 2009). 
Interleukins are cytokines which may play a role in tumour progression, due to 
their contribution to cell proliferation. Zta has also been observed to upregulate 
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DHRS9, an enzyme which plays a role in the conversion of retinol into the 
active form, retinoic acid, by directly binding to ZREs in the promoter (Jones et 
al., 2007).  The majority of the ZREs discovered thus far have been shown to 
cause activation of expression, however the expression of one of these genes, 
CIITA, a component of the MHC Class II antigen presentation pathway, was 
actually downregulated in the presence of Zta binding. In this manner, Zta 
contributes to virus immune evasion (Li et al., 2009). Interestingly, both of the 
ZREs found in this promoter are also found in other promoters, one which is a 
match to a ZRE found in the viral OriLyt region, and the other found in the 
promoter of IL13, where it activates expression. This suggests that the final 
outcome of Zta binding to promoters is affected by the cellular context, perhaps 
the relative abundance of other proteins, or the modifications on any of these 
proteins.       
Unlike other transcription factors, Zta has been shown to preferentially bind to 
methylated response elements and activate transcription of the associated gene 
(Bhende et al., 2004). This has major implications in understanding how Zta 
may reverse the epigenetic silencing imposed upon the EBV genome by the 
host cell. The ability of Zta to interact with methylated DNA is severely 
compromised if C189 or S186 are mutated. This has further implications, as 
C189 is highly conserved amongst bZIP proteins, suggesting that other 
transcription factors may have the same epigenetic reversal potential (Karlsson 
et al., 2008a). There are 3 ZREs in Rp, numbered 1 to 3 (figure 1.7A), and all 3 
are important for activation of the gene (Chiu et al., 2007), although RpZRE1 
appears to be unnecessary on a fully methylated template (Bhende et al., 
2004).  
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The different behaviour of Zta with each of these ZREs led to the classification 
of the sites into three classes. RpZRE1 does not contain a CpG dinucleotide, so 
is therefore unaffected by methylation, and is classified as a Class I ZRE. 
RpZRE2 contains one CpG, and Zta has been shown to bind to it in the 
unmethylated state but to possess enhanced binding ability when the CpG is 
methylated, leading to this becoming classed as a Class II ZRE. RpZRE3 
contains two CpGs, and Zta does not bind detectably to the unmethylated form, 
only the methylated form (Bhende et al., 2004). This is referred to as a Class III 
ZRE (Karlsson et al., 2008b). Each of the ZREs in table 1.2 are classified in this 
way.    
Another example of a lytic gene promoter under the same mechanism of 
methylation dependent control was recently discovered (Dickerson et al., 2009). 
Nap, the promoter of the BRRF1 gene, has been shown to contain two 
methylation dependent ZREs (figure 1.7B). Furthermore, Zta only activates Nap 
efficiently when it is in the methylated form (Dickerson et al., 2009). BRRF1 
encodes the protein Na, an early viral protein which induces c-jun 
phosphorylation and also plays a part in BZLF1 transcription activation 
(Adamson et al., 2000). The Nap ZRE1 site requires both CpGs within the 
sequence to be methylated for effective binding. The Nap ZRE2 site contains 
only one CpG, and although it differs by only 1 base from the RpZRE2 site, Zta 
can only bind when it is methylated. Therefore both sites could be defined as 
class 3 ZREs. Both sites are required for activation of Nap in vivo. S186 is 
required to bind methylated Nap; however C189 is not (Dickerson et al., 2009), 
contrary to the behaviour of the C189 mutants in RpZRE3 (Karlsson et al., 
2008a).  
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Figure 1.7 Gene promoters with CpG containing ZREs in the promoter region.  
A: The BRLF1 viral gene promoter. B: The BRRF1 viral gene promoter. C: The egr1 
human gene promoter.  The CpG dinucleotides that can be methylated are highlighted in 
red. 
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An example of methylation affecting Zta binding in human promoters has also 
been observed. Egr1 encodes a human transcription factor which has been 
shown to be induced by Zta (Chang et al., 2006). 2 potential binding sites were 
identified (Chang et al., 2006) and mapped (Heather et al., 2009) to elucidate 
the mechanism of binding (1.7C).  Interestingly, the distal site contains a CpG 
motif. According to one study (Seyfert et al., 1990) the promoter of egr1 is 
methylated in B cells, however according to a more recent human B cell 
methylome (Rauch et al., 2009) is it not, suggesting that perhaps the 
methylation status of this area is unstable or subject to cell-specific 
mechanisms. Methylation of this distal site CpG enhanced Zta binding by at 
least 10 fold, compared to unmethylated binding, and can also activate 
expression in vivo, however this latter effect appears to be cell line specific 
(Heather et al., 2009).  
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1.8 Aims 
To investigate the value of existing prediction tools for transcription factor 
(specifically Zta) binding sites. 
To develop better tools for predicting ZREs. 
To investigate the prevalence and position of ZREs within both the viral and the 
host genome. 
To identify new Zta targets in both viral and human genes using existing 
methylome and transcriptome data. 
Question the relevance of ZREs in the human genome and investigate host 
proteins that may share regulatory mechanisms with Zta. 
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Chapter 2. Materials and Methods 
2.1 Materials 
Reagent Use Supplier 
Dimethyl sulfoxide (DMSO) Cell culture GIBCO 
Penicillin Strep Glutamine Cell culture GIBCO 
Fetal Calf Serum Cell Culture GIBCO 
DMEM/RPMI Cell culture GIBCO 
Anti IgG EBV lytic reactivation in 
cell culture Dako 
Acyclovir Inhibition of EBV 
replication Sigma 
EcoR1 10u/µl restriction enzyme digest Roche 
Buffer H (10X) restriction enzyme digest Roche 
Ethanol Ethanol extraction of DNA University Stores 
Phenol:chloroform:isoamyl 
alcohol (125:24:1) 
phenol-chloroform 
extraction of RNA Promega 
Isopropanol phenol-chloroform 
extraction of RNA Fisher 
[35S] Methionine Radiolabelling in vitro translated proteins Perkin Elmer 
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Stacking Buffer protein gels National Diagnostics 
Protogel (30%) 
37.5:1 
Acrylamide:Bisacrylamide 
protein gels National Diagnostics 
Protogel Buffer 
Stacking:    0.5M TrisHCl 
                    0.4% SDS 
                    pH 6.8 
Resolving: 1.5M Tris HCl 
                   0.384% SDS 
                   pH 8.8 
protein gels National Diagnostics 
10% w/v Ammonium 
Persulfate protein and EMSA gels Sigma 
Tetramethylethylenediamine 
(TEMED)  protein and EMSA gels Sigma 
Sample buffer, Laemmli 2X 
concentrate  loading protein gels Sigma 
AccuGel (40%) 
29:1 
Acrylamide:Bisacrylamide 
EMSA gels National Diagnostics 
Polynucleotide Kinase 
(PNK) 10u/µl 
radiolabelling 
oligonucleotides Roche 
10X Polynucleotide Kinase radiolabelling Roche 
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(PNK) buffer oligonucleotides 
[32P] γ ATP 3000mCi/mmol radiolabelling 
oligonucleotides Perkin Elmer 
G25 columns purifying radiolabelled 
oligonucleotides GE Healthcare 
5X EMSA binding buffer: 
     50mM Tris HCl 
     2.5mM MgCl2  
     2.5mM EDTA 
     2.5mM DTT 
     250mM NaCl 
     0.25µg/µl PolydI:dC 
     20% glycerol 
     pH 7.5 
EMSAs Promega 
M.SssI Methyltransferase In vitro DNA methylation New England Biolabs 
S-adenosylmethionine 
(SAM) In vitro DNA methylation 
New England 
Biolabs 
NEBuffer 2 (10X) 
50 mM NaCl 
10 mM Tris-HCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25°C 
In vitro DNA methylation New England Biolabs 
0.1M DTT EMSAs Sigma 
60 
 
 
Gel loading solution, Type 1  EMSAs Sigma 
Protein A sepharose beads Immunoprecipitation Sigma 
Protein G sepharose beads Immunoprecipitation Sigma 
anti-Zta antibody sc-17503 Immunoprecipitation Santa Cruz Biotechnology 
SensiMix SYBR QPCR Bioline 
Table 2.1: Reagents used and supplier 
Solutions Use Composition 
10X Tris-Glycine-SDS 
buffer 
Running buffer for 
SDS PAGE protein 
gels 
0.25M Tris base (Fisher) 
1.92M Glycine (Fisher) 
1% w/v SDS (Sigma) 
In water 
Fixing solution Fixing protein and 
EMSA gels 
10% v/v acetic acid 
(Fisher) 
20% v/v methanol (Fisher) 
In water 
10X TBE buffer Running buffer for 
DNA gels (1X) and 
EMSA gels (0.5X) 
0.89M Tris base (Fisher) 
0.89M Boric Acid (Acros 
Organics) 
0.025M EDTA (BDH) 
In water 
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pH 8.3 
TE Diluting and 
maintaining EMSA 
probes 
0.01M Tris-HCl 
0.001M EDTA (BDH) 
In water 
pH 7.5 
Nuclear Extract buffers   
Solution A  10mM Hepes pH 7.9  
10mM KCl  
1.5mM MgCl2   
0.1mM EGTA (chelating 
agent) 
0.5mM DTT (reducing 
agent) 
0.5mM PMSF (phenyl 
methane sulfoyl fluoride) 
(serine protease inhibitor) 
Solution C  10mM Hepes pH 7.9 
400mM NaCl 
1.5mM MgCl2 
0.1mM EGTA (chelating 
agent) 
0.5mM PMSF (phenyl 
methane sulfoyl fluoride) 
(serine protease inhibitor) 
5% Glycerol 
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ChIP buffers   
Cell lysis buffer 
 
 85mM KCl 
0.5% NP-40  
5mM PIPES pH 8.0 
1mM PMSF 
1 large protease inhibitor 
tablet per 50ml  
(Roche) 
In water 
SDS lysis buffer  1% SDS  
10 mM EDTA  
50 mM Tris pH 8.0 
1mM PMSF 
1 large protease inhibitor 
tablet per 50ml (Roche) 
In water 
IP Dilution Buffer   
 
 0.01% SDS  
1.1% Triton X-100 
1.2 mM EDTA 
16.7 mM Tris pH 8.0 
167 mM NaCl 
1mM PMSF 
1 large protease inhibitor 
tablet per 50ml (Roche) 
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In water 
Low salt wash buffer  
 
 0.1% SDS 
1% Triton X-100 
2 mM EDTA 
20 mM Tris pH 8.0 
150 mM NaCl  
In water 
High salt wash buffer    0.1% SDS 
1% Triton X-100 
2 mM EDTA 
20 mM Tris pH 8.0 
500 mM NaCl  
In water 
LiCl wash buffer  250 mM LiCl 
1% NP-40 
1% Na-deoxycholate 
1 mM EDTA 
10 mM Tris pH 8.0 
In water 
Elution buffer  0.01M Tris-HCl 
0.005M EDTA (BDH) 
pH 7.5  
1% SDS 
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In water 
 Table 2.2: Solutions used, their compositions and suppliers. 
Kit Use Supplier Components 
RiboMAX 
Large Scale 
RNA 
Production 
System SP6 
In vitro 
transcription Promega 
Enzyme mix (RNA Polymerase, 
Recombinant Rnasin 
Ribonuclease Inhibitor and 
Recombinant Inorganic 
Pyrophosphatase) 
Transcription 5X buffer 
100mM ATP, CTP, GTP, UTP  
RQ1 RNAse-Free DNAse 1u/µl 
3M Sodium Acetate (pH 5.2) 
Nuclease-Free water 
Wheat 
Germ 
Extract 
In vitro 
translation Promega 
Wheat Germ Extract 
1M Potassium Acetate 
1mM Amino Acid Mix minus 
Methionine 
1mM Amino Acid Mix minus 
Leucine 
1mM Amino Acid Mix minus 
Cysteine 
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Rabbit 
Reticulocyte 
Extract 
In Vitro 
translation 
 
Promega 
Rabbit Reticulocyte Extract 
Ribonuclease inhibitor (40U/µl) 
Nuclease-free water 
PCR 
purification 
Kit 
Purification 
of DNA 
from 
enzymatic 
reactions 
(post ChIP 
or 
methylation 
protocol) 
Qiagen PB, a high salt buffer 
PE, an ethanol containing wash 
buffer 
EB, a low salt elution buffer 
Table 2.3: Kits used, and their components. 
Vector Use Reference 
pSP64-Zta  In Vitro transcription (Hicks et al., 2003) 
pSP64-Zta C189S In Vitro transcription (Schelcher et al., 
2005) 
pSP64-Zta C189A In Vitro transcription (Karlsson et al., 
2008a) 
pSP64-Zta S186A In Vitro transcription (Karlsson et al., 
2008a) 
Table 2.4: Expression vectors used and source. 
Oligonucleotides were ordered from Invitrogen or Sigma. When indicated in the 
results text, specific CpG dinucleotides were methylated during synthesis by 
66 
 
 
Sigma. Alternatively, the oligonucleotides were methylated at all possible CpG 
dinucleotides using M.SssI methyltransferase, detailed in section 2.2.2.7. 
Name Sequence (5' - 3') Chapter 
RpZRE3 F GTTTATAGCATCGCGAATTTTGAGTGC 4,5,6 
RpZRE3 R GCACTCAAAATTCGCGATGCTATAAAC 4,5,6 
Z3CH8 F GCTTCCCGGCTCGCGAAAGGGAGGACC 4 
Z3CH8 R GGTCCTCCCTTTCGCGAGCCGGGAAGC 4 
HDAC2 F TCCCCCACTGTCGCGAAGCTCCCGCCC 4,6 
HDAC2 R GGGCGGGAGCTTCGCGACAGTGGGGGA 4,6 
XPC F GGTGCGTCACTCGCGAAGTGGAATTTG 4 
XPC R CAAATTCCACTTCGCGAGTGACGCACC 4 
MNT F CCGCGGCGTCTCGCGAAGGGAGGGGCG 4 
MNT R CGCCCCTCCCTTCGCGAGACGCCGCGG 4 
CyclinL2 F GGGCGGCTCCTCGCGAAGCTCCACGGC 4,6 
CyclinL2 R GCCGTGGAGCTTCGCGAGGAGCCGCCC 4,6 
CAPN2 F CCGGGGAGGCTCGCGAATCGCGGTCCA 4 
CAPN2 R TGGACCGCGATTCGCGAGCCTCCCCGG 4 
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CDO1 F CGTCCCAGCGTCGCGAACCACAGCGGC 4 
CDO1 R GCCGCTGTGGTTCGCGACGCTGGGACG 4 
FALZ F GGCGCGCAGCTCGCGAAATGCCCGGCG 4 
FALZ R CGCCGGGCATTTCGCGAGCTGCGCGCC 4 
KIF1B F GCTTCGGCCCTCGCGAAACTCCGCCCG 4 
KIF1B R CGGGCGGAGTTTCGCGAGGGCCGAAGC 4 
LLGL1 F TCGGCCGGGCTCGCGAAGGGACGCCCG 4 
LLGL1 R CGGGCGTCCCTTCGCGAGCCCGGCCGA 4 
LMO4 F GGATCCCGGGTCGCGAAGGGCAGCCCA 4 
LMO4 R TGGGCTGCCCTTCGCGACCCGGGATCC 4 
 MBD4 F CCTCCTGCTCTTCGCGAACCGCCCCGC 4 
MBD4 R GCGGGGCGGTTCGCGAAGAGCAGGAGG 4 
PLEKHJ1 F AGCCGCTCCCTCGCGAAAGTTGGCCCC 4 
PLEKHJ1 R GGGGCCAACTTTCGCGAGGGAGCGGCT 4 
PRKD1 F CTTCCTGGGGTCGCGAACTTCCCGGGC 4 
PRKD1 R GCCCGGGAAGTTCGCGACCCCAGGAAG 4 
SEC14L F CGCCCGCTACTCGCGAAGCCCAGCCCG 4 
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SEC14L R CGGGCTGGGCTTCGCGAGTAGCGGGCG 4 
 TADA3L F GCTGCGCTTCTCGCGAAAGGGCAGGCA  4 
TADA3L R TGCCTGCCCTTTCGCGAGAAGCGCAGC 4 
TOP2B F CCGCGCCCCATCGCGAAGATCCGGAGC 4 
TOP2B R GCTCCGGATCTTCGCGATGGGGCGCGG 4 
XPCLMNTR F GGTGCGTCACTCGCGAAGGGAGGGGCG 4 
XPCLMNTR R CGCCCCTCCCTTCGCGAGTGACGCACC 4 
MNTLXPCR F CCGCGGCGTCTCGCGAAGTGGAATTTG 4 
MNTLXPCR R CAAATTCCACTTCGCGAGACGCCGCGG 4 
XPC mut core F GGTGCGTCACCCCCTTAGTGGAATTTG 4 
XPC mut core R CAAATTCCACTAAGGGGGTGACGCACC 4 
XPC LM3 F GGTCCGCCTCTCGCGAAGTGGAATTTG 4 
XPC LM3 R CAAATTCCACTTCGCGAGAGGCGGACC 4 
XPC LM3 mut 
core F GGTCCGCCTCCCCCTTAGTGGAATTTG 4 
XPC LM3 mut 
core R CAAATTCCACTAAGGGGGAGGCGGACC 4 
AP1 mut F GATCCACCCCTTAGAGGAAAACATACG 4 
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AP1 mut R CGTATGTTTTCCTCTAAGGGGTGGATC 4 
RpZRE3LCyclinL
2R F GTTTATAGCATCGCGAAGCTCCACGGC 4 
RpZRE3LCyclinL
2R R GCCGTGGAGCTTCGCGATGCTATAAAC 4 
CyclinL2LRpZRE
3R F GGGCGGCTCCTCGCGAATTTTGAGTGC 4 
CyclinL2LRpZRE
3R R GCACTCAAAATTCGCGATGAGCCGCCC 4 
ATF3 F ATTAATAGCATTACGTCAGCCTGGGACT 4 
ATF3 R AGTCCCAGGCTGACGTAATGCTATTAAT 4 
PENK F GCGTAGGGCCTGCGTCAGCTGCAGCCC 4 
PENK R GGGCTGCAGCTGACGCAGGCCCTACGC 4 
FN F ACAGTCCCCCGTGACGTCACCCGGAGCCCG 4 
FN R CGGGCTCCGGGTGACGTCACGGGGGACTGT 4 
CpG5 1F CTCATAGGTCAGAGCGACATAGAGGCG 5 
CpG5 1R CGCCTCTATGTCGCTCTGACCTATGAG 5 
CpG5 2F AAGCGATGGCCGAGCGATGACTCGTGT 5 
CpG5 2R ACACGAGTCATCGCTCGGCCATCGCTT 5 
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CpG5 3F GCCGCCGCACTCAGCGAGGAGGCCTGC 5 
CpG5 3R GCAGGCCTCCTCGCTGAGTGCGGCGGC 5 
CpG5 4F TCCAGATGACTGAGCGCACGGCCTCAA 5 
CpG5 4R TTGAGGCCGTGCGCTCAGTCATCTGGA 5 
CpG5 5F CTTTGCGCTCTGCGCGAGGACGAGCTC 5 
CpG5 5R GAGCTCGTCCTCGCGCAGAGCGCAAAG 5 
CpG5 6F TTTCAAGTCGTGGGCGAATTAACTGAG 5 
CpG5 6R CTCAGTTAATTCGCCCACGACTTGAAA 5 
CpG5 7F TTGGAAAACATTAGCGACATTTACCTG 5 
CpG5 7R CAGGTAAATGTCGCTAATGTTTTCCAA 5 
CpG5 8F GCAGGGCCCCCGCGCGATCTAGGTAGG 5 
CpG5 8R CCTACCTAGATCGCGCGGGGGCCCTGC 5 
CpG5 9F CCAATGTCTGCGTGCGAGCCGGGCTTG 5 
CpG5 9R CAAGCCCGGCTCGCACGCAGACATTGG 5 
CpG5 10F CGAGGAGGCCTGCGCGTGTTCCTCAAC 5 
CpG5 10R GTTGAGGAACACGCGCAGGCCTCCTCG 5 
CpG5 11F AGCAAGGTGCTGGGCGTGGACCGCGCG 5 
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CpG5 11R CGCGCGGTCCACGCCCAGCACCTTGCT 5 
CpG5 12F TTTGGCGTCATGTGCGTCTGGATGACA 5 
CpG5 12R TGTCATCCAGACGCACATGACGCCAAA 5 
CpG5 13F CAGACTCTGGTTTGCGAGGCTGGGCGG 5 
CpG5 13R CCGCCCAGCCTCGCAAACCAGAGTCTG 5 
CpG5 14F AAAGATCTGGTTGGCGATCCGGTACAC 5 
CpG5 14R GTGTACCGGATCGCCAACCAGATCTTT 5 
Zp (-96) F TAAATTTAGGTGTGTCTATGAGGTACA 5 
Zp (-96) R TGTACCTCATAGACACACCTAAATTTA  5 
Rp (-204) & 
RpZRE2 F 
CATCTTGTCCTGTGATAAAATCGCTCATAAGC
TTAGT 5 
Rp (-204) & 
RpZRE2 R 
ACTAAGCTTATGAGCGATTTTATCACAGGACA
AGATG  5 
RpZRE2 F TGTGATAAAATCGCTCATAAGCTTAGT 5 
RpZRE2 R ACTAAGCTTATGAGCGATTTTATCACA  5 
Rp (-439 & -447) 
F 
ATGACTCGGGTGTGTCCTTGTGTGAGGTCTC
ACCTG 5 
Rp (-439 & -447) 
R 
CAGGTGAGACCTCACACAAGGACACACCCG
AGTCAT  5 
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Rp (-114) F CACTCATACTTAAGCGATGCTGATGCA 5 
Rp (-114) R TGCATCAGCATCGCTTAAGTATGAGTG  5 
BMRF1p (-173) 
F TGGGGGGTGGTGTGCCATACAAGGGAGC 5 
BMRF1p (-173) 
R GCTCCCTTGTATGGCACACCACCCCCCA 5 
BMRF1p (-248) 
F CCTTGGTGGATGTGCGAGCCATAAAGCA 5 
BMRF1p (-248) 
R TGCTTTATGGCTCGCACATCCACCAAGG  5 
BMRF1p (-148) 
F GTCATGTAGGTGAGCGGGCAGTCCTTG 5 
BMRF1p (-148) 
R CAAGGACTGCCCGCTCACCTACATGAC  5 
RpZRE3 m2 F GTTTATAGCATCGCGCTTTTTGAGTGC 6 
RpZRE3 m2 R GCACTCAAAAAGCGCGATGCTATAAAC 6 
RpZRE3mutcore 
F GTTTATAGCACCTTTTCTTTTGAGTGC 6 
RpZRE3mutcore 
R GCACTCAAAAGAAAAGGTGCTATAAAC 6 
Table 2.5: Oligonucleotides used in EMSAs. The core ZRE binding sequence is 
underlined. 
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Name Sequence (5' - 3') Code 
Absolute 
genomic position 
(Type 1) 
BKRF4 F CATTGCTCTCTGAGCGGTTA SR 109 98591-98611 
BKRF4 R ACCAGATGCTTCTTGGAGTTG SR 110 98688-98667 
BGLF4 F ACCGAGGCTCTTAGTTGCTG SR 111 111611-111631 
BGLF4 R GTTGCGGACATGGTGACTTA SR 112 111686-111666 
BTRF1 F AGCTACGCAATCGGAGTCA SR 113 126981-127000 
BTRF1 R GGAGGCGCAGTCTAGCAG SR 114 127052-127034 
Region with 
no ZREs F CCGCATGTCCAACCACCACG SR 7 139875-139895 
Region with 
no ZREs R ATGCTACCTAGGCCTGCGTCC SR 8 139997-139976 
Table 2.6: QPCR primers. 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Maintenance of cell lines 
Akata cells, an EBV positive Burkitt’s lymphoma tumour cell line (B cells), are 
suspension cells and are maintained in RPMI (Invitrogen). HEK293 cells, a 
human kidney epithelial cell line, are adherent cells and are maintained in 
DMEM (Invitrogen). The media is supplemented with 100U/ml of penicillin, 
100µg/ml of streptomycin and 2mM of L-glutamine, which was added from a 
pre-mixed solution PSG (Invitrogen). 10% (v/v) final volume Foetal Bovine 
Serum (FBS) (Invitrogen) was also added. 
The EBV within Akata cells can be induced into lytic cycle by cross-linking the B 
cell receptors using anti-IgG at a final concentration of 0.125% (v/v). 
Replication of viral genome can be inhibited by treatment with acyclovir. A 
100mM stock of acyclovir was made in DMSO. Akata cells were concentrated to 
2x106 cells per ml of media, and acyclovir was added to a final concentration of 
100µM. After 24 hours the cells were diluted to between 2-6x105 cells per ml, 
and an appropriate amount of acyclovir was added to maintain the 100µM 
concentration. After 48 hours, the cells were harvested. 
2.2.2 Nucleic Acids Methods 
2.2.2.1 Vector linearisation 
SP64 transcription vectors were prepared for use in the in vitro transcription 
assay by linearising with EcoRI restriction enzyme in the following manner: 
Plasmid DNA  20µg 
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10X Buffer H   5µl 
EcoR1   10µl 
Water    up to 50µl 
Incubate for 2 hours at 37°C.  
2.2.2.2 Ethanol Precipitation  
The linear DNA was purified by ethanol precipitation in the following manner. 
0.1X the total volume of 3M Sodium Acetate (pH 5.2) and 2.5X the total volume 
of cold ethanol were added, before centrifugation at 13,000rpm for 20 minutes 
at 4°C.  
The ethanol was replaced with 100µl 70% (v/v) ethanol. The solution was 
centrifuged at 13,000rpm for a further 10 minutes at 4°C, before the ethanol 
was removed, and the purified DNA resuspended in water to generate a final 
DNA concentration of approximately 1µg/µl.  
DNA is a polar molecule due to the charged phosphate backbone, and is 
dissolved in water, a polar molecule. Ethanol is less polar than water, and 
therefore allows the DNA to form stable ionic bonds and precipitate out of 
solution. The presence of positive ions, such as sodium, aids this process. 
Centrifugation allows collection of the precipitated DNA. The pellet is washed to 
remove leftover salt from the precipitation procedure, and then centrifuged to 
collect the pellet before resuspending in pure water. 
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 2.2.2.3 In Vitro Transcription 
10µg linear DNA was used for RNA synthesis using a Ribomax Large Scale 
RNA Production System Kit. 
Linear DNA     10µl (1µg/µl) 
rNTPs (25mM ATP,CTP,GTP,UTP) 20µl 
5X SP6 transcription buffer  20µl 
Nuclease free water    40µl 
SP6 RNA polymerase mix   10µl 
Incubate for 2 to 4 hours at 37°C, to allow transcription of RNA from the linear 
DNA template.  
10µl of RQ1 RNase free DNase (1u/µl) was added to the transcription mixture 
and incubated at 37°C for 15 minutes to digest the DNA template. 
2.2.2.4 Phenol Chloroform Extraction 
An equal volume of phenol:chloroform:isoamyl alcohol (125:24:1) was added to 
the mixture and vortexed for 1 minute, before centrifugation at 13,000rpm at 
room temperature for 2 minutes. Proteins are denatured by phenol and 
chloroform, whilst the nucleic acid remains in the aqueous phase. The upper 
aqueous phase was transferred to a fresh tube, and an equal volume of 
chloroform: isoamyl alcohol (24:1) was added and vortexed for 1 minute. This 
additional extraction is performed to reduce the loss of nucleic acids due to 
insoluble RNA:protein complexes that form at the interface between the organic 
and aqueous phases. This was centrifuged at 13,000rpm at room temperature 
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for 2 minutes. The upper aqueous phase was transferred to a fresh tube and 
0.1X the total volume of 3M Sodium Acetate and 1 volume isopropanol was 
added. The sample was placed on ice for 5 minutes, to precipitate the nucleic 
acid, before centrifugation at 13,000rpm at room temperature for 10 minutes. 
The supernatant was removed and the RNA pellet was washed carefully with 
1ml 70% (v/v) ethanol. The pellet was allowed to air dry and then resuspended 
in 100µl of water. The concentration was determined using UV absorbance, and 
stock RNA was diluted to 1µg/µl to be stored at -80°C.    
2.2.2.5 DNA purification using the Qiaquick PCR purification kit 
A Qiagen PCR purification kit was used to purify DNA sample after enzymatic 
reactions, such as methylation of oligonucleotides or proteinase K digestion. 
PB, a high salt buffer, was added to each sample, before applying the sample to 
the QIAQuick spin column. In the high salt conditions, DNA binds to the silica 
membrane of the column. The DNA was then washed with PE, an ethanol 
containing buffer, before the DNA was eluted using EB or water, where the low 
salt conditions allows the DNA to leave the membrane.  
2.2.2.6 QPCR 
Quantitative PCR is a technique used to assay relative amounts of specific 
regions of DNA in a sample. This was used to analysis the ChIP samples. 
Each reaction contained: 
SensiMix SYBR 12.5µl 
 Forward primer  2.5µl of 3µM primer, final concentration in reaction 0.3µM 
Reverse primer 2.5µl of 3µM primer, final concentration in reaction 0.3µM  
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Water   5.0µl 
Template DNA 2.5µl 
The samples were analysed using an Applied Biosystems 7500 real time PCR 
machine, and subjected to the following program:  
95°C  10 minutes 
95°C 15 seconds 
60°C 1 minute 
95°C 15 seconds 
60°C 1 minute  
95°C 15 seconds 
A series of dilutions of input control DNA (1/4, 1/16, 1/64 and 1/256) from Akata 
cells were used to create input standard curves for each primer set. Results 
were expressed as percentage input control. 
2.2.2.7 DNA methylation 
The enzyme M.SssI was used to methylate CpG dinucleotides in double 
stranded oligonucleotides for use in EMSAs or competition EMSAs. The 
following reagents were combined for each methylation reaction: 
33.3nM double stranded oligonucleotide/probe  10µl  
10X NEBuffer 2     2µl 
1600µM S-adenosylmethionine (SAM)  2µl 
40 cycles 
Disassociation curve  
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Water       5µl 
M.SssI Methyltransferase    1µl 
An equivalent mock reaction, replacing the enzyme with water, was performed 
as a control. 
The samples were mixed by pipetting and incubated at 37°C for at least 2 hours 
to allow the methylation reaction to take place. The samples were then 
incubated at 60°C for 20 minutes to inactivate the enzyme. To reanneal the 
oligonucleotides, the samples were incubated at 95°C for 2 minutes, 65°C for 
10 minutes, and 37°C for 30 minutes. Oligonucleotides/probes were then 
purified using the Qiaquick PCR purification kit. 
Methylation status can be checked using BstUI digestion in 
oligonucleotides/probes where the motif CGCG is present.  
2.2.3 Protein Methods 
2.2.3.1 In vitro translation 
Wheatgerm extract was used to express Zta and binding mutants C189S Zta, 
C189A Zta and S186A Zta. 
Wheatgerm extract    100µl 
Amino acid mix without methionine 16µl 
[35S]-methionine    1µl   
Potassium acetate    8µl 
RNA (1µg/µl)     10µl    
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This was incubated at 25°C for 2 hours.  
To allow comparable quantification of the different Zta proteins, [35S]-Methionine 
was added to the amino acid mix, radioactively labelling the proteins.  
2.2.3.2 Protein electrophoresis 
The in vitro translated proteins were resolved on a 15% protein gel, before 
quantitation of proteins using phosphor imaging and ImageQuant software. 
 15% polyacrylamide protein gels 
Stacking gel   
-      0.6ml stacking buffer 
-      0.6ml Protogel (30%) 37.5:1 acrylamide:bisacrylamide   
-      1.3ml water 
-      20µl 10% w/v Ammonium Persulfate  
-      2µl Tetramethylethylenediamine (TEMED)   
Resolving gel 
-      1.3ml Protogel buffer  
-      2.5ml Protogel (30%) 37.5:1 acrylamide:bisacrylamide  
-      1.2ml water 
-      20µl 10% w/v Ammonium Persulfate  
-      2µl Tetramethylethylenediamine (TEMED)  
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The gels were made using the BioRad Mini-PROTEAN 3 gel casting system. 
The resolving gel was poured into the mould to 1cm below where the bottom of 
the wells would be. 1ml of water was layered on top to ensure an even interface 
between the stacking and resolving gel. Once the resolving gel was set, the 
water was removed and the stacking gel added, into which the comb was 
inserted and allowed to set. 
2µl in vitro translated protein was added to 10µl Sample buffer, Laemmli 2X 
concentrate and heated to 95°C for 10 minutes to denature the proteins. These 
samples were loaded onto the gel and run for 50 minutes at 200 volts in 1X 
Tris-Glycine-SDS running buffer, in BioRad Mini-PROTEAN 3 apparatus. The 
gel was incubated at room temperature in fixing solution for at least 1 hour, 
before drying at 80°C for at least 1 hour under vacuum.  
2.2.3.3 Cell Extracts for EMSAs 
Cells were grown to 80% confluence before harvesting in PBS and subjected to 
centrifugation at 13,000rpm at 4°C for 5 minutes. The supernatant was 
removed, and the cell pellet was resuspended in 1 packed cell volume of 
solution A. The solution was allowed to swell on ice for 15 minutes. The cells 
were then lysed using a 25 gauge hypodermic needle, but preparing the 
chamber with solution A, before slowly drawing the cell suspension up into the 
chamber and quickly expelling it a total of five times. The cells were then 
subjected to centrifugation for at 13,000rpm at 4°C For 20 seconds. The 
supernatant is discarded at this point, and the cell pellet resuspended in 2 thirds 
of one packed cell volume. This was incubated at 4°C for 30 minutes with 
agitation. A final centrifugation step was performed at 13,000rpm at 4°C for 5 
82 
 
 
minutes. The supernatant was then collected to use as nuclear extract. 
(Protocol adapted from (Lee et al., 1988) ) 
2.2.4 Interaction Studies 
2.2.4.1 In Vitro: Electrophoretic Mobility Shift Assay (EMSAs) 
2.2.4.1.1 EMSA probe labelling 
To generate a binding site probe to use in the assay, the oligonucleotide 
required was labelled with [γ-32P]-ATP via a using polynucleotide kinase 
reaction on one strand before both strands were annealed together.  
Forward single strand oligonucleotide (10µM)  0.6µl  
10X PNK buffer       0.6µl 
[γ- 32P]- ATP 3000mCi/mmol (2X molar excess)  3.0µl 
PNK enzyme (u/µl)       0.3µl 
Water        1.5 µl (total volume 6 µl) 
The reagents above were combined and incubated at 37°C for 30 minutes to 
allow phosphorylation of the 5’ end of the forward oligonucleotide.  To inactivate 
the enzyme, the reaction was incubated at 65°C for 10 minutes. A 2X excess 
(1.2µl of 10µM) of the 10µM reverse strand oligonucleotide was added, and the 
mixture was then incubated at 95°C for 2 minutes to denature any secondary 
structure that may have formed within the single stranded forward strand. The 
temperature was then decreased to 65°C for 10 minutes and 37°C for 30 
minutes to allow annealing between the forward and the reverse strand. The 
sample was added to a G25 column (GE Healthcare), to remove any 
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unincorporated 32P γ ATP. TE was added to make a final volume of 180µl, and 
G25 columns (GE Healthcare) were used to purify to probe. The final 
concentration of the double stranded DNA probe was 33.3nM, and was stable 
for approximately 2 weeks. Where EMSAs are presented, they are 
representative of at least 2 experiments.  
 2.2.4.1.2 EMSA reaction 
A master mix was made so that per 10µl reaction the following components 
were present: 
5X EMSA binding buffer    2µl 
0.1M DTT      0.4µl 
Water       4.6µl  
To each reaction 2µl of Zta protein and 1µl of radioactively labelled probe were 
added, making a total reaction volume of 10µl. The mixture was incubated at 
room temperature for 30 minutes, and the 8% EMSA gel was pre-run for 30 
minutes at 100 volts in 0.5X TBE. 2µl gel loading solution (Type 1) (Sigma) was 
added to each reaction, and 10µl of this was loaded onto the gel, which was 
electrophoresed at 100 volts for 1 hour in 0.5X TBE, to separate free probe and 
probe complexed with protein. The gel was incubated for 1 hour in fixing 
solution and then dried under vacuum for 1 hour. The dried gel was then 
subjected to phosphor imaging for complex quantification. 
 2.2.4.1.3 EMSA gels 
8% acrylamide EMSA gels were made using the BioRad Mini-PROTEAN 3 gel 
casting system. Stock EMSA gel mix was made up in the following manner: 
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AccuGel (40%) 29:1 Acrylamide:Bisacrylamide 75ml 
10X TBE      25ml (0.5X final concentration) 
Water       300ml (final volume 500ml) 
200µl 10% (w/v) Ammonium Persulphate and 10µl Tetramethylethylenediamine 
(TEMED) was added to 6ml of the stock EMSA mix, mixed and immediately 
poured into the gel moulds. A comb was inserted and the gel was allowed to 
polymerise at room temperature. 
2.2.4.1.4 Preparation of double stranded competitors 
Equal quantities of each of the complementary oligonucleotides were added to 
an appropriate volume of TE and diluted to produce a solution of concentration 
3.33µM. This was incubated at 95°C for 2 minutes, 65°C for 10 minutes and 
37°C for 30 minutes. The labelled probe has a concentration of 33.3nM; 
therefore this competitor is 100 times the concentration of the probe.  
2.2.4.1.5 Competition EMSA 
A master mix was made in the same manner as previously detailed in 1.5. To 
each reaction 1µl of Zta protein, 1µl of the radioactively labelled probe and 1µl 
of a non-labelled double stranded DNA competitor, as described in 1.6, were 
added. This mixture was subjected to the same method as detailed in 1.5. 
 2.2.4.2 In Vivo Interaction studies: Chromatin Immunoprecipitation (ChIP) 
2.2.4.2.1 Chromatin Preparation 
After IgG treatment or an equivalent mock treatment, Akata cells were 
harvested at 48 hours post lytic induction. Formaldehyde was added, at a final 
concentration of 1%(v/v), and incubated at room temperature on a rocker for 10 
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minutes, to crosslink the proteins to the DNA within the cells. The reaction was 
then quenched with glycine, at a final concentration of 0.125M, and the cells 
pelleted by centrifugation at 13,000rpm at 4°C for 5 minutes. The cells were 
washed with DPBS twice, before a final centrifugation at 2000rpm at room 
temperature for 5 minutes. 
Chromatin was extracted by using 300µl of ChIP cell lysis buffer per 1x107 cells. 
This was incubated on ice 15 minutes, before centrifugation at 8,000 rpm at 4°C 
for 5 minutes. The supernatant was removed and the pellet was resuspended in 
200µl ChIP SDS lysis buffer per 1x107 cells. The sample is then sonicated to 
fragment the chromatin to between 200 and 600 basepairs in length. This was 
done on ice for 10 cycles of 10 second pulses, 30% output.  
2.2.4.2.2 Immunoprecipitation 
100µl of 50% bead slurry is required per immunoprecipitation. Protein A and 
Protein G beads were combined in a 1:1 ratio and washed 3 times with ChIP 
dilution buffer and centrifugation at 3000 rpm at 4°C for 5 minutes, and 
resuspended in ChIP dilution buffer. The beads were then preblocked by 
incubation with 55µl of 10mg/ml salmon sperm DNA per ml of 50% bead slurry, 
at 4°C with rotation for 30 minutes.  
The chromatin was diluted with ChIP dilution buffer 1:10. 1ml was taken for 
each immunoprecipitation and precleared by adding 40µl bead slurry and 
incubated at 4°C with rotation for 30 minutes. The samples were then 
centrifuged at 3000 rpm at 4°C for 5 minutes, and the supernatant was 
transferred to fresh tubes. 40µl was removed from each sample at this point 
(4% total volume) to use as input controls. 
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10µg of antibody were added to each sample and incubated at 4°C with rotation 
for at least 30 minutes. 55µl of beads to each sample and incubated at 4°C with 
rotation overnight. 
The beads were recovered by centrifugation at 3000 rpm at 4°C for 5 minutes. 
The beads were then washed in 4 different buffers at 4°C with rotation for 15 
minutes in the following order: 
ChIP low salt buffer 
ChIP high salt buffer 
ChIP LiCl buffer 
TE buffer 
150µl ChIP elution buffer was added to each sample and incubated at 65°C for 
20 minutes, agitating once to mix. This elutes the antibody-protein-DNA from 
the beads. The beads were pelleted by centrifugation at 3000 rpm at 4°C for 5 
minutes and the supernatant was transferred to new tubes. 150µl of elution 
buffer was also added to the input controls. All samples were then incubated at 
65°C overnight to reverse cross-linking.  
The samples were briefly centrifuged, before the addition of 45µg of proteinase 
K and 150µl of TE buffer to each tube and incubation at 50°C for 3 hours to 
degrade the protein.  
A Qiagen PCR purification kit was then used to purify the DNA sample. PB, a 
high salt buffer, was added to each sample, before applying the sample to the 
QIAQuick spin column. In the high salt conditions, DNA binds to the silica 
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membrane of the column. The DNA was then washed with PE, an ethanol 
containing buffer, before the DNA was eluted using EB or water, where the low 
salt conditions allows the DNA to leave the membrane.  
Serial 4 fold dilutions were then made using water in preparation for QPCR, as 
described in section. 
2.2.5 In silico methods 
2.2.5.1 Pattern Match 
E. Hellen (BSMS) wrote a perl program designed to search large amounts of 
genomic data for specific DNA sequences. The program was used on a Linux 
operating system to search 500 base pairs upstream of every human gene in 
ensembl build 49 for the characterised RpZRE3 sequence TCGCGAA. The 
output contains the ensembl accession code and the position offset of the ZRE. 
The pattern match search was developed and extended to include more 
sequences and rewritten in Java by D. Thomas (BSMS). This program 
searched 1000 basepairs upstream of every Havana annotated (protein coding) 
human gene in ensembl build 57, and also the entirety of the EBV genome 
(type 1). The Human herpesvirus 4 (Epstein-Barr virus) 
Genome NC_007605 was extracted from the NCBI in GenBank format. 
Features were extracted to create a table of gene locations within the genome. 
An experimentally verified list of 32 ZRE sequences, in forward and reverse 
complement form, were compared to the sequence and a table of matches 
produced. This data can be accessed through a website created in collaboration 
with D. Thomas at http://bioinf.biochem.sussex.ac.uk/EBV/.  
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2.2.5.2 Position Weight Matrices and Position Frequency Matrices 
Position weight matrices use position frequency data collated from a collection 
of a specific protein DNA binding sites to calculate log likelihoods and attempt to 
identify conserved residues within the binding site. These position weight 
matrices can be used to predict other sites where the protein of interest may 
bind. E.Hellen (BSMS) wrote a perl program, using TFBS perl modules, 
designed to use position weight matrix data to search gene promoters for likely 
binding sites. This was used to filter our data from the initial search, after the 
first 5 sites had been tested via EMSA.  
Position Weight Matrices use log likelihood values, whereas Position Frequency 
Matrices use absolute frequency values. Whilst using MatScan for ZRE 
prediction, the difference between PFM and PWM predictions was found to be 
negligible, and therefore PFMs were used.  
2.2.5.3 Sequence logo generation 
Weblogo, found at http://weblogo.berkeley.edu/, was used to generate 
sequence logos to represent position frequency matrices. 
2.2.5.4 GO term over-representation and CpG island analysis 
The GO terms associated with each gene were retrieved using BioMART and 
those annotations which were manually curated or experimentally verified were 
retained. The number of genes retrieved for each GO term was compared to the 
total number of genes in Ensembl with the same annotation. Terms which 
occurred with a higher frequency were retrieved, and genes that were not 
annotated with these over-represented terms were removed to reduce the 
number of candidate genes (E.Hellen, BSMS). 
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DAVID analysis (Huang da et al., 2009b, Huang da et al., 2009a) was also used 
for GO term overrepresentation. 
CpG island locations were predicted in the promoter sequences, using the 
EMBOSS program CpGPlot with the default settings: a window size of 100; a 
step of 1; a minimum average observed to expected ratio of C plus G to CpG in 
a set of 10 windows of 0.6; a minimum average percent of G plus C in a set of 
10 windows of 50% and a minimum length of 200 nucleotides. The positions of 
the predicted CpG islands were compared to the positions of the ZRE3 motifs to 
identify those ZRE3 motifs that fell within a CpG island (E.Hellen, BSMS). 
2.2.5.5 PROMO and MatScan prediction 
PROMO uses position frequency matrix data from version 8.3 of TRANSFAC, a 
database of transcription factor binding sites, to search the input DNA sequence 
for putative transcription factor binding sites. The settings can be adjusted to 
allow different extents of variability. The search options allow you to choose to 
search only human factors, selected species factors or all factors. The sites to 
be considered can also be specified; only human sites, selected species sites or 
all sites can be considered.  
MatScan is a linux-run program, similar to PROMO, with the ability to input your 
own position frequency matrix for your transcription factor of choice (Blanco et 
al., 2006).  
2.2.5.6 Comparing and aligning lists  
To identify genes which appeared in more than one list, the “match” function in 
Windows Excel 2007 was used. To align the lists, a macro was adapted from 
code written by Cy Bones at 
90 
 
 
http://www.neowin.net/forum/index.php?s=d3abcb574ea5c0136be1f5d321b32a
6f&showtopic=652034&pid=589603274&st=0&#entry589603274 (Accessed 
May 2009) 
 2.2.5.7 DAVID analysis 
The online software DAVID (Huang da et al., 2009b, Huang da et al., 2009a) 
was used to annotate gene lists, convert gene names from one nomenclature to 
others and to search for overrepresented annotations.
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Chapter 3: Methylation Sensitive ZREs in the human 
genome 
3.1. Introduction 
DNA methylation of the promoters of human genes is associated with the 
formation of heterochromatin, a structure of proteins and DNA that is repressive 
to transcription. Methylation occurs at CpG motifs, and is preserved throughout 
cell divisions, catalysed by DNA methyltransferases (DNMTs) (Sharma et al., 
2010). It creates a repressive chromatin environment by interfering with the 
protein:DNA interactions of transcription factors, such as c-myc (Prendergast 
and Ziff, 1991) and MLTF (Watt and Molloy, 1988), and by recruiting chromatin 
remodelling factors, for example HDACs, via methyl binding proteins like 
MeCP2 (Jones et al., 1998, Nan et al., 1998). The very presence of these 
methyl-binding proteins could also prevent transcription factor binding. Zta 
interacts with DNA directly through sequence-specific sites known as Zta 
Response Elements (ZREs), some of which contain CpG motifs. Zta has the 
unusual ability of interacting with methylated ZREs (Bhende et al., 2004). The 
different effects methylation has upon Zta:DNA binding, depending on the 
specific site, has led to the classification of ZREs (Karlsson et al., 2008b). Class 
III ZREs contain a CpG motif, and are recognised only when methylated. At the 
start of this project, three genes containing this class of ZREs were studied: 
EBV BRLF1 and BRRF1, and human Egr1. The methylation dependent 
regulation of BRLF1 is best characterised, and the interaction of Zta with a 
methylated ZRE was crucial to the reactivation of EBV into lytic cycle in B cells 
(Bhende et al., 2004, Bhende et al., 2005, Karlsson et al., 2008a). The BRLF1 
promoter, Rp, contains three ZREs, RpZRE1,2 and 3, two of which contain a 
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CpG motif. A single point mutation of Zta, C189S, was able to destroy the 
binding to methylated RpZRE3, but not to RpZRE1 or 2, allowing the specific 
activation of transcription through this methylated site to be confirmed (Karlsson 
et al., 2008a). The viral promoter of the early lytic viral gene BRRF1 contains 
two Class III ZREs, both allowing Zta to bind in their methylated form only 
(Dickerson et al., 2009). The discovery of ZREs in the promoter region of the 
human gene Egr1 which allowed Zta to successfully activate expression (Chang 
et al., 2006) quickly led to further investigation into the effect of CpG 
methylation on this binding, and confirmed methylation dependence (Heather et 
al., 2009). This suggested that Zta may play a further role in overturning the 
epigenetic silencing of host genes, in an attempt to modulate the host cell 
expression. 
In order to investigate the potential epigenetic overturn of silenced human 
genes by Zta, the RpZRE3 core sequence (TCGCGAA), which has most clearly 
been shown to be required for methylation dependent activation, was chosen to 
identify all human genes that contain an exact match of this site. This allowed 
identification of potential methylation dependent Zta responsive human genes. 
The effect of flanking sequence on methylation-dependent binding was 
questioned, and the utilisation of bioinformatic tools and techniques was 
required for candidate gene selection. Existing binding mutants were also 
tested, in an attempt to confirm previous findings in new flanking regions. 
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3.2. Results 
3.2.1 Identification of Human Promoters Containing RpZRE3-Core 
Elements: Initial Sampling 
Promoter regions (defined as −500 to +1 base pairs from the gene start site) of 
a sample of human protein-coding genes in Ensembl build 49 (Hubbard et al., 
2007) were extracted using the Biomart data management system (Haider et 
al., 2009). The sample represented 40% of the human genome. A search was 
made for all occurrences of an exact (forwards and reverse) match to identify 
those promoters with the TCGCGAA RpZRE3 core element (performed by E. 
Hellen, BSMS) 
The initial search for RpZRE3-core elements in a sample of human promoters 
revealed 67 genes with an RpZRE3-core element. Five of these that are 
involved in gene regulation were selected for DNA binding analysis. These five 
genes were Z3CH8 (ENSG00000144161), HDAC2 (ENSG00000196591), XPC 
(ENSG00000154767), MNT (ENSG00000070444) and CyclinL2 
(ENSG00000116148) and together with the RpZRE3 element from the 
viral BRLF1 promoter (Rp), formed the RpZRE3-promoter-6 data-set. 
DNA-binding assays were undertaken with the methylated forms of each of the 
five human promoters using 27mer double strand oligonucleotides 
encompassing the 7-nucleotide core element and 10-nucleotide flanking region 
on each side together with RpZRE3 from Rp. Electrophoretic mobility shift 
assays (EMSA) were undertaken with in vitro translated Zta protein. Zta 
protein/DNA complexes formed readily with the oligonucleotides from all six 
promoters (Figure 3.1). The specificity of the assay is shown by the lack of 
complex formation with non-programmed negative control protein (wheatgerm  
94 
 
 
 
 
Figure 3.1 Interaction of Zta with methylated RpZRE3 core element from five human 
promoters. 
A The nucleotide sequence of one strand of each oligonucleotide spanning the indicated 
ZREs is shown, with the conserved RpZRE3 core element (TCGCGAA) aligned. Double 
strand versions of these sequences were used as probes in EMSA, with the 2 cytosines 
within the CpG core motif methylated. The RpZRE3 from EBV BRLF1 promoter is 
included. This comprises the RpZRE3-promoter-6 data-set. B Double strand 
oligonucleotides were generated with the core ZRE sequence and at least 10 nucleotides 
of cognate sequence on either side. Following radiolabeling, these were incubated with in 
vitro translated Zta and subject to EMSA. The reactions contained no protein, 0, control 
lysate, C or Zta, Z. C Competition of each ZRE sequence (at 100X excess) against 
labelled RpZRE3 was determined by competition EMSAs. Data from at least 2 
experiments was taken to calculate competition i.e. the percentage of labelled probe 
displaced by unlabelled competitor. Methylated ZREs were used for both probe and 
competition. AP1 mut, an oligonucleotide previously shown not to interact with Zta was 
used as a negative control to define the level of non-specific binding. Error bars indicate 
standard error. 
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lysate without the addition of BZLF1 RNA). In addition, competition experiments 
were undertaken with an excess of unlabelled oligonucleotides and included a 
version with a mutant ZRE to further probe the specificity of the interaction. This 
confirms that Zta interacts with all six RpZRE3 core elements specifically. It also 
appears that flank may affect the strength of binding, but not specificity. 
3.2.2 Identification of Human Promoters Containing RpZRE3-Core 
Elements: Whole Genome Scanning 
An identical screen was undertaken on the entire human genome from Ensembl 
(50) (Flicek et al., 2008) resulting in the identification of 274 promoters which 
were designated the RpZRE3-promoter-274 data-set (See Appendix I). To 
assess whether there was an influence of flanking sequence on the interaction 
of Zta with these ZREs, selection of a sub-set of sites was required, so a 
systematic filtering process was undertaken with assistance from 
bioinformatician E. Hellen (BSMS), as outlined in Figure 3.2 A. The 7 
nucleotides of the RpZRE3 core element, along with 10 flanking nucleotides on 
each side, were extracted from each of the five genes from the initial sampling. 
The Transcription Factor Binding Site (TFBS) Perl modules (Lenhard and 
Wasserman, 2002) were used to create a Position Weight Matrix (PWM) based 
on the entire length of these 27-nucleotide sequences. TFBS Perl modules 
were also used to search the promoter regions (−500 to +1) of all human protein 
coding genes in Ensembl build 50 (Flicek et al., 2008) which were extracted 
using Biomart (Haider et al., 2009). Those promoters that matched the PWM 
with a threshold value >80% and contained an exact match to the RpZRE3-core 
element were additionally filtered using two criteria (a) the presence of CpG 
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Figure 3.2 Identification of human promoters containing RpZRE3 core elements in 
the human genome. 
A The bioinformatics analysis undertaken for the genome wide scan is represented as a 
flow diagram. Genetic input or output is represented by ovals, and filters by trapeziums. B 
A Position Weight Matrix (PWM) was created using the aligned sequences of the 
RpZRE3-promoter-6 data-set. These sequences are shown in figure 4.1A. This was used 
to filter the genomic data from the human promoter sequences (−500 to +1). C 
Overrepresented GO terms found for the 274 genes were identified. D The 13 genes 
identified as candidate genes, 12 previously unknown genes and 1 from the initial screen, 
and their associated Ensembl accession codes. 
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islands and (b) function (based on the over-representation of Gene Ontology 
(GO) terms (Ashburner et al., 2000)). The location of CpG islands were 
predicted using the EMBOSS program CpGPlot (Rice et al., 2000) with default 
options. Only genes with a CpG island present in the promoter were retained. 
The GO term annotations for molecular function and biological processes were 
extracted from Ensembl for each gene (Flicek et al., 2008). The number of 
genes in the RpZRE3 promoter dataset with each GO term annotation was 
compared with the total number of genes in Ensembl with the same GO term. 
The GO terms that occurred with a significantly higher frequency (p<0.05) in the 
RpZRE3 dataset, compared to entire genome, were defined as over-
represented. This resulted in 12 previously unidentified promoters and a further 
one that had been identified in the initial screen. Together with the promoters 
from the initial screen and the viral BRLF1 promoter (RpZRE3-promoter-6 data-
set), these form the RpZRE3-promoter-18 data-set. Oligonucleotides were 
designed using the same principles with 10 nucleotides of flanking sequence on 
each side of the RpZRE3-core element, and the ability of Zta to interact with 
each site in its methylated form was assessed. The EMSA analysis revealed 
that all twelve of the newly identified methylated ZREs were recognised by Zta 
(Figure 3.3). This analysis demonstrated that for the RpZRE3-promoter-18 data-
set, the flanking sequence surrounding the methylated core 7-mer element did 
not have a profound effect on the ability of Zta to interact with promoters and 
therefore the core element was sufficient to facilitate binding. This was 
illustrated by the generation of a PWM using sequence from the RpZRE3-
promoter-18 data-set (Figure 3.4), which revealed negligible sequence 
conservation outside of the core element. 
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Figure 3.3 Interaction of Zta with methylated RpZRE3s found in human promoters 
EMSA analysis with in vitro translated Zta protein (Z) or an unprogrammed translation lysate 
(C) with the probes indicated to the right of each gel was carried out as described in figure 3.1.  
 
Figure 3.4 Analysis of the RpZRE3 core element flanking sequence. 
A Position Weight Matrix (PWM), created using the probe sequences of the dataset RpZRE3-
promoter-18. 
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3.2.3 Recognition of the Non-Methylated RpZRE3-Core Elements 
Zta is able to recognise many response elements which do not contain a CpG 
motif and therefore do not have a methylated core element (Class I ZREs) 
(Sinclair, 2003) (Karlsson et al., 2008b). In addition, Zta recognises one CpG 
containing ZRE, RpZRE2, even in the absence of methylation (Class II 
ZREs) (Bhende et al., 2004). The ability of Zta to recognise the promoters in 
their non-methylated forms may impact on the ability of EBV to alter their gene 
expression, so the classification of ZRE for each of the 17 human promoters 
was investigated. 
A series of DNA binding experiments with the oligonucleotides representing the 
human promoters in the RpZRE3-promoter-18 data-set, were undertaken 
comparing non-methylated with methylated RpZRE3-core elements. The 
interaction of Zta with the sites was quantitative, as demonstrated by the 
reduction in complex formation as the Zta protein concentration was titrated on 
each of the methylated promoters (Figure 3.5). All bar one display negligible 
binding to the non-methylated oligonucleotides (at least 10-fold lower than to 
the methylated sites) and can therefore be classified as class III ZREs. 
Zta displayed a reproducible interaction with the non-methylated XPC 
oligonucleotide; the interaction reached 50% of the binding observed with the 
methylated oligonucleotide. This raises the possibility that the XPC core 
RpZRE3 element is influenced by the flanking sequence to behave as a class II 
ZRE. 
100 
 
 
 
101 
 
 
Figure 3.5 Comparison of Zta interaction with non-methylated and methylated 
RpZRE3s from human promoters. 
DNA binding analysis of in vitro translated Zta protein (Z) or an unprogrammed translation 
lysate (C) with both non-methylated and methylated versions of the probes indicated to the 
right of each gel was carried out by EMSA as previously described. A titration of Zta protein 
(1, 1:2, 1:4, 1:8) was used to compare non-methylated binding to that of the methylated 
equivalent. Quantitation of the complexes formed between Zta and the non-methylated and 
methylated probes, from at least two experiments, is represented as a histogram to the right 
of the corresponding gel. Complex formation is represented in the histograms  relative to the 
maximum binding for each probe. Error bars indicate standard error. 
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3.2.4 Analysis of Flank Contribution to ZRE classification 
To identify whether sequences conferring methylation independent recognition 
was confined to a specific flank of XPC, a series of mutant oligonucleotide 
probes that exchanged flanking sequences between XPC and a class III site 
(MNT), that is not recognised when non-methylated, were designed. Analysis of 
the interaction with Zta by EMSA revealed that the ability to confer Zta binding 
resided within the 5’ sequence of XPC; the hybrid XPCLMNTR was able to bind 
but MNTLXPCR was not (Figure 3.6 A). This suggested that the 5’ XPC flanking 
sequence of the RpZRE3-core element influenced binding. However, it was 
surprising to discover that mutation of the RpZRE3 core element within XPC did 
not prevent interaction with Zta (Figure 3.6 B). 
A further explanation for the interaction of Zta with the non-methylated XPC 
promoter is that an obscure ZRE is present in the 5’ flank. To address this 
further we attempted to identify putative ZREs in the XPC promoter using the 
transcription factor binding site prediction program PROMO (Farre et al., 2003, 
Messeguer et al., 2002). Although this program contains a PFM for Zta binding 
sites, none were predicted in this sequence. However, PROMO predicted the 
presence of AP1, c-fos and c-jun binding sites within the 5’ flank of XPC 
(5’TGCGTCA) (Figure 3.7). c-fos and c-jun proteins are both members of the 
bZIP transcription factor family; they form AP1 DNA binding activity as either 
homodimers or heterodimers. It is relevant that fos/jun dimers share some DNA 
recognition motifs with Zta (Sinclair, 2003, Farrell et al., 1989, Urier et al., 1989, 
Lieberman et al., 1990, Chang et al., 1990). 
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Figure 3.6 The effect of flanking region upon Zta binding to non-methylated XPC 
probe. 
A Schematic representation of the probes, illustrating the XPC and MNT probes, and the 
flank swap probes XPCLMNTR and MNTLXPCR, adjacent to the corresponding EMSA 
analysis, carried out in the same manner as described previously. Quantification of the 
complexes formed with each probe, from 2 experiments was undertaken. Complex formation 
is represented as a percentage of the Zta complex with the non-methylated XPC probe. Error 
bars indicate standard error. B Schematic representation of probes, indicating mutated core 
sequence. EMSA analysis was carried out as described previously. Quantitation of the 
complexes formed with each probe, from two experiments was undertaken. Complex 
formation is represented as a percentage of the Zta complex formed with the non-methylated 
XPC probe. Error bars indicate standard error. 
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  Figure 3.7 Uncovering an additional ZRE in the 5′ flank of the XPC probe. 
A PROMO transcription factor binding site prediction identified an AP1 site which is 
highlighted in the 5′ flank sequence of XPC. Percentage values represent dissimilarity score 
from prediction PWM for each respective site/transcription factor. B The specific nucleotide 
mutations are underlined. The complexes formed by EMSA are shown to the right of the 
corresponding probe sequence. Quantitation of the complexes formed with each probe, from 
2 experiments, was undertaken. Complex formation is represented as a percentage of the 
Zta complex formed with the XPC mutated core probe. Error bars indicate standard error. 
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This led to the hypothesis that the predicted AP1 site in the 5’ flanking 
sequence is an additional ZRE that is responsible for binding to the non-
methylated XPC oligonucleotide. To test the hypothesis, further mutations were 
introduced into the 5’ XPC flanking sequence in the predicted AP1 site 
(5’TCCGCCT). The ability of Zta to interact with the double AP1/core mutant 
site (XPCLM3Mcore) was compared with the core-only mutant. Dual mutation of 
the predicted AP1 site and the core abrogated the ability of Zta to interact with 
the XPC oligonucleotide, demonstrating that binding of Zta to the non-
methylated XPC site resided with this AP1 site (Figure 3.7).  
To confirm the methylation dependent binding of Zta to the core RpZRE3 core 
in the XPC flanking environment, the novel ZRE (predicted AP1 site) was 
mutated to abolish binding through this site (Figure 3.8A). The oligonucleotide 
underwent an in vitro methylation using M.SssI, or an equivalent mock reaction 
(Figure 3.8B) and was subjected to EMSA. Significant complex formation 
occurred with the methylated oligonucleotide only (Figure 3.8C).  
This analysis showed that the RpZRE3 core element is not recognised in its 
non-methylated state in the context of any of the viral or cellular promoters in 
the RpZRE3-promoter-18 data-set, and that this ZRE is specifically recognised 
when methylated. Further investigation into this additional site, a novel Zta 
binding sequence, will be returned to later in this chapter, in sections 3.2.6 and 
3.2.7. 
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  Figure 3.8 Confirmation of methylation dependent binding of core RpZRE3 element. 
A Flow diagram of in vitro methylation method. Single stranded forward oligonucleotide was 
labelled with P32 by polynucleotide kinase (PNK), before annealing to the corresponding 
reverse oligonucleotide. Radioactive probes were then subjected to a methylation reaction 
using M.SssI and S-Adenosyl methionine (SAM), modifying every cytosine in a CpG motif. 
An equivalent mock reaction, performed without the M.SssI, was performed as a control for 
each oligonucleotide. B Oligonucleotide XPC LM3. Contains the core RpZRE3 element in the 
XPC cognate sequence, with the novel ZRE discovered in the left flank mutated to a non-
binding sequence. C In vitro translated Zta was incubated with XPC LM3 oligonucleotide 
which has undergone either a methylation reaction or an equivalent mock reaction.  
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3.2.5 Data comparison 
RpZRE3-promoter-274 data-set provides a list of human genes which contain 
an RpZRE3-core element in their immediate promoter region, defined as -500 to 
+1 of each gene start. The question remains whether these sites provide 
functional response elements for Zta, and under what conditions. A microarray 
performed in 2006 (Yuan et al., 2006) in Akata cells, an EBV positive B cell line 
which can be activated into lytic cycle by cross-linking with IgG (Takada, 1984), 
provided a list of 122 human genes affected at least 2 fold by lytic cycle 
activation compared to EBV negative cells cross-linked in the same manner. 
This list was compared with the RpZRE3-promoter-274 data-set, and only 2 
genes were found to match: LMO4 and CEP250. LMO4 is a transcriptional 
activator over expressed in approximately half of primary breast cancer cases, 
and high expression is associated with poor prognosis (Sum et al., 2005). 
CEP250 (also known as CEP2) is a core centrosomal protein important in cell 
cycle progression, as it is required for centriole-centriole cohesion during 
interphase (Mack et al., 2000). 
Yuan states that LMO4 is significantly downregulated 24-48 hours post lytic 
induction. However, upon further investigation of the heatmap representation of 
the expression data (Figure 3.9), it appears that upregulation occurs at 8-12 
hours, and that downregulation is prevented at 4 hours.   
No statement is made about CEP250 in the text. However it can be seen from 
the heatmap that downregulation at 4-12 hours appears to be prevented by the 
presence of EBV, and at 8-12 hours it is upregulated compared to expression in 
EBV negative cells upon anti-IgG treatment.  
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The RpZRE3-promoter-274 data-set was also compared to smaller subset of 
genes from another microarray (Broderick et al., 2009a); in this study, the genes 
were identified as being differentially regulated 6 hours after the induction of 
lytic cycle in Akata cells; however no matches were found.  
Zta could therefore potentially play a role in the regulation of these 2 genes. 
However, it is important to consider whether these genes are methylated, as the 
presence of an RpZRE3-core element alone is not enough for Zta to bind; the 
CpG motif must be methylated. 3 datasets of methylome data were obtained. 
The first was published in 2009 (Rauch et al., 2009) from which a list of 
methylated promoters in circulating CD19+ B cells was produced. This was 
produced using a technique known as MIRA-ChIP, (Methylated CpG Island 
Recovery Assay Chromatin Immunoprecipitation). This uses GST-tagged 
MBD2b protein and His-tagged MBD3L1 protein to form a high affinity 
methylated DNA binding complex in order to enrich for methylated DNA, which 
can then be eluted, and subjected to standard microarray hybridisation 
techniques. The tiling arrays contained DNA probes 50-75 bps long and median 
probe spacing was 100bp. 
Figure 3.9 Expression profile of LMO4 and CEP250.  
Cropped from Yuan et al, 2006 heatmap, expression patterns of human genes containing 
core RpZRE3 elements in their promoter region.  The colour scale represents expression 
levels relative to time zero. Green indicates relative down-regulation, red indicates relative 
up-regulation, black indicates no change. mRNA expression was measured in Yuan et al 
from 3 independent experiments. 
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In addition, methylome data was explored from germinal centre B cells, and 
LCLs which were generated by infecting the germinal centre B cells with EBV 
(Leonard et al., 2011). This data was generated using a MeIP approach, in 
which antibodies for methylated CpGs are used to enrich for the methylated 
DNA, which are then hybridised to tiling microarrays. From this, methylated 
promoter lists were produced, and compared to the RpZRE3-promoter-274 
dataset (which had to first be converted from Ensembl code to HGDC gene 
name), using macro-enabled Excel. (Table 3.1) A total of 90 of the promoter 
regions containing RpZRE3s (RpZRE3-promoter-274 data-set) were found to 
be methylated in at least one cell type, 44 in at least two cell types, and eight in 
all three cell types (Figure 3.10). CEP250 was found to be methylated in all 
three B cell types, whereas LMO4 was found to be methylated in circulating 
CD19+ B cells. Therefore both genes are regulated in EBV lytic cycle, contain a 
methylation dependent ZRE in their promoter region, and these promoters are 
known to be methylated in at least one B cell type.  
 
  
Figure 3.10 Gene promoters containing RpZRE3 core sequences and methylated in at 
least one of three cell types.  
A Euler diagram was constructed from comparison of gene lists containing RpZRE3 core 
elements and methylated genes in differing B cell types. Full data is shown in table 3.1.  
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Table 3.1 Methylation status of human genes containing RpZRE3 core sequences in the 
promoter region in three different B Cell backgrounds.  
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3.2.6 Novel CpG-containing ZREs  
The novel ZRE discovered in the flank of XPC RpZRE3 oligonucleotide in 
section 3.2.4 contained a CpG motif within the core sequence, which suggests 
the potential of methylation dependent regulation of binding. Further research 
into this site, using the TRANSFAC database (Matys et al., 2006) revealed that 
it matched a confirmed binding site of c-jun, in the promoter region of PENK 
known as ENKCRE-2 (Mar et al., 1992). c-jun is an important human 
transcription factor, and like Zta, a member of the bZIP family of transcription 
factors due to the characteristic leucine zipper region. c-jun can form 
homodimers, and, more often, heterodimers with other members of the bZIP 
family such as c-fos, ATF2 etc. (Shaulian and Karin, 2001). The methylation of 
the PENK promoter region by HpaII (CmCGG) was shown to inhibit AP2 binding 
to another site in the promoter, however the other CpG containing sites 
(ENKCRE1 and 2) were not investigated specifically (Comb and Goodman, 
1990). Two further sequences were identified as c-jun binding sites that 
contained a CpG motif in the same position of the core sequence; these were 
found in the promoter regions of ATF3 (Liang et al., 1996) and FN (Shino et al., 
1997).  
Oligonucleotide probes were generated for use in EMSAs to question binding of 
Zta to these AP1 response elements, alongside the XPC mut core probe from 
section 3.2.4. All new sites formed complexes at a comparable affinity to XPC 
mut core probe, with the exception of FN, which although forming a distinct 
band, was much weaker (Figure 3.11). 
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3.2.7 Methylation Independent Binding of Novel CpG-Containing ZREs 
The 4 new AP1-like ZREs were subjected to the same methylation treatment as 
described in Figure 3.8, and subjected to EMSA (Figure 3.12). No significant 
increase in complex formation can be observed in the methylated form for any 
of the sequences. It appears that the methylation of this CpG-motif within the 
AP1-like ZREs has minimal effect on the binding affinity of Zta. This classifies 
the novel sites as Class II sites.  
Figure 3.11 AP1-like CpG containing core sequences. 
A Oligonucleotides with AP1-like CpG containing sites and natural flanking sequence. B In vitro 
translated Zta was incubated in a standard EMSA reaction with each of the oligonucleotides 
listed in A, compared to RpZRE3 unmethylated and methylated. Quantitation was performed 
relative to Zta:RpZRE3meth complex. 
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3.2.8 Unexpected effect of known binding mutants  
The C189 residue of Zta has been shown to be required for binding to 
methylated RpZRE3, and the mutant C189S was shown to bind less than 10% 
the efficiency of wild type Zta. Combined C189A and S186A mutations ablated 
complex formation completely (Karlsson et al., 2008a). However, it was found 
that Zta C189S was not deficient in binding to methylated sites in the Nap 
(Dickerson et al., 2009). The S186A mutant has been shown to bind to some 
ZREs, such as those found in the promoter of BMRF1 (Adamson et al., 2000, 
Francis et al., 1999), but not all, for example ZREs found in the promoter of 
Figure 3.12 Methylation of AP1 like CpG containing ZREs appears to have a nominal 
effect. 
In vitro translated Zta was incubated with oligonucleotides which had either undergone a 
methylation reaction using M.SssI or an equivalent mock reaction (as previously described 
in figure 4.8), and binding was assessed. Oligonucleotides used previously in Figure 4.7 
and new oligonucleotides containing the AP1 like ZREs were assessed to question the 
methylation independence of the XPC flank site, and quantitation verifies this. Each was 
quantified separately, relative to each oligonucleotide which underwent the methylation 
reaction. 
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BRLF1 (Bhende et al., 2005). To question whether the effect of each of these 
binding mutants was context independent, EMSAs were performed on the 
RpZRE3-promoter-6 data-set, identified at the beginning of this chapter. All the 
Zta mutants had compromised binding ability to methylated RpZRE3, matching 
previous observations. However, the impaired ability of C189S to bind was not 
as pronounced as previously published, showing a 50% reduction in binding 
(Figure 3.13C). C189A was incapable of binding to the RpZRE3-promoter-6 
data-set, confirming that C189 or S189 is absolutely required for DNA binding. 
S186A was also incapable of binding to all but one oligonucleotide, XPC. This is 
most likely explained by the presence of the AP1-like site in the flank, as the Zta 
mutant S186A can interact with some ZREs, and other bZIP proteins with 
alanine in the equivalent position of S186 in their DNA binding domain can still 
interact with their respective sites. C189S however, has a greater affinity than 
wild type Zta for each of the new sites.  
There are several possibilities as to the increased binding affinity of C189S to 
these sites. Perhaps there is some flanking effect in these oligonucleotides that 
is not present in the RpZRE3 oligonucleotide, or vice versa, whether it is a 
separate site, a general environment effect, or a specific residue. Apart from 
XPC, none contain an alternative ZRE-like sequence in the flank when analysed 
by PROMO, ruling out the possibility of a separate site. The sequences of 
several of the sites that Zta binds to were aligned in an attempt to discover if 
there was an affect of the flank on C189S binding, and a sequence logo was 
created to represent these sequences, to allow comparison with the RpZRE3 
sequence (Figure 3.14). RpZRE3 is particularly A:T rich in the 3’ (right) flank  
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Figure 3.13 Unexpected binding with known DNA binding mutants of Zta. 
A. Zta wild type, plus 3 binding mutants (C189S, C189A, S186A) were in vitro translated 
and run on a protein gel to ensure they were of comparable concentration. This was 
quantitated in B. C. In vitro translated protein was incubated with pre-methylated 
oligonucleotides (Sigma) or equivalent unmethylated probes, encompassing the core 
RpZRE3 sequence and the flanking region. Quantitation is shown adjacent from each 
EMSA. Wild type Zta with each site in the methylated state is set as 100%, and all other 
quantitation in each separate EMSA is relative to this. 
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directly adjacent to the core site, and also in the left flank further away, 
compared to the sequence logo composite of the other sites in which C189S 
has been observed not to serve to ablate binding. The crystal structure of Zta 
bound to an AP1 site, solved using the C189S mutant, suggests a contact 
between S189 and the phosphate backbone between -3 and -4 positions of the 
centre of the ZRE. This is between the outermost residue of the ZRE, and the 
Figure 3.14 Flanking sequence may affect Zta mutant binding to core site.  
A The RpZRE3 oligonucleotide sequence, a sequence logo to represent other methylation 
dependent binding sites and the flanking regions, and the frequency table used to create the 
sequence logo. B From Petosa et al, 2006, the proposed crystal model of Zta binding to an 
AP1 site, with mutation C189S in place, and from Karlsson et al 2008, the proposed model for 
RpZRE3 core methylated binding. 
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first flanking nucleotide. A change in this nucleotide may have the potential to 
affect binding ability, based upon the proximity. However, the model produced 
for Zta binding to methylated RpZRE3 suggests that C189 is required for 
binding to the methyl-group on CpG motif 1 in the methylated state. Perhaps 
C189 binds to this methylated group if present, but binds to the phosphate 
backbone if not. Replacing cysteine with serine would be expected to cause a 
reduced binding ability, due to the lack of a methyl group, and therefore less 
binding overall, however some flanking residues may provide a more attractive 
binding position, stabilising the interaction without direct interaction with the 
methylated residue. However, C189S did not bind significantly to the 
unmethylated version of these oligonucleotides either.  
In an attempt to elucidate the flank affect on binding, oligonucleotides were 
designed in which the left and right flanks of RpZRE3 and CyclinL2 were 
swapped. 
Newly synthesised Zta protein was tested on the pre-methylated probes of 
RpZRE3 and CyclinL2 (Figure 3.15). The previously observed difference in 
binding between wild type and C189S was not as clear in these EMSAs, 
however it still appeared that C189S bound with a greater affinity to CyclinL2 
(Figure 3.15C).  The new oligonucleotides testing the effect of flank on Zta 
binding required in vitro methylation; the C189S effect so far had only been 
seen using pre-methylated probes direct from Sigma, therefore RpZRE3 and 
CyclinL2 were methylated in vitro alongside the flank swaps as a control (Figure 
3.16). Surprisingly, the binding to C189S was not more than wild type. The flank 
swap EMSAs appeared to show a small affect of flank on the binding ability,  
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Figure 3.15 Reproduction of C189S increased binding ability is difficult 
A new batch of protein synthesised in the presence of S35  methionine and quantified in B 
relative to C189A.C 2 representative EMSAs, to show the reproducibility issues. EMSAs 
were carried out as previously described with Sigma methylated probes. D Quantitation 
relative to wild type Zta complex with oligonucleotide. 
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Figure 3.16 Flank affect on C189S binding deficiency in RpZRE3 oligonucleotide  
appears to reside in the right flank 
A Schematic representation of the probes, illustrating the RpZRE3 and CyclinL2 probes, and 
the flank swaps. B EMSA reactions were carried out as previously described with in vitro 
methylated probes or probes that had undergone an equivalent mock reaction, as previously 
described. Adjacent is quantitation of complex formation, relative to wild type Zta complexed 
with methylated  oligonucleotide. 
120 
 
 
with the oligonucleotide containing the right flank of RpZRE3 returning the 
C189S deficient binding behaviour (Figure 3.16). In order to address the 
apparent inconsistencies of the binding complex, the reaction conditions were 
examined. An important aspect of Zta interaction with DNA is that it appears to 
be required to be reduced, and therefore DTT is added to the reaction (the 
amount of DTT found in the binding buffer is not sufficient). DTT is labile, but 
can be stored for long periods of time at -20°C. All EMSAs had been performed 
using fresh dilutions from a number of stock 1M DTT tubes, all made in 2007. 
This stock DTT was tested against a new stock of DTT to establish whether this 
would affect the apparent difference in binding between Zta wild type and 
C189S (Figure 3.17).  
 
 
 
Figure 3.17 Concentration of DTT in the reaction affects relative binding of C189S 
Zta compared to wild type.  
A In vitro translated Zta was incubated with labelled RpZRE3 probe with differing stocks or 
concentrations of DTT. B Quantitation of complex formed is relative to wild type:probe 
complex for each different DTT condition, to allow C189S comparison. 
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An increase in DTT, whether due to the fresh stock or the increased amount, 
increased the binding ability of the wild type protein. This increases the 
difference between wild type Zta DNA binding and Zta C189S DNA binding. 
This can be explained by the fact that this mutant has lost the cysteine at which 
disulphide bonds can form, therefore the increase in DTT affects the complex 
formation less than the wild type.  However, the observable difference in 
complex formation between wild type Zta and the C189S mutant was not as 
considerable as previously observed (Karlsson et al., 2008a). The error bars are 
large, indicating inconsistency, and reproduction of the effect was very difficult.  
All EMSAs so far have been performed with Zta protein in vitro translated using 
wheatgerm extract. Where C189S mutation was shown to have the greatest 
affect on binding the protein was expressed using rabbit reticulate lysate 
(Karlsson et al., 2008a). Different translation conditions could affect the 
oxidation state of the protein overall, so the EMSAs were repeated with proteins 
expressed using the rabbit reticulate lysate system (Figure 3.18). The binding of 
the probes tested to C189S appeared to almost completely ablated, and the 
binding appeared more consistent. Therefore when the conditions are right for 
wild type Zta to bind maximally, C189S has a reduced not enhanced binding 
ability. The phenotype in vivo is still unclear and which translation system best 
represents in vivo conditions is unknown.  
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Figure 3.18 Translation system affects relative binding of C189S Zta compared to 
wild type, in a similar manner to DTT concentration. 
A Zta in vitro translated in the rabbit reticulate lysate system was incubated with 
labelled oligonucleotide probes in standard EMSA conditions as previously described. 
B Quantitation of complex formed is relative to wild type Zta:probe complex for each 
separate probe used. 
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3.3. Discussion 
A computational search revealed a set of 274 human genes with cellular 
promoters containing the 7-mer RpZRE3 core element. Flanking sequence can 
influence the interaction of some transcription factors with DNA; for example, 
the interaction of the E2F family with DNA is influenced by a region of at least 8 
nucleotides 5’ and 11 nucleotides 3’ to the central nucleotide (Tao et al., 1997). 
Before assigning all 274 genes as candidates for regulation by Zta, it was 
important to assess whether the cognate flanking sequence had a profound 
effect on binding by Zta. Consideration of the sequences represented in the 
flanking sequence of this set of genes revealed it to be diverse; all four 
nucleotides were represented in 55% of positions and three of the four 
nucleotides were represented at the remaining positions. Indeed, the immediate 
flank of the RpZRE3 core element, consisting of four nucleotides both 5’ and 3’, 
had 100% representation of all four nucleotides. It can therefore be concluded 
that the flanking sequence does not prevent binding to the methylated RpZRE3 
core, and a sequence logo generated from a PWM of the RpZRE3-promoter-18 
data-set showed little conservation outside the core motif. In contrast, the 
interaction with the non-methylated core element initially appeared to be 
influenced by flanking sequence in only one of the 18 promoters. However, 
further analysis revealed this to be due to the presence of a second ZRE in the 
flanking sequence. 
These results show that the approach of undertaking a computational pattern 
match search for the 7-mer RpZRE3 core element is a fast and reliable method 
to identify promoters containing ZREs that are recognized by Zta only when 
they are methylated (class III ZREs). 
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The identification of two adjacent juxtaposed ZREs in the XPC promoter 
presents an interesting problem; can both sites be occupied at once? The 
natural juxtaposition of ZREs has been previously described for a viral 
promoter, BZLF1 and a cellular promoter, Egr1. In the BZLF1 promoter, the 
elements are situated with 12 base pairs between the central nucleotides; both 
can be occupied simultaneously and both are functionally relevant (Flemington 
and Speck, 1990a, Urier et al., 1989, Lieberman et al., 1990). For 
the Egr1 promoter, the elements are immediately adjacent with just 8 
nucleotides between the central nucleotides (Chang et al., 2006, Heather et al., 
2009). There is no evidence for simultaneous occupation by Zta and only one 
element appears to be functional in vivo (Heather et al., 2009). The 
arrangement of the XPC promoter places the centre of the elements 8 
nucleotides apart, identical to Egr1, and there is no evidence from the DNA-
binding experiments for simultaneous occupation of the sites. As one ZRE is 
recognised in a methylation-dependent manner and the other is recognised 
when non-methylated, it is possible that the arrangement may provide a fail-
safe mechanism to ensure that the gene is regulated in both its methylated and 
non-methylated states, more likely by a host regulatory factor, the mechanism 
of which could be taken advantage of by Zta. 
The simple computational approach taken to identify the location of this 
methylation-dependent and novel DNA-binding motif in human gene promoters 
identified 274 genes potentially regulated by overcoming epigenetic silencing 
during the viral replicative cycle. Given the known functions of Zta in 
reprogramming viral gene expression, disrupting cell cycle control and 
replicating viral DNA, it is interesting to note that the Gene Ontology terms that 
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are over-represented in the RpZRE3-promoter-274 gene-set are largely 
involved in transcription, chromatin re-modelling and mitosis. This strongly 
suggests that Zta may activate this set of cellular genes in order to accomplish 
these functions. Testing whether these genes are activated during latency 
disruption in memory B-lymphocytes in vivo is technically challenging given both 
the scarcity of memory B-lymphocytes in peripheral circulation and the 
infrequency of latency disruption in vivo. 
The co-location of the RpZRE3 core element in 274 human promoters is 
unlikely to have been driven by an evolutionary advantage to the virus, but may 
reflect the involvement of a cellular transcription factor interacting with the same 
element. This would suggest that this set of genes share a common mode of 
regulation during human development or differentiation. Furthermore, it would 
be interesting to question whether co-occurrence of the RpZRE3-core element 
with other transcription factor binding sites forming a co-operative cis-regulator 
module which may illuminate the regulation of these host and viral genes. 
The identification of a novel ZRE in the flank of one of the RpZRE3 core 
sequence sites led to further investigation regarding the nature of this site, and 
others like it. Through the TRANSFAC database, it was found to match exactly 
that of an AP1 site found in the promoter of PENK, and the presence of a CpG 
motif opened the possibility of an effect by methylation status. Other AP1 sites 
were identified with a CpG motif in the same position of the site, and these also 
became binding candidates for Zta. All sites were found to bind in vitro in a 
methylation independent manner to varying degrees. It is interesting to consider 
how methylation of a CpG motif in one sequence can have such a profound 
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effect, whereas the methylation of a CpG motif in a displaced by one nucleotide 
position within the site has almost none.  
C189S is an interesting Zta mutant, as it appears to play a role in methylation 
dependent binding, and has been successfully used to show the importance of 
methylation dependent activation of the BRLF1 promoter through RpZRE3 
(Karlsson et al., 2008a). C189 regulates the redox-sensitivity of DNA-binding 
activity (Wang et al., 2005). Therefore it was valuable to check how it interacted 
with the new pattern match sites, to ascertain whether flank has any role to play 
in binding behaviour of this mutant. The result was surprising, and ultimately 
unclear. Initially it suggested that the effect of the mutation was reversed; that 
the replacement of cysteine with serine actually made complex formation 
stronger with the new RpZRE3 core sequences. However, this only applied to 
the new sites, as RpZRE3 probe had reduced binding with C189S, although the 
extent to which the binding was reduced (approx. 50%) was not as much as 
previously observed (<10%). There was also discrepancy between probes that 
were methylated in different ways; initially all probes were synthesised by 
Sigma in the methylated state, however when more probes were required with 
very slight differences, in vitro methylation with M.SssI was used. When the 
binding of wild type and C189S mutant Zta protein was investigated to these 
different sets of probes, more conflicting evidence emerged. The DTT 
concentration seems to play an important role in consistent EMSA complex 
formation, and this could go a long way to explaining some of the 
inconsistencies observed. Another element to consider is the different 
translation systems, and the possibility of Zta protein being more reduced when 
made in rabbit reticulate lysate compared to wheatgerm. C189S is less affected 
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by the reduction state due to the loss of cysteine, therefore it is hypothesised 
that this binding would remain more constant, whereas the increase in DTT 
would cause wild type Zta increased reduction, and therefore greater binding 
affinity. The poor reproducibility of these results indicates that more factors are 
at work than were controlled for. To fully investigate this issue, the assays 
would need to be controlled in every possible way, something that would be 
easier using a reliable non-radioactive labelling technique, which has not yet 
been optimised for Zta:DNA interactions.  
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Chapter 4: ZRE prediction and mapping in the viral and 
human genome 
4.1. Introduction 
The RpZRE_274_dataset from the previous chapter identifies all those human 
genes with the potential to have their epigenetic silencing reversed by Zta 
binding to the RpZRE3 core sequence found in the promoter region. However, it 
only takes into account one methylation dependent site, whereas there are 
currently four published methylation dependent unique sequence ZREs found in 
viral promoters, and another found in a human promoter. There is also no 
evidence to suggest that these are the only methylation dependent sites. 
Additionally, it would not be possible to say without doubt that a particular gene 
can only be activated by Zta when methylated; it may contain other non-
methylation dependent binding sites in the same region. This chapter aims to 
provide a fuller picture of the potential of Zta-controlled regulation in both viral 
and human promoter regions, using and extending techniques developed in the 
previous chapter. 
 The infection of human B-lymphocytes by Epstein-Barr virus results in the 
establishment of a latent state in which a highly restricted set of viral genes are 
expressed (Rowe et al., 2009). This is accompanied by extensive methylation of 
CpG motifs in non-expressed viral gene promoter regions (Fernandez et al., 
2009, Kalla et al., 2010). In response to physiological stimuli, such as 
engagement of the B-cell receptor, epigenetic silencing of the viral genome is 
evaded, resulting in widespread activation of viral gene expression and lytic 
replication (Bhende et al., 2005, Fernandez et al., 2009). The expression of a 
subset of host genes is also altered during this period (Chang et al., 2006, Yuan 
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et al., 2006, Broderick et al., 2009a). As previously discussed, Zta is the key 
lytic activator protein which switches the virus expression from latency to lytic 
cycle, and methylation dependent binding is critical to this. Interestingly, 
methylation of the EBV genome has been shown to be required for lytic 
reactivation (Kalla et al., 2010). The genome enters the cell during infection in 
the unmethylated state and gradually becomes methylated over time. The ability 
of Zta to bind methylated ZREs suggests that it might have a direct role in 
evading the epigenetic silencing of the viral genome to activate expression from 
viral promoters required for lytic replication. 
An additional function of the methylation requirement for Zta binding could 
contribute to the establishment of latency during the immortalisation of infected 
cells. It is known that Zta is expressed transiently during early infection (Halder 
et al., 2009). However, it does not activate the complete lytic cycle cohort of 
genes at this early stage. A plausible explanation for this is that key lytic cycle 
genes are controlled by class III ZREs that do not function unless the CpG 
ZREs are methylated. Zta has also been shown to be required for 
immortalisation (Kalla et al., 2010). Thus far the only direct targets of Zta are 
lytic genes, however perhaps Zta has a further role to play during early infection 
by activating other genes though different ZREs. 
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4.2. Results 
4.2.1 Computational prediction of ZREs core sequences bound by Zta 
using PROMO 
In order to test the accuracy of existing prediction tools and to find novel ZRE 
core sequences, three well-characterized Zta-responsive promoters from the 
EBV genome were analysed by James Heather (BZLF1 promoter [Zp] 
[Flemington and Speck, 1990a, Lieberman et al., 1990, Urier et al., 1989, 
Packham et al., 1990], BRLF1 promoter [Rp] [Bhende et al., 2004, Packham et 
al., 1990, Lieberman et al., 1990, Sinclair et al., 1991] and BMRF1 promoter 
[Quinlivan et al., 1993, Taylor et al., 1991, Kenney et al., 1992]) using PROMO, 
an online transcription factor binding site (TFBS) prediction tool (Farre et al., 
2003, Messeguer et al., 2002). PROMO uses a position frequency matrix (PFM) 
created from the Transfac 8.3 (Matys et al., 2006) Zta transcription factor entry 
T00923 (Figure 4.1A). This is made up from six existing ZRE sequences, which 
match sequences found in the orilyt region, ZRE1, ZRE3, ZRE4, ZRE6 and 
ZRE5. ZRE3, ZRE4 and ZRE6 are the same core sequences, and are repeated 
3 times in this matrix. The identity of the 6th site was not available from the 
public Transfac database (7.0) and does not match any known ZREs. The 
search was conducted 500bp upstream of the published transcription start site. 
PROMO provides dissimilarity rates to score matches, and a positive match 
was taken as one with a dissimilarity rate of <= 15%. 
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Figure 4.1 ZREs in essential early lytic promoters. 
A The ZRE sequences used by PROMO to create a Position Frequency Matrix (PFM), the 
PFM itself and a sequence logo representation of the prediction matrix. B Previously 
known ZREs are represented by black boxes, ZREs predicted using PROMO at default 
settings are represented by black boxes. An asterix (*) indicates the presence of a CpG 
motif within the ZRE. RpZRE1 is the only existing ZRE that was also predicted by PROMO 
and is indicated in both black and white.  
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These three promoters contain eight previously published sites (Zp (2) (Sinclair 
et al., 1991, Bhende et al., 2004), Rp (3) (Urier et al., 1989, Flemington and 
Speck, 1990a, Lieberman et al., 1990, Sinclair et al., 1991) and BMRF1p (3) 
(Kenney et al., 1992, Taylor et al., 1991, Quinlivan et al., 1993). However, the 
PROMO algorithm only predicted one of these sites (RpZRE1 (Sinclair et al., 
1991)) but in addition predicted six novel sites (Figure 4.1B and Table 4.1). The 
ability of Zta to interact with each predicted site was assessed using 
electrophoretic mobility shift assays (EMSA), in collaboration with James 
Heather and final year BSc project students. Conditions were chosen in which 
in vitro synthesized Zta forms readily detectable complexes with previously 
characterized ZREs, as shown for BMRF1ZRE (-44), BMRF1ZRE (AP1) and 
RpZRE2 (-194) (Figure 4.2A). Zta interacted with two of the predicted sites 
(BMRF1ZRE (-173) and ZpZRE (-96)) but not with a DNA probe containing the 
predicted RpZRE (-439), RpZRE (-447) or RpZRE (-204) sites. 
Promoter Position ZRE core sequence EMSA Binding Methylation-dependent 
Zp -96 TGTGTCT + N/A 
Rp -204 TGTGATA - N/A 
Rp -439 TGTGTCC - N/A 
Rp -447 TGTGTGA - N/A 
BMRF1 -173 TGGCACA + N/A 
BMRF1 -248 TGTGCGA + + 
 
Table 4.1 PROMO predicted sites 
The ZRE core sequence predicted is shown, alongside the promoter name, the offset from the 
published transcription start site, the binding status in vitro and the methylation dependence.  
 
 
133 
 
 
 
 
 
 
 
 
Figure 4.2 Interrogating ZRE PROMO predictions by EMSA. 
A Double stranded oligonucleotides were generated with the core ZRE sequence and at 
least 10 nucleotides of cognate sequence on either side. Following radiolabelling, these 
were incubated with in vitro translated Zta and subject to EMSA. The reactions contained 
no protein, 0, control lysate, C, or Zta, Z. B Double stranded oligonucleotides were 
generated with the core ZRE sequence and 10 nucleotides of cognate sequence on either 
side. Following radiolabeling, these were subject to in vitro methylation with M.SssI methyl 
transferase, or a mock reaction. Subsequently, they were incubated with in vitro translated 
Zta and subjected to EMSA. The reactions contained control lysate, C, or Zta, Z. EMSAs 
in this figure were performed by undergraduate students, with the exception of ZpZRE(-
96).  
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One predicted site in BMRF1p contains a CpG motif (BMRF1ZRE (-248)). Zta 
only displays a marginal interaction with the site (6-10 fold less than another 
ZRE from the same promoter) in its non-methylated form (Figure 4.2B). In 
contrast, complex formation was dramatically enhanced following in vitro 
methylation of the CpG motif, identifying it as a methylation-dependent class III 
ZRE. 
Of the PROMO predicted sites, four were found to bind (one was a previously 
known ZRE, one of these in a methylation dependent manner), but the 
prediction tool missed six known ZREs.  
4.2.2 Testing a novel ZRE PFM to predict CpG containing ZREs 
A position frequency matrix (PFM) was generated using the CpG-containing 
ZRE core binding sites (denoted PFMCpG5) (Figure 4.3). The accuracy of the 
matrix was evaluated by searching for ZREs in the three well-characterised viral 
promoters, using MatScan (Blanco et al., 2006) in collaboration with James 
Heather (University of Sussex). The PFMCpG5 identified all five CpG containing 
sites (used to create the PFM) and predicted two novel sites; one located in Rp, 
centred on -114 (RpZRE (-114)), and one located in the BMRF1 promoter, 
centred on -148 (BMRF1ZRE (-148)). DNA binding experiments demonstrate 
that Zta interacts with both sites in a methylation-dependent manner, 
characteristic of class III ZREs (Figure 4.4).  
4.2.3 Optimisation of the prediction matrix 
The discovery of these novel ZREs invites the question as to whether inclusion 
of the new sites would improve the prediction capabilities. A new PFM including 
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the two new CpG containing ZREs discovered in Rp and BMRF1p, as well as 
an  
 
Figure 4.3 Generation of PFMCpG5  
A 5 CpG containing ZREs, found in viral promoters B A Position Frequency Matrix (PFM) 
showing the frequency of each base at a given position. This was supplied to MatScan to 
predict new CpG-containing sites. C A sequence logo, graphical representation of the 
motif, generated using WebLogo.  
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  Figure 4.4 Newly predicted CpG-containing ZREs in the promoters of BRLF1 and 
BMRF1. 
A The PFMCpG5 was used in MatScan to predict further CpG containing ZREs. These 
newly predicted sites are indicated in the promoter maps by white boxes, with the name in 
bold and underlined. B Double stranded oligonucleotides were generated with the core 
predicted ZRE sequence and 10 nucleotides of cognate sequence on either side. 
Following radiolabeling, these were subject to in vitro methylation with M.SssI methyl 
transferase, or a mock reaction. Subsequently they were incubated with in vitro translated 
Zta and subjected to EMSA. The reactions contained control lysate, C or Zta, Z.  
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existing methylation dependent site found in the promoter of Egr1 (Chang, Lee 
et al. 2006), was created and denoted PFMCpG8.  
In order to compare these matrices, both PFMCpG5 and PFMCpG8 were used in 
MatScan to search the entirety of the Type 1 EBV genome (Ref Seq 
NC_007605) (Figure 4.5). Core sequences were identified and duplicates due 
to multiple instances were removed, creating two lists of unique core sequence 
predictions. This was compared to the eight previously identified CpG 
containing ZREs. PFMCpG5 predicted a total of 22 unique core sequences, eight 
of which matched the previously identified CpG containing ZREs, and 14 novel 
sequence predictions. PFMCpG8 predicted a total of 13 unique sequences, six of 
which matched the previously identified CpG containing ZREs, and seven novel 
sequence predictions, all of which were predicted by PFMCpG5. I questioned 
which list was more accurate. PFMCpG8 missed the RpZRE3 and NapZRE1 
sequences in the prediction, despite the fact these are contained within the 
PFM. It was therefore decided to continue the investigation using the 
predictions from PFMCpG5, as this matrix did not miss any of the known sites.   
4.2.4 In vitro confirmation of predicted binding site sequences 
The 14 novel discrete ZRE core sequences, denoted CpG5A-N (Table 4.2), 
predicted by PFMCpG5 in the Type 1 EBV genome were tested by EMSA in both 
the unmethylated and methylated state (Figure 4.6). All predicted core ZRE 
sequences bound in the methylated form, except CpG5 H and N. No sites 
bound significantly in the unmethylated form, except CpG B. Therefore 11 out of 
14 predictions can be classified as Class III ZREs, and one can be classified as 
Class II. Overall, the prediction matrix PFMCpG5 has predicted a total of 22  
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Table 4.2 Predicted ZRE core sequences  
ZRE predictions from PFMCpG5 used in MatScan on the entire EBV genome, together with 
their respective score, a numerical representation of the differences between the 
predicted site and the max score possible from PFMCpG5 . 
Figure 4.5 Attempt to improve CpG containing ZRE prediction 
A Sequence logo motif representations of the PFMCpG5 and PFMCpG8 to illustrate the effect 
of three additional sites on the motif appearance. B A Euler diagram comparing the 
predictions made using PFMCpG5 and PFMCpG8 . 
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Figure 4.6. Confirmation of Zta recognition and methylation dependence of PFMCpG5 
predicted CpG containing core ZREs. 
Double strand oligonucleotides were generated with the core predicted ZRE sequence and 
10 nucleotides of cognate sequence on either side. Following radiolabeling, these were 
subject to in vitro methylation with SssI methyl transferase (+), or a mock reaction (-). 
Subsequently, they were incubated with in vitro translated Zta and subject to EMSA. The 
reactions contained control lysate, C; or Zta, Z.  
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unique sequences, 20 of which can be seen to form complexes in vitro, a 91% 
successful prediction tool.  
4.2.5 Genomic position prediction of ZRE core binding sequences in the 
EBV genome 
Global predictions for the 171,823 nucleotide type 1 Epstein-Barr virus genome 
(Ref Seq NC_007605) was undertaken by bioinformatician D. Thomas (BSMS), 
using an exact pattern match with 32 validated ZRE sequences (Table 4.3, 
Figure 4.7). This revealed 469 locations within the genome that matched one of 
the 32 ZRE core sequences (Appendix II).  
The occurrence of ZREs in each promoter regulatory region was analysed. The 
promoters of the EBV genes was taken as between 500 base pairs upstream 
and 200 base pairs downstream because the annotated gene start sites are 
known not to correlate fully with known mRNA start sites. This revealed that 79 
out of 86 EBV regulatory regions contained at least one ZRE core sequence 
(Table 4.3). The occurrence of ZREs in 92% of EBV regulatory regions 
suggests that Zta has the potential to regulate the expression of most EBV 
genes. Furthermore, 58 EBV regulatory regions contained at least one CpG 
containing ZRE (Table 4.3), potentially controlling the expression of 41 lytic 
genes. These regions are all methylated during latency (Fernandez et al., 2009, 
Kalla et al., 2010), allowing methylation-dependent Zta interaction with ZREs 
that could influence the expression of a broad range of EBV genes once Zta is 
expressed during lytic cycle.  
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ZRE Core Sequence Class Names References Forward Reverse 
TGAGCCA TGGCTCA I 
Zp ZREIIIA 
(Flemington and 
Speck, 1990a, 
Lieberman and 
Berk, 1990) (Urier 
et al., 1989)  
Rp ZRE1 (Sinclair et al., 1991) 
Zp (-365) This chapter 
TTAGCAA TTGCTAA I Zp ZREIIIB 
(Flemington and 
Speck, 1990a, 
Lieberman and 
Berk, 1990) 16 
TGTGTAA TTACACA I DSL ZRE1 (Lieberman and Berk, 1990) 
TGAGCAA TTGCTCA I 
DSL ZRE2 (Lieberman and Berk, 1990) 
DSL ZRE7 (Lieberman and Berk, 1990) 
BMRF1ZRE(-44) (Taylor et al., 1991) 
BMRF1ZRE(-
107) 
(Quinlivan et al., 
1993) 
TGTGTCA TGACACA I 
DSL ZRE3 (Lieberman and Berk, 1990) 
DSL ZRE4 (Lieberman and Berk, 1990) 
DSL ZRE6 (Lieberman and Berk, 1990) 
DHRS9 ZRE1 (Jones et al., 2007) 
TGTGCAA TTGCACA I DSL ZRE5 
(Lieberman and 
Berk, 1990) 
CIITA (221) (Li et al., 2009) 
TGAGTCA TGACTCA I 
BSLF2+BMLF1 (Taylor et al., 1991) 
BMRF1 AP-1 
(Kenney et al., 
1992) (Quinlivan et 
al., 1993) 
IL8 AP1 (Hsu et al., 2008) 
DHRS9 (ZRE2) (Jones et al., 2007) 
TGACTAA TTAGTCA I Fp AP-1-Like Site 
(Zetterberg et al., 
2002) 
TGTGTCT AGACACA I Zp (-96) This chapter 
TGGCACA TGTGCCA I BMRF1 (-173) This chapter 
TGAGTAA TTACTCA I CIITA (Li et al., 2009) IL13 (Tsai et al., 2009) 
GTTGCAA TTGCAAC I IL-8 ZRE (Hsu et al., 2008) 
GGAGCGA TCGCTCC III Egr1 (Heather et al., 2009) 
142 
 
 
TGAGCGA TCGCTCA II Rp ZRE2 
(Sinclair et al., 
1991) (Bhende et 
al., 2004) 
TTCGCGA TCGCGAA III Rp ZRE3 (Bhende et al., 2004) 
TAAGCGA TCGCTTA III BRLF1 (-114) This chapter 
TGAGCGG CCGCTCA III BMRF1 (-148) This chapter 
TGTGCGA TCGCACA III BMRF1 (-248) This chapter 
TGAGCGT ACGCTCA III Nap ZRE2 (Dickerson et al., 2009) 
CGGGCGA TCGCCCG III Nap ZRE1 (Dickerson et al., 2009) 
CGAGCGA TCGCTCG III CpG5 A This chapter 
TGAGCGC GCGCTCA II CpG5 B This chapter 
TTGGCGA TCGCCAA III CpG5 C This chapter 
TTAGCGA TCGCTAA III CpG5 D This chapter 
TGTGCGT ACGCACA III CpG5 E This chapter 
TTTGCGA TCGCAAA III CpG5 F This chapter 
TCAGCGA TCGCTGA III CpG5 G This chapter 
CGTGCGA TCGCACG III CpG5 I This chapter 
TGCGCGA TCGCGCA III CpG5 J This chapter 
CGCGCGA TCGCGCG III CpG5 K This chapter 
AGAGCGA TCGCTCT III CpG5 L This chapter 
TGGGCGA TCGCCCA III CpG5 M This chapter 
 
Table 4.3 ZRE32  
The 32 ZREs characterised by EMSA or DNase footprinting, including the novel ZREs 
discovered in this work.     
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Interestingly 22 EBV gene regulatory regions contain only CpG ZRE binding 
sequences (highlighted in Table 4.4). Those genes are prime contenders to be 
regulated in a strictly methylation-dependent manner by Zta, as binding will 
primarily occur when the promoter region is methylated. These genes were 
originally classified as displaying early lytic, late lytic and latent patterns of gene 
expression, but importantly, a more recent genome wide expression study 
shows that all are upregulated during lytic cycle in Akata BL cells, with the 
majority reaching a peak expression value approximately 24 hours after lytic 
expression (Yuan et al., 2006). 
cycle 
phase 
Promoter 
name 
Class 
I 
Class 
II 
Class 
III Total 
late lytic BNRF1 1 0 0 1 
unknown EBER 1 1 0 0 1 
unknown EBER 2 1 0 1 2 
late lytic BCRF1 3 0 1 4 
latent Cp 0 0 3 3 
unknown BWRF1 0 0 3 3 
latent Wp 0 0 1 1 
early lytic BHLF1 4 0 0 4 
early lytic BHRF1 4 0 0 4 
early lytic BFLF2 2 0 0 2 
unknown BFRF1A 4 0 0 4 
early lytic BFLF1 4 0 0 4 
early lytic BFRF1 4 0 0 4 
early lytic BFRF2 0 0 0 0 
late lytic BFRF3 1 0 1 2 
latent Qp 2 0 2 4 
unknown BPLF1 1 0 2 3 
late lytic BORF1 0 0 3 3 
unknown BOLF1 0 0 2 2 
early lytic BORF2 1 0 1 2 
early lytic BaRF1.1 1 0 2 3 
early lytic BMRF1 4 0 2 6 
late lytic BMRF2 1 0 0 1 
early lytic BSLF2/BMLF1 4 1 0 5 
early lytic BSLF1 2 1 0 3 
late lytic BSRF1 1 2 2 5 
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late lytic BLRF1 1 0 0 1 
early lytic BLLF3 2 0 0 2 
late lytic BLRF2 2 0 0 2 
early lytic BLLF2 0 0 1 1 
late lytic BLLF1 2 0 1 3 
late lytic BZLF2 0 0 0 0 
early lytic BZLF1 4 0 0 4 
early lytic BRRF1 0 0 2 2 
early lytic BRLF1 1 1 2 4 
late lytic BRRF2 1 1 2 4 
late lytic BKRF2 0 1 1 2 
unknown BKRF3 1 1 1 3 
early lytic BKRF4 0 0 3 3 
late lytic BBRF1 0 0 2 2 
early lytic BBLF4 0 0 3 3 
late lytic BBRF2 1 0 0 1 
late lytic BBRF3 0 0 2 2 
early lytic BBLF2/BBLF3 0 0 1 1 
late lytic BBLF1 0 0 0 0 
early lytic BGLF5 2 0 3 5 
early lytic BGLF4 0 1 1 2 
unknown BGLF3.5 2 0 2 4 
late lytic BGRF1/BDRF1 0 0 1 1 
unknown BGLF3 0 0 0 0 
late lytic BGLF2 0 1 0 1 
late lytic BGLF1 2 0 1 3 
early lytic BDLF4 1 0 0 1 
unknown BDLF3.5 3 0 2 5 
late lytic BDLF3 2 0 1 3 
late lytic BDLF2 0 0 0 0 
late lytic BDLF1 0 0 1 1 
early lytic BcRF1.2 2 0 0 2 
late lytic BcLF1 1 1 1 3 
late lytic BTRF1 0 0 1 1 
late lytic BXLF2 1 0 0 1 
late lytic BXRF1 1 0 1 2 
early lytic BXLF1 2 0 2 4 
early lytic BVRF1 2 0 2 4 
late lytic BVRF2 1 0 3 4 
unknown BVLF1 1 0 2 3 
late lytic BdRF1 1 0 0 1 
late lytic BILF2 4 0 1 5 
unknown RPMS1 2 0 1 3 
early lytic LF3 2 0 0 2 
unknown LF2 1 0 4 5 
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unknown LF1 3 0 0 3 
unknown BILF1 1 0 3 4 
unknown A73 1 0 1 2 
early lytic BALF5 1 1 0 2 
late lytic BALF4 0 0 3 3 
unknown BARF0 0 0 2 2 
unknown BALF3 1 0 3 4 
early lytic BALF2 1 0 3 4 
early lytic BALF1 0 2 2 4 
early lytic BARF1.2 0 2 1 3 
latent LMP-2A 1 0 0 1 
early lytic BNLF2b 2 1 0 3 
early lytic BNLF2a 2 1 0 3 
latent LMP-1 1 0 0 1 
latent LMP-2B 1 0 0 1 
Table 4.4 ZRE predictions in all EBV genes. Those genes with only CpG-containing ZREs in 
the promoter region are highlighted. 
 
The three AP1 like-sites discussed in Chapter 4 were omitted from the ZRE list, 
due to unconvincing binding data regarding their methylation dependency at the 
time of analysis. However, when they are included in retrospect, these three 
core sequences are found a total of 28 times within the EBV genome, 
increasing the total number of ZRE matches found to 497. Two genes which 
were previously found to contain no ZREs, BBLF1 and BGLF2, contain at least 
one of these AP1 like sites. Their inclusion does not significantly affect the list of 
genes which are contenders for methylation dependent regulation, as these 
sites can be bound in their unmethylated state, therefore Zta is not prevented 
from binding. (Full table can be found in appendix III). 
The 22 predicted methylation dependent Zta responsive regions were examined 
to identify ChIP candidates, and primers were designed for the CpG-ZREs in 
three gene promoters: BKRF4, BGLF4 and BTRF1. The position of the ZREs 
and the region amplified by the qPCR primers is shown in figure 4.8A. Lytic 
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cycle was activated by anti-IgG treatment in Akata cells and acyclovir treatment 
was used to inhibit replication, to retain the methylation pattern of the 
unreplicated genome. Chromatin was harvested at the 48 hour time point and 
subjected to Zta immunoprecipitation in conjunction with S. Ramasubramanyan 
(University of Sussex). QPCR was undertaken and the enrichment relative to 
percent input is shown in figure 4.8B, successfully demonstrating the ability of 
Zta to bind to these novel ZREs at the onset of replication. Zta binds to these 
regions to a comparable amount to that seen in the Zp (Ramasubramanyan, S., 
unpublished data).    
4.2.6 Integrating ChIP Seq data with positional ZRE predictions 
Bergbauer et al performed a ChIP Seq experiment using a mutant version of 
Zta, a GFP-tagged protein lacking the transactivation domain (residues 149-
245) (Bergbauer et al., 2010), referred to hereafter as ZtaMUT. The reasoning 
behind this was to identify only regions of the genome where Zta bound directly 
to the DNA through the binding domain, and not indirectly through interactions 
with other proteins through the transactivation domain. However this approach 
does not recognise the potential for the transactivation domain to affect the 
DNA binding ability of Zta. The basepair resolution data was kindly shared with 
us for the 4 conditions they used; in vitro unmethylated, the 165 kbp genomic 
DNA of EBV B95.8 strain cloned in E.coli and incubated with purified ZtaMUT, in 
vitro methylated, the same cloned DNA but incubated with purified ZtaMUT after 
it had undergone CpG methylation by de novo methyltransferase M.SssI, in vivo 
Raji, a cell line which is strictly latent, and in vivo B95.8, a cell line semi-
permissive for lytic cycle. Both in vivo cell lines stably expressed the ZtaMUT.  
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Figure 4.8 ChIP Analysis of candidate genes. 
A Regions of EBV selected for Chromatin Immunoprecipitation (ChIP). Green triangles 
indicate Class III ZREs, red stars indicate Class II ZREs. B Quantitation by QPCR shown 
relative to % input. 
 
149 
 
 
The in vitro unmethylated and methylated binding profiles give us an idea of the 
potential of Zta binding in the absence of other viral or cellular proteins, 
whereas the in vivo data provides a snapshot of binding in a cellular 
environment.  
The ChIP Seq data was aligned to the 172kbp B95.8 EBV genome (Baer et al., 
1984) which has some differences to the Type 1 genome sequence used so far, 
containing a different number of W repeats and a deleted region over the LF1, 2 
and 3 genes, and orilyt right. An exact pattern match of the ZRE32 sequences 
was performed on this sequence, revealing a total of 443 ZRE positional 
predictions. To ensure gene mapping consistency between the genomes, each 
regulatory region of interest was aligned with the B95.8 sequence using BLAST. 
The ChIP Seq data and the ZRE positional predictions were then plotted for the 
specified promoter regions. Initially, the three well characterised promoters, 
previously used in the chapter to initially predict ZREs (BRLF1, BMRF1 and 
BZLF1) were plotted to question these predictions (Figure 4.9). Rp shows peaks 
both in vitro and in vivo over RpZRE1 and RpZRE2, and less obvious 
“shoulders” of binding peaks over RpZRE (-114) and RpZRE3. There is a 
considerable increase in binding in the methylated in vitro experiment, 
compared to the unmethylated in vitro experiment.. BMRF1p shows a broad 
peak of binding across all the sites both in vitro, where it appears to be 
methylation dependent, and in vivo. Zp exhibits a small binding peak over 
ZpZREIII A and B, which are slightly more pronounced in vitro, but none over a 
ZpZREIIIA pattern match, denoted RpZRE(-365). To question why there was no 
peak, I undertook EMSAs to assess in vitro binding of Zta to a double stranded  
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Figure 4.9 Integration of Bergbauer et al ChIP Seq data with ZRE position 
predictions: the three well characterised promoters. 
The ZtaMUT ChIP Seq data and the ZRE position predictions were extracted for each 
previously defined promoter region of the 3 well defined promoters initially investigated, 
and plotted. Blue lines on the x axis indicate ZRE position. The in vitro data is plotted as 
negative for the sole purpose to separate the data, and should be read as equivalent 
binding as above the x axis. The ZREs from left to right are (i) Rp: RpZRE1, RpZRE(-114), 
RpZRE2, RpZRE3 (ii) BMRF1p: BMRF1ZRE(-248), BMRF1(-173), BMRF1(-148), 
BMRF1p(-107), BMRF1 AP-1, BMRF1(-44) (iii) Zp: ZpZRE(-96), ZpZREIIIB, ZpZREIIIA, 
ZpZRE(-365). ZpZRE(-365) is an exact match to the core sequence of ZpZREIIIA, and the 
ability of Zta to bind in this context was confirmed by EMSA, as shown adjacent to the Zp 
graph. Approximately 500bp upstream and 200bp downstream is shown.  
(ii) 
(iii) 
(i) 
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oligonucleotide consisting of the core sequence, with 10 basepairs of cognate 
sequence on both flanks. Binding was confirmed in this context, suggesting that 
the inability of Ztamut to bind in the ChIP experiments is not due to the immediate 
surrounding sequence.  
The 22 regulatory regions containing only CpG ZREs were also plotted. BALF1, 
BARF1.2, BBLF4 and BGLF2 all showed specific methylation dependent 
binding in vitro that aligned with at least 1 of the predicted CpG-containing 
ZREs, and also exhibited strong in vivo binding (Figure 4.10). BBLF2/BBLF3, 
BBRF3, BKRF2 and BKRF4 showed a small but specific methylation dependent 
binding in vitro, and some in vivo binding (Figure 4.11).  BALF4, BARF0, 
BGLF4, BOLF1, BORF1, BTRF1 and Cp showed some specific methylation 
dependent binding in vitro but none in vivo (Figure 4.12). BBRF1, BDLF1, 
BGRF1/BDRF1, BLLF2, BRRF1, BWRF1 repeats and Wp showed no increase 
in Zta binding (not shown).  
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Figure 4.10  Integration of Bergbauer et al ChIP Seq data with ZRE position 
predictions: significant ZtaMUT binding peaks. 
The ChIP Seq data and the ZRE position predictions were extracted for each of the 
defined promoter region and plotted. Blue lines on the x axis indicate ZRE position.  The in 
vitro data is plotted as negative for the sole purpose to separate the data, and should be 
read as equivalent binding as above the x axis. The ZRE prediction matches from left to 
right are (i) BALF1p: RpZRE2, RpZRE2, PFMCpG5 M, NapZRE2 (ii) BARF1.2p: PFMCpG5 M, 
RpZRE2, RpZRE2 (iii) BBLF4p: PFMCpG5 A, BMRF1(-248), NapZRE2 (iv) BGLF2p: 
RpZRE2. . Approximately 500bp upstream and 200bp downstream is shown.  
(ii) 
(iii) 
(i) 
(iv) 
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  Figure 4.11 Integration of Bergbauer et al ChIP Seq data with ZRE position 
predictions:  specific ZtaMUT binding peaks at a lower magnitude. 
The ChIP Seq data and the ZRE position predictions were extracted for each defined 
promoter and plotted. Blue lines on the x axis indicate ZRE position. The in vitro data is 
plotted as negative for the sole purpose to separate the data, and should be read as 
equivalent binding as above the x axis. The ZRE prediction matches from left to right are 
(i) BBLF2/BBLF3p: PFMCpG5 M (ii) BBRF3p: PFMCpG5 F, PFMCpG5 M (iii) BKRF2p: PFMCpG5 
B, PFMCpG5 D (iv) BKRF4p: PFMCpG5 I, BMRF1 (-148), PFMCpG5 D. . Approximately 500bp 
upstream and 200bp downstream is shown.  
(ii) 
(iii) 
(i) 
(iv) 
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Figure 4.12 Integration of Bergbauer et al ChIP Seq data with ZRE position 
predictions: in vitro binding only. 
The ChIP Seq data and the ZRE position predictions were extracted for each of the 
defined promoter region and plotted. Blue lines on the x axis indicate ZRE position. The in 
vitro data is plotted as negative for the sole purpose to separate the data, and should be 
read as equivalent binding as above the x axis. The ZRE prediction matches from left to 
right are (i) BALF4p: PFMCpG5 J, PFMCpG5 A, PFMCpG5 E (ii) BARF0p: RpZRE2, PFMCpG5 A 
(iii) BGLF4p: PFMCpG5 B, BRLF1 (-114) (iv) BOLF1p: NapZRE1, PFMCpG5 G (v) BORF1p: 
BMRF1(-148), PFMCpG5 J, NapZRE1 (vi) BTRF1p: PFMCpG5 M (vii) Cp: Egr1, PFMCpG5 F, 
PFMCpG5 M. . Approximately 500bp upstream and 200bp downstream is shown.  
(ii) 
(iii) 
(i) 
(iv) 
(v) (vi) 
(vii) 
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The previous analysis suggests that ZtaMUT binds to some of these predicted 
sites but not to others. To obtain a genome-wide view, and further assess the 
newly predicted sites, the ChIP Seq data corresponding to the 500 basepairs 
up- and down-stream of each unique predicted ZRE position was extracted, and 
averaged before plotting on a graph. The profile for each region was also 
plotted separately. 0 corresponds to the first nucleotide of the ZRE. RpZRE1, 2 
and 3 were first analysed in this manner to assess the confidence with which 
the data can be analysed in this way (Figure 4.13). RpZRE2 shows significant 
specific methylation dependent binding of ZtaMUT in the in vitro data, and this is 
reflected by the in vivo data. The individual plots of each of the 17 occurrences 
shows that all exhibit a peak of binding in the in vitro methylated data, between 
487 depth and 3129 depth, and similar peaks can be seen in the in vivo data, 
except for 2 Raji occurrences, where there is no data due to deletions. RpZRE1 
shows small peaks at the sites in all cell lines, and as RpZRE1 does not contain 
a CpG motif this is reflected by the similarity of the in vitro unmethylated and 
methylated binding. The peaks are however very small compared to RpZRE2. 
When each separate site is plotted individually, six out of the 24 occurrences of 
the RpZRE1 sequence show peaks of at least 500 depth, whereas the other 
binding profiles are relatively flat, accounting for the smaller average peaks. In 
the Raji data there is only one corresponding peak, which matches the 
occurrence in Rp, and in the B95.8 data there are six peaks, but the peaks are 
much lower than in vitro. RpZRE3 shows no specific binding peaks, and this is 
confirmed by the separate plots as well as the average. However this is 
ambiguous, as in some of the separate plots there are shoulders of binding, as 
seen figure 4.9 for BRLF1p, which RpZRE3 appears to contribute to.  
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  Figure 4.13 Individual site analysis of pattern matches to the RpZREs. 
ChIP Seq data surrounding each occurrence of the predicted ZRE match positions of 
RpZRE2 (n=17), RpZRE1 (n=25) and RpZRE3 (n=6) was extracted and plotted either as 
an average with standard error as the error bars, or as a separate plot. 
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The two PFMCpG5 predictions that did not bind in EMSAs, H and N, were 
analysed in the same manner (Figure 4.14). This shows that H has no binding 
peaks in both the average analysis and the 9 separate plots. N does not appear 
to show any specific peaks on average, however the 16 separate plots are 
slightly harder to interpret. Whilst no specific peaks are seen, there are 3 
broader peaks to which N could be contributing, depending upon the surround 
sites. Overall however, it appears that the inability of Zta to bind these two 
sequences in EMSAs is matched by the ChIP Seq data.  
The same analysis was performed on all the predicted sites made using 
PFMCpG5. BMRF1 -248 and PFMCpG5 A both show distinct, methylation specific 
binding peaks, with large error bars (Figure 4.15). The 3 separate plots reveal 
two significant peaks for BMRF1 -248 and one smaller peak, both in vitro  
Figure 4.13 Continued. 
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Figure 4.14 Individual site analysis of pattern matches to the PFMCpG5  Predictions 
that did not bind by EMSA  
ChIP Seq data surrounding each occurrence of the  PFMCpG5  H (n=9) and N (n=16) 
predictions was extracted and plotted either as an average with standard error as the error 
bars, or as a separate plot. 
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Figure 4.15 Individual site analysis of pattern matches to the PFMCpG5  Predictions 
that appear to bind significantly in the ChIP Seq data. 
ChIP Seq data surrounding each occurrence of the BMRF1(-248) (n=3) and PFMCpG5  A 
(n=5) predictions was extracted and plotted either as an average with standard error as 
the error bars, or as a separate plot. 
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methylated and in vivo. PFMCpG5 A has varying peaks in vitro methylated, but 
only one out of five in vivo, which corresponds to the promoter region of BBLF4, 
identified previously. PFMCpG5 K and D show some binding on average but at a 
lower level to the previous site predictions (Figure 4.16). All five PFMCpG5 D 
sites show some binding in vitro, but only 1 appears to bind in vivo. One out of 
the three PFMCpG5 K binds both in vitro and in vivo. PFMCpG5 F and I have very 
low average peaks, but specific methylation dependent peaks can still be seen 
in the ten separate plots in vitro but only on two occasions for PFMCpG5 F and 
once for PFMCpG5 I in the in vivo B95.8 data (Figure 4.17). PFMCpG5 G, J, E, M, 
B, BMRF1-148 and RpZRE (-114) show almost no detectable binding on 
average, however in at least one of the separate plots the site looks to 
contribute some binding to the peak profile (Figure 4.18). PFMCpG5 C and L 
appear to show no binding peaks in any condition (Figure 4.19).  
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Figure 4.16 Individual site analysis of pattern matches to the PFMCpG5  Predictions 
that appear to show weak binding in the ChIP Seq data. 
ChIP Seq data surrounding each occurrence of the PFMCpG5  D (n=5) and K (n=3) 
predictions was extracted and plotted either as an average with standard error as the error 
bars, or as a separate plot. 
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Figure 4.17 Individual site analysis of pattern matches to the PFMCpG5  Predictions 
that appear to show weak binding in the in vitro ChIP Seq data. 
ChIP Seq data surrounding each occurrence of the PFMCpG5  I (n=10) and F(n=10) 
predictions was extracted and plotted either as an average with standard error as the error 
bars, or as a separate plot. 
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Figure 4.18 Individual site analysis of pattern matches to the PFMCpG5  Predictions 
that appear to bind at least 1 site  in the in vitro ChIP Seq data. 
ChIP Seq data surrounding each occurrence of the PFMCpG5 G (n=24), J (n=7), E (n=8), M 
(n=31), B, BMRF1-148 (n=17) and RpZRE (-114) (n=5) predictions was extracted and 
plotted either as an average with standard error as the error bars, or as a separate plot. 
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Figure 4.18 Continued 
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Figure 4.19 Individual site analysis of pattern matches to the PFMCpG5  Predictions 
that do not appear to bind in the ChIP Seq data. 
ChIP Seq data surrounding each occurrence of the PFMCpG5  L (n=14) and C(n=5) 
predictions was extracted and plotted either as an average with standard error as the error 
bars, or as a separate plot. 
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4.2.7 Genomic position prediction of ZRE core binding sequences in the 
Human genome 
Global predictions for the 3.2Gb Human Genome (NC GRCh37 extracted from 
Ensembl 57 (Flicek et al., 2009)) was undertaken by bioinformatician D. 
Thomas (BSMS), using an exact pattern match with the 32 validated ZRE core 
sequences. Of the 22,224 regulatory regions searched, 7,538 (33.9%) genes 
contained at least one CpG ZRE, whereas 3,390 (15.3%) genes contained CpG 
ZREs but have no methylation independent ZREs in their regulatory regions 
(Figure 4.20A). Methylation-dependent ZRE core sequences are therefore fairly 
common in human promoters. 
To explore whether Zta may overturn epigenetic silencing of the host genes that 
contain methylation-dependent ZRE core sequences in their regulatory regions, 
we first questioned whether these regulatory regions are methylated in B-cells. 
EBV infects and establishes latency in B-cells and epithelial cells. Data-sets 
containing methylome information from circulating B cells (CD19+) (Rauch et 
al., 2009), germinal centre (GC) B cells and EBV-infected lymphoblastoid cell 
lines (LCL) derived from GC B cells (Leonard et al., 2011), were interrogated to 
identify those CpG ZRE containing promoters that are methylated in a 
representative B-cell, as was done in the previous chapter. This identified about 
7% of human genes that are both methylated and contain a methylation-
dependent ZRE in their regulatory regions (Figure 4.20B). The differences in 
methylation status between the methylomes in this gene list are shown in Figure 
4.20 C and D.  
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  Figure 4.20 Interrogating methylome data to identify methylated promoter regions 
with CpG-containing ZREs 
A A graph to show percentage of total gene promoters searched with (i) at least one 
CpG-containing ZRE (ii) only CpG-containing ZREs. B A graph to show percentage of 
total gene promoters searched and found to be methylated in at least one cell type with 
(i) at least one CpG-containing ZRE (ii) only CpG containing ZREs. C A Venn diagram to 
represent the methylome data compared to the human gene lists of those promoters with 
at least one CpG-containing ZRE.D A Venn diagram to represent the methylome data 
compared to the human gene lists of those promoters with only CpG-containing ZREs.  
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Genes that are regulated when Zta is expressed during EBV lytic cycle from two 
published transcriptome studies (Broderick et al., 2009b, Yuan et al., 2006) 
were compared with the set of methylated promoters that contain methylation 
dependent ZREs. This revealed 30 genes that contain the features required to 
be regulated by Zta through a methylated ZRE in their promoter regions (Table 
4.5). The up- or down-regulation of the each of the genes was assessed from 
either the classification in the paper, if one was made, or the immediate 
behaviour following lytic induction (between 0 and 12 hours) by interrogating the 
heat map. 12 genes appear to be down-regulated, and the remaining 18 up-
regulated.  
These 30 genes were analysed using the online bioinformatic program DAVID 
(Huang da et al., 2009b, Huang da et al., 2009a). This clusters similar terms 
together to create clusters of similar function genes. In this gene set the 
enrichment scores were fairly low, suggesting many different functions are 
regulated. 
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Microarray Ensembl ID Gene name Class I Class II Class III -/+  
Yuan et al, 
2006 
ENSG00000167393 PR48 0 0 7 - 
ENSG00000084652 DKFZp451J0118 0 0 1 - 
ENSG00000106236 NPTX2 0 0 1 - 
ENSG00000170889 RPS9 3 0 3 - 
ENSG00000149418 ST14 3 0 1 - 
ENSG00000110324 IL10RA 1 0 2 - 
ENSG00000130193 LOC51337 1 0 2 - 
ENSG00000143603 KCNN3 1 1 1 - 
ENSG00000204237 LOC339229 1 0 2 - 
ENSG00000143013 LMO4 1 0 1 - 
ENSG00000148154 UGCG 0 0 3 + 
ENSG00000138166 DUSP5 0 0 1 + 
ENSG00000161011 SQSTM1 0 0 1 + 
ENSG00000167460 TPM4 0 0 1 + 
ENSG00000170876 MGC3222 0 0 1 + 
ENSG00000173334 C8FW 3 2 2 + 
ENSG00000120910 PPP3CC 1 0 3 + 
ENSG00000007168 PAFAH1B1 2 0 1 + 
ENSG00000115738 ID2 1 0 2 + 
ENSG00000021355 SERPINB1 1 0 1 + 
ENSG00000139718 KIAA1076 0 1 1 + 
ENSG00000140650 PMM2 1 0 1 + 
ENSG00000153113 CAST 1 0 1 + 
ENSG00000167720 SRR 1 0 1 + 
ENSG00000170542 SERPINB9 1 0 1 + 
ENSG00000186480 INSIG1 1 0 1 + 
Broderick et 
al, 2009  
ENSG00000163110 PDLIM5 2 0 1 - 
ENSG00000125354 SEPT6 0 0 2 - 
ENSG00000160957 RECQL4 0 0 4 + 
ENSG00000104856 RELB 0 0 2 + 
 
Table 4.5 Human gene promoters with at least 1 CpG-containing ZRE, and associated 
gene expression shown by microarray to be affected by lytic induction in Akata cells. 
The Ensembl code and associated gene name are shown, and the microarray source of data is 
indicated by the publication. The sites are broken down into the appropriate classes, and the 
affect of lytic cycle upon expression is signified by either “-” corresponding to downregulation, or 
“+” upregulation
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4.3. Discussion 
Following several iterations of a predictive and evaluative approach, we 
identified a set of 32 distinct sequence variants in the core 7 nucleotide 
sequence to which Zta can bind. This includes 20 sites containing a CpG motif, 
the majority of which are only recognized by Zta when they are methylated.  
The consensus binding site identified for non-CpG ZREs is similar to the binding 
sites originally described for Zta. In contrast, the consensus binding site for CpG 
containing ZREs is remarkably different (Figure 4.21).  This sequence is 
dominated by an almost invariant G 5’ to the absolute prerequisite for me-CpG 
at positions 1’ and 2’ in the right-half of the core sequence. Beyond that, there is 
some resemblance to the non-CpG consensus only at the extreme 5’ and 3’ 
ends.  
The identification of 58 EBV genes that contain methylation dependent CpG 
ZREs in their proximal regulatory regions, combined with the knowledge that the 
EBV genome is heavily methylated during latency (Fernandez et al., 2009, Kalla 
et al., 2010), suggests that Zta plays an important role in overturning epigenetic 
silencing of over half of the EBV genes during lytic replication. ZtaMUT-bound 
sequences resulted in a similar consensus site with an almost invariant GCG 
(Bergbauer et al, 2011) to that shown in Figure 4.21. It has previously shown 
that wild-type Zta interacts with both Rp (Karlsson et al., 2008b) and the BRRF1 
promoter (Dickerson et al., 2009) in vivo. In contrast, ZtaMUT was unable to 
interact with the full set of ZREs in Rp, nor did it recognize the BRRF1 promoter 
(Bergbauer et al., 2010). These conflicting data can be rationalised if it is 
considered that the regions of Zta excluded from the mutant form influence 
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Figure 4.21 Sequence logo representations of methylation dependent and 
independent ZREs. 
The ZRE32 list was split into those containing CpG motifs and those without. Position 
Frequency Matrices (PFMs) were created and Sequence Logos were produced to 
represent the consensus sequence of each.  
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the stability of DNA binding in vivo. This therefore casts some doubt over the 
completeness of this ChIP Seq study, and repetition of this with full length Zta 
would be beneficial.  
The 22 EBV genes that contain methylation dependent but no methylation 
independent ZREs are particularly interesting and informative. Several of these 
genes are required for EBV replication and include components of the 
helicase/primase complex (BBLF4, BBLF2/BBLF3), the viral protein kinase 
(BGLF4), and glycoproteins gL (BKRF2) and gB (BALF4). All of these 
regulatory regions are heavily methylated during viral latency yet unmethylated 
following replication and immediately after infection (Fernandez et al., 2009, 
Kalla et al., 2010). The promoter for BBLF4 has been validated as being 
absolutely dependent on methylation for Zta activation, and the ZREs in 
BBLF2/3 were shown to be dependent on methylation for binding in EMSAs 
(Bergbauer et al., 2010). The binding of Zta to some of the novel ZREs was 
confirmed in this chapter in replication stalled IgG treated Akata cells by ChIP, 
including those found in viral protein kinase BGLF4 and 2 other regions, BKRF4 
and BTRF1, tegument proteins. 
 The discovery that around 20% of EBV regulatory regions contain CpG ZREs 
but have no methylation independent ZREs in their regulatory regions strongly 
supports the hypothesis that the unmethylated status of the EBV genome 
guards against the expression of the full range of lytic genes and therefore lytic 
replication during the establishment of latency. However, a further five gene 
promoter regions were shown in the same paper to require methylation for 
expression (BRLF1, BALF2, BMRF1, BBLF1 and BALF5); these regions were 
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overlooked in this analysis due to the fact that they contain methylation 
independent Class I ZREs in their promoter as well as the CpG-containing 
ZREs. This suggests that even in the presence of Class I sites, a methylation 
dependent mode of activation could still be required, increasing the number of 
genes potentially controlled in this manner to 58.  
It is interesting to compare the results of our ChIP with that of the Ztamut ChIP. 
Demonstration of full length Zta binding to the promoter region of BKRF4 was 
also shown in the ChIP seq data, to a lesser extent. However, BGLF4 and 
BTRF1 promoter binding was not reflected in an equivalent manner, with the 
ChIP Seq only displaying some binding in vitro. This could be due to the 
differences in the protein (full length versus truncated version) or cell 
background (Akata versus Raji/B95.8).  
Each unique ZRE sequence was analysed by averaging the ChIP Seq values 
for the positions where each occurrence was found. This allowed the behaviour 
of the site with ZtaMUT both in vitro and in vivo to be assessed. First the well-
described ZREs within Rp were analysed, to assess the suitability of this 
technique for evaluating the novel ZRE sequences. The sequence logo 
resulting from the ChIP Seq (Bergbauer et al, 2010) very closely matched 
RpZRE2, and by averaging the 17 occurrences of this ZRE, there is a clear 
binding peak in both in vivo samples, and in the methylated in vitro experiment, 
compared to almost non-existent binding in the unmethylated in vitro condition. 
However, the same could not be shown to a comparable extent for RpZRE1 
and RpZRE3. There are several possibilities to explain the differences. The 
ChIP Seq used ZtaMUT lacking the transactivation domain, suggesting that this 
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region could influence sequence-specific DNA binding. It would be interesting to 
investigate the ability of the ZtaMUT to bind to the predicted ZREs in EMSAs. 
Equally, comparison with ChIP Seq data performed using wild type Zta would 
reveal the full binding possibilities within the EBV genome.  
The continuous nature of the ChIP Seq binding data can make it difficult to 
specifically interpret the binding ability of each novel PFMCpG5 predicted site. 
The proximity of other ZREs also makes analysis difficult. However, the 
predictions can be placed upon a scale of increasing binding ability, starting 
with those that do no appear to bind at all (PFMCpG5 H and N), those which can 
only be seen to bind in EMSAs (PFMCpG5 C and L), or not able to bind in all 
contexts (PFMCpG5 B, E, G, J, M, BMRF1(-148) and RpZRE(-114)), those which 
bind to varying extents, perhaps performing better in vitro than in vivo (PFMCpG5 
F and I, PFMCpG5 K and D) and those which show fairly well defined binding 
profiles (BMRF1 (-248) and PFMCpG5 A). It is interesting to note that the main 
CpG containing sequences picked out by the analysis in the Bergbauer et al 
paper were matches to RpZRE2 and BMRF1(-248); this data is therefore likely 
to confirm these as competent ZREs.  
The in vitro binding gives a good indication of the potential of Zta to bind to a 
specific sequence, which is more similar to the effects seen in EMSAs. 
However, in cell lines where normal chromatin formation will occur, the actual 
binding positions of Zta may be obscured by these structures, or even other 
binding proteins, including methyl-binding proteins. Perhaps in the latter case, 
the relative binding affinities of the proteins will affect overall expression. 
Another factor which has not been taken into account is whether the 
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occurrences of each novel site fall within promoter regions; the data was not 
filtered in this way previous to analysis, and therefore does not take this into 
account. A hypothesis would be that Zta is more likely to bind in promoter 
regions, therefore the averaged binding data of specifically those found there 
may form more specific averaged peaks, when analysed without sites that occur 
outside the defined promoter regions. However, due to the compact nature of 
the EBV genome, it is difficult to assess whether many of these positional 
predictions do occur outside a potential promoter region. 
Analysis of the host genome exposed a set of genes with regulatory regions 
resembling those of EBV genes. They contain methylation dependent ZREs, 
are methylated in cells targeted by EBV and are regulated following expression 
of Zta. These promoters therefore share the characteristics that would allow 
epigenetic silencing to be overturned during EBV replication through the 
interaction of Zta with methylated ZREs. Zta has been shown to both upregulate 
(Egr1, Il-8, Il-13) and downregulate (CIITA) human gene expression, and these 
opposite effects can occur through interaction with the same core ZRE; the ZRE 
found in the promoter of CIITA, causing down-regulation, is an exact match to 
that found in the promoter IL13, where interaction of Zta with this site has been 
shown to cause up-regulation. The potential for gene expression control is 
divergent, and not reliant on a specific ZRE sequence. How can one protein 
interacting with the same DNA sequence have two such differing roles? 
Perhaps the inhibitive effect of Zta on this promoter is due to overlapping of the 
ZRE with another response element, usually required for a different protein to 
interact with and activate gene expression. Another possible mechanism would 
involve cis-acting modules of other transcription control proteins in the same 
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promoter; for activation, one set of proteins is required and for inhibition, a 
separate set is involved. The overall effect of Zta binding to the promoter would 
be a context and environmental dependent outcome.  
ZtaMUT, used by Bergbauer et al in the ChIP Seq data interrogated in this 
chapter, lacks the transactivation domain. The behaviour of this mutant in some 
specific regions of the EBV genome is different to previously published data, 
and ChIP PCR performed in this chapter. This discrepancy suggests that this 
region could influence sequence-specific DNA binding, perhaps due to any 
effect these domains may have on overall structure or dimerisation ability, or the 
interaction of Zta with other proteins. It would be interesting to investigate the 
ability of the ZtaMUT to bind to the predicted ZREs in EMSAs. Equally, 
comparison with ChIP Seq data performed using wild type Zta would reveal the 
full binding possibilities within the EBV genome. The transactivation domain is 
known to interact with other proteins, and this may lead to co-operative binding 
to some DNA sequences. Therefore without this region in ZtaMUT may not bind 
to all the sites shown in a wild type Zta ChIP. The EMSAs were performed with 
in vitro translated Zta, and without all the cellular proteins that would be present 
in a nuclear extract, or in a ChIP experiment. However, some other proteins are 
present in the translation systems, which sometimes show as non-specific 
bands on an EMSA gel. These could contribute to complex formation.  
In a ChIP experiment, the binding of Zta to specific DNA sequences is affected 
by the surrounding chromatin structure; if the sequence is hidden within a 
condensed section of chromatin, Zta will be unable to interact with that 
sequence. It would not be surprising if Zta was prevented from binding in some 
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contexts for this reason, and this would explain some of the graphs with large 
error bars showing the averaged binding to specific sequences. 
Chromatin structure will also affect the sonication step; silenced chromatin does 
not shear to the same extent as euchromatin, leading to an overrepresentation 
of long fragments in heterochromatic regions. These long fragments would not 
pass the size-selection of the protocol, and also have less fragment ends within 
the region, reducing the number of reads (Teytelman et al., 2009). All these 
reasons would lead to underrepresentation of the silenced regions (Liu et al., 
2010).   
Regions with a higher GC content have been shown to have a high correlation 
to an increased number of reads (Dohm et al., 2008), which again will lead to 
overrepresentation of specific regions. This could be due to the higher 
temperature required to melt GC DNA, therefore AT rich DNA may be 
denatured and unusable at a lower temperature prior to PCR, allowing GC rich 
DNA to perpetuate due to their increased stability (Dohm et al., 2008, Margulies 
et al., 2001). However, GC rich regions that possess strong secondary structure 
with a higher melting point can be difficult to amplify in standard PCR reactions 
(Hube et al., 2005), such as that which would be used as to amplify the DNA 
before sequencing. This would lead to an underrepresentation of GC rich 
regions, making the overall effect of GC content on reliability of ChIP Seq data 
difficult to predict. Sequencing biases would be controlled for by using an 
appropriate input sequencing run concurrently. 
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Chapter 5: Host methylation dependent DNA binding 
factor 
5.1. Introduction 
The occurrence of methylation dependent ZREs in the human genome does not 
necessarily imply they are there for the benefit of EBV infection; rather it 
suggests that Zta shares a common mechanism with a host DNA binding 
protein. This led to the question of whether a host factor could bind to the 
RpZRE3 sequence in a methylation dependent manner.  
DNA methylation status strongly correlates with the associated gene 
expression, and aberrant methylation is linked to cancer (Esteller, 2008). 
Hypomethylation of specific genes was first shown to differentiate between 
cancerous and normal cells (Feinberg and Vogelstein, 1983). Hypermethylation 
of tumour suppressor genes such as VHL (Herman et al., 1994) and p16 
(Herman et al., 1995, Merlo et al., 1995) provided further evidence linking 
methylation status with expression and hence cell behaviour in cancer.  
Whether this is merely an association, or a causative mechanism has long been 
a source of controversy. A recent paper appeared to confirm a causative link; 
methylation of 2 specific tumour suppressor genes (HIC1 and RassF1A) was 
shown to transform mesenchymal stem cells into cancer stem cells (Teng et al., 
2011).   
The methylation of CpGs is thought to contribute to silencing in 3 main ways. 
The methylated CpG motif directly interferes with the interaction between 
transcription factors and DNA; this has been confirmed for a number of 
transcription factors, including CREB (Iguchi-Ariga and Schaffner, 1989), MLTF 
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(Watt and Molloy, 1988) and c-myc (Prendergast and Ziff, 1991). It also 
provides a binding site for methyl-binding proteins such as chromatin 
remodelling factors, and in this way it contributes to the packaging of the DNA 
region (Esteller, 2008). These binding proteins may also play a role in 
obstructing the access of transcription activating proteins. CpG methylation can 
also affect nucleosome positions on the DNA by affecting the rigidity of the 
double helix (Segal and Widom, 2009). In the same way as the methyl binding 
proteins, this may prevent transcription machinery loading onto promoters. 
Although long associated with the silencing of genes, DNA methylation is 
increasingly being shown to be involved in more complicated mechanisms. The 
requirement of CpG methylation was first shown in the Rp promoter, allowing 
Zta to bind and activate transcription (Karlsson et al., 2008a, Bhende et al., 
2004, Bhende et al., 2005). In this way, CpG methylation is creating a binding 
site for Zta, similar to the way it destroys binding sites for other transcription 
factors. 
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5.2. Results 
5.2.1 Host methylation dependent binding protein in HEK293 extract  
Nuclear extract from HEK293 cells was titrated in an EMSA with a double 
stranded oligonucleotide encompassing the central RpZRE3 core sequence, 
and 10 basepairs of cognate flank sequence on either side, in both the 
unmethylated and methylated state. A large complex is only visible with the 
methylated form of the probe, and increases in intensity with increasing amount 
of nuclear extract, denoted “M”. Conversely, a lower molecular weight complex 
can be seen only with the unmethylated probe, denoted “U”, but this complex 
could not be reliably reproduced. A cluster of 3 bands beneath the “M”  complex 
are hard to differentiate, however there appears to be a complex formed only 
with the methylated oligonucleotide, denoted as “A” (Figure 5.1).  
 
 
 
 
 
Figure 5.1 Host protein binding to ZRE affected by methylation. 
Double stranded oligonucleotides were generated with the core RpZRE3 sequence and 
at least 10 nucleotides of cognate sequence on either side, with the two CpG motifs 
within the ZRE either unmethylated or methylated. Following radiolabelling, these were 
incubated with HEK293 nuclear extract.  
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To confirm the specificity of these unknown complexes for methylated RpZRE3, 
oligonucleotides were synthesised with a mutated core sequence that Zta has 
previously been shown not to bind, known as RpZRE3 mut core. Another 
mutant oligonucleotide (replacing the 3’ AA with CT), Mut2, was synthesised to 
question whether the complexes were forming due to the double CpG 
nucleotide in the centre of RpZRE3 wild type sequence (Figure 5.2A).  
Complex M was confirmed to require the central RpZRE3 motif in the 
methylated state, including the 3’ AA. Complex A requires methylation but does 
not require the 3’ AA (Figure 5.2B).  
This is summarised by the model in Figure 5.3, and highlights the following 
question; is the binding confined to our definition of the site boundaries, or does 
it overlap with the flanking sequence specific to the BRLF1 promoter? If the 
binding of M is specific to the core sequence only, then the protein that binds 
here would also bind in all of the host sites identified in chapter 4 that contain 
this sequence, and would suggest an equivalent host mechanism for 
methylated DNA dependent binding.  
5.2.2 Host methylation dependent binding protein is specific to the 
RpZRE3 context 
To question whether this core sequence alone is sufficient for host factor 
binding, previously used RpZRE3-site oligonucleotides CyclinL2 and HDAC2 
were incubated with nuclear extract, in both the unmethylated and methylated 
state. These oligonucleotides were chosen after analysis by PROMO showed 
that these sequences had the least number of predicted binding sites for other 
host proteins. This EMSA suggests that complex M requires a specific  
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Figure 5.2 Mapping methylation dependent host protein binding. 
A Double stranded oligonucleotides were generated with the core RpZRE3 sequence, or 
a mutated version of the sequence, and at least 10 nucleotides of cognate sequence on 
either side, with the 2 CpG motifs of RpZRE3 or RpZRE3 mut core CGCG either 
unmethylated or methylated. B Following radiolabelling, these were incubated with 
HEK293 nuclear extract, and subjected to EMSA analysis.  
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Figure 5.3 Host protein binding to RpZRE3 model.  
Both complex A and M form in the presence of methylated CpG dinucleotides, indicated 
by red Cs. Complex M requires the 3’ AA of the core RpZRE3 site, whereas complex A 
does not. The extent of the binding site of each protein has been not fully revealed.  
186 
 
 
environment that is provided by the flank of the RpZRE3 oligonucleotide, but 
that complex A is less dependent on a specific flanking sequence (Figure 5.4). 
This implies that complex M is specific to the RpZRE3 in the BRLF1 promoter, 
requiring part of the 3’ flank to the core RpZRE3 site, and may not bind to all 
instances where the sequence can be found in the host genome. In contrast, 
complex A is unaffected by the change in flank. This, combined with the effect 
of the oligonucleotide mut2, suggests that A is specific to the sequence 
TCGCG.    
5.2.3 C/EBPalpha as a candidate for complex M 
At this stage of the investigation, the ability of C/EBPalpha to bind to the 
methylated version of a CpG containing CRE sequence (TGACGTCA) was 
revealed (Rishi et al., 2010). C/EBPalpha is a bZIP protein, like Zta, and 
dimerises to bind to DNA (Ramji and Foka, 2002). The consensus sites of Zta 
and C/EBPalpha are very similar. A comparison using protein BLAST (NCBI) 
was carried out (Figure 5.5). Zta possesses C189 within the DNA binding 
domain, a residue shown to be required for interaction and activation through 
RpZRE3 (Karlsson et al., 2008a) and therefore postulated to be required for 
methylation dependent binding. However, C/EBPalpha contains a serine 
residue in the corresponding position. 
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Figure 5.4 Methylation dependent host protein binding affected by flanking 
sequence. 
Oligonucleotides with the same core RpZRE3 sequence but differing flank regions were 
synthesised in both the unmethylated and methylated state. After radiolabelling, 
oligonucleotides were incubated with nuclear extract from HEK293 cells and subjected to 
EMSA.  
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5.2.4 PROMO analysis of RpZRE3 oligonucleotide 
 In an attempt to discover the identity of the unknown host binding protein, 
PROMO (Messeguer et al., 2002, Farre et al., 2003) was used to predict 
transcription factor binding sites in the RpZRE3 oligonucleotide, and both the 
mutated core versions (Figure 5.5). Several C/EBP isoforms had predicted sites 
in all the oligonucleotides (data not shown), however these were either confined 
to the flanking regions, or were very short recognition sequences, such as CGC, 
which had already been controlled for in the EMSA mutations. However, these 
C/EBP isoforms could be candidates for complex A. This short consensus site 
does not match the most recent publications on C/EBPalpha sites. Transcription 
factors with sites predicted only in the wild type RpZRE3 were identified (and 
not the HDAC2 and CyclinL2 oligonucleotides), and then filtered for only those 
containing a CpG dinucleotide. This identified 5 transcription factors, all with 
predicted binding sites that overlapped the core site and the 3’ flank, making 
them candidates for complex M identification (Figure 5.6). 
 
Figure 5.5 Protein BLAST alignment of C/EBPalpha and Zta 
The DNA binding domains and bZIP dimerisation domains of both proteins are 
highlighted. The important C189 residue for the ability of Zta to bind to methylated 
RpZRE3 sequence is also highlighted, and the equivalent residue in C/EBPalpha. 
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Figure 5.6 PROMO predictions of CpG containing transcription factor binding sites 
found in RpZRE3 oligonucleotide. 
The RpZRE3 oligonucleotide sequence was input into the PROMO prediction tool, and 
the transcription factor predictions were compared with those found in the mutated 
oligonucleotides. Those found only in the wild type oligonucleotide and containing a CpG 
dinucleotide are shown here. The coloured blocks represent the respective transcription 
factor binding site position in the RpZRE3 oligonucleotide.  
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5.3. Discussion 
The potential for a host binding protein with the same methylation dependent 
binding mechanism as Zta introduces complications to the existing silencing 
theories of DNA methylation, and also provides a potential evolutionary 
ancestor to the viral protein. A methylated promoter is not necessarily silenced, 
depending on the expression of methylation dependent binding factors.   
In this chapter, a complex (labelled M) is shown to form with the methylated 
version of the RpZRE3 oligonucleotide, and that this complex formation requires 
the presence of the core site, not merely the methylated double CpG 
dinucleotide. However, the core RpZRE3 sequence is not sufficient for complex 
formation, implicated the flank of the oligonucleotide in the binding ability. A 
second complex, (labelled A) is also shown to form with the methylated 
RpZRE3 oligonucleotide, but only appears to require the first (5’) 5 nucleotides 
of the site. The approximate binding positions of these complexes, with the 
potential binding dynamics with regards to Zta complex formation, is depicted in 
figure 5.7. 
After these EMSAs were performed, C/EBPalpha was shown to bind in a 
methylation dependent manner to the CRE sequence TGACGTCA, and that this 
activity was important for the activation of methylated promoters during 
keratinocyte differentiation (Rishi et al., 2010). C/EBPbeta was also shown to 
bind in a similar manner in the initial investigation; however this was not 
pursued further in this paper. This CRE sequence matches the site found in the 
FN oligonucleotide. Zta has been shown in chapter 4 to bind to this site 
relatively weakly, in both the unmethylated and the methylated state. The  
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Figure 5.7 Host protein/Zta dynamics of binding to the methylated RpZRE3 
oligonucleotide. 
Potential displacement of these human factors by Zta upon BZLF1 expression. 
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possibility of C/EBPalpha binding to the RpZRE3 oligonucleotide in a 
methylation dependent manner is considered here.  
C/EBPalpha could have the potential to bind to RpZRE3 and other CpG 
containing sequences in the same methylation dependent manner as Zta. 
TTGCGCAA is the consensus C/EBPalpha binding site, to which it can bind in 
unmethylated form, but preferentially binds when it is methylated (Rishi et al., 
2010). It contains the invariant GCG shown in the position frequency matrix; 
however it is difficult to know how to align this site with ZREs, due the fact it is 
an octamer compared to the heptamer ZREs. The site to which it was shown to 
bind in a methylation dependent manner contains a single central CpG 
dinucleotide, which again is difficult to align with known ZREs; the CpG 
dinucleotide is seen to be offset from the centre in all the specifically 
methylation dependent sites. The CpG motif is found centrally in the AP-1 like 
sites, investigated in chapter 4. These sites were bound by Zta in both the 
unmethylated and methylated state, suggesting that both the unmethylated and 
the methylated residue can be tolerated at this position.  
The binding abilities of C/EBPalpha could be classified in the same way as Zta. 
C/EBPalpha binds to non-CpG containing, and therefore methylation 
independent, sites, like the Class I ZREs. The consensus site of C/EBPalpha 
contains a CpG, and can be bound in both the unmethylated and methylated 
states, Class II ZRE behaviour. Finally, the CREB consensus site is bound in a 
completely methylation dependent manner, like the Class III ZREs.   
The C189 residue is known to be required for Zta interaction with RpZRE3 
sequence (Karlsson et al., 2008a) however this has not been confirmed for 
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other ZREs (such as NaZREs (Dickerson et al., 2009)). The fact that 
C/EBPalpha does not contain this residue in an equivalent position after 
aligning the protein sequences using BLAST may suggest that this residue is 
only required to stabilise the interaction of Zta with RpZRE3, whereas other 
bZIP transcription factors may not require this for interaction with the same site. 
The consensus sequences for the PROMO predicted transcription factors were 
examined. Cutl1, POU1F1A, POU3F2 and HSF1 do not contain a CpG 
dinucleotide, however the predicted binding site does. PROMO allows a 
maximum of 15% dissimilarity from the consensus sequence, which obviously 
can lead to nucleotide differences in the predicted sequence. This does not 
necessarily mean that these proteins will not bind to this sequence, but it has 
not yet been confirmed and the effect of methylation is unknown. Cutl1, 
POU1F1A and POU3F2 are members of the homeodomain family of DNA 
binding proteins. Other members of this family of DNA binding proteins, Oct1 
and Oct2, have been shown to be involved in control of BRLF1 expression, but 
this is not via DNA binding; Oct1 activates lytic cycle, via interaction with Rta 
through Rta Response Elements (RREs) and Oct2 is thought to inhibit lytic 
cycle. Oct2 is restricted to B cells, suggesting a mechanism for latency 
establishment, whereas Oct1 is found in a wide variety of cell types (Robinson 
et al., 2011). HSF1 (Heat Shock Factor 1) contains a leucine zipper, and 
functions as a homotrimer when a cell undergoes heat shock or stress (Batista-
Nascimento et al., 2011). 
The predicted binding site of Dof2, a transcription factor currently found only in 
maize with an unusual zinc finger-like structure (Tapia-Ramirez et al., 1997), 
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contains a CpG dinucleotide at the very start of the consensus site. It is 
unknown whether the methylation of this CpG dinucleotide would affect the 
ability of Dof2 to bind.  
Unfortunately all these predicted proteins appear to be unlikely candidates, due 
to differences between the consensus and predicted sites, or the unlikelihood of 
their occurrence in human epithelial cells. Based upon the optimisation carried 
out to improve the position frequency matrix for ZRE prediction in chapter 5, it is 
perhaps not surprising that PFMs in PROMO for the binding sites of other 
transcription factors may be found deficient. Alternatively, the protein that binds 
in these nuclear extract EMSAs may not be very well characterised, and 
therefore the binding sites not well predicted by PROMO. 
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Chapter 6: Discussion 
The prediction of methylation dependent ZREs in a number of lytic promoters, 
supports the model that methylation is required for full lytic cycle activation, and 
the lack of methylation works to prevent lytic gene expression during primary 
infection.   
Upon infection, the genome circularises and expresses some latency genes 
which help drive the virus into the latent phase of the life cycle. Zta has been 
shown to be present at this early stage just after infection (Halder et al., 2009) 
so therefore has the potential to bind to promoters and activate expression. 
However, as the genome is unmethylated, Zta cannot bind to all of the required 
response elements. As identified in chapter 5, the promoters of some viral 
genes required for full lytic replication, including components of the replication 
machinery, appear to only contain ZREs that require methylation for interaction 
with Zta. The unmethylated state of these promoters at this early stage prevents 
their expression. This in turn prevents the full cohort of lytic gene expression 
and replication, ensuring that gene products that induce an immune response 
are not expressed, allowing the viral genome to establish latency and remain 
hidden from the host. The genome becomes progressively methylated over the 
coming weeks, becoming almost fully methylated after 3 weeks (Kalla et al., 
2010). At this stage an external stimulus, such as activation of the B cell 
receptor, could activate expression of Zta. Those genes containing only 
methylation dependent ZREs will now be successfully activated, as they are 
now methylated. Full lytic cycle will then ensue.  
196 
 
 
As discussed in chapter 4, the ztaMUT ChIP, performed by Bergbauer et al, has 
its limitations, and it was prudent to attempt a ChIP using full length Zta. This 
has been undertaken in the lab after I left. They have used conditions in which 
lytic cycle is activated by cross-linking of Akata cells with IgG, but replication is 
stalled with the addition of acyclovir. This allows a “snapshot” of the binding 
profile of Zta to be taken. The results so far have been interesting, and one key 
observation that verifies the ZRE position predictions has been that all the early 
lytic genes exhibit Zta ChIP signal greater than 1.75 reads per million. For 
comparison, OriLyt, a region we know relevant Zta binding is occurring, has a 
ChIP signal of approximately 2 reads per million. 
An important factor to consider in ChIP-seq profiling of Zta is the different 
template environments at different points of the life cycle. Without a fully 
synchronised homogenous population of cells, a mixture of these templates will 
be present. Upon infection, the genome is unmethylated and naked with 
regards to histone and chromatin formation. The expression of Zta has been 
shown to be important in the immortalisation of the cell at this point (Kalla et al., 
2010). During latency, the genome is methylated and bound by histones to form 
a chromatin structure, and this will be the state the template is in upon induction 
of lytic activation. After the lytic activation, the replicated genome will be naked 
and unmethylated. These 3 different situations could account for the ability of 
Zta to bind to some sites and not others. 
Replication of the genome potentially provides a mechanism to shift the binding 
of Zta from these methylated response elements, some of which Zta has been 
shown to have a higher affinity for (Bergbauer et al., 2010), to those response 
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elements that do not require methylation. As the double stranded DNA genome 
is unzipped for replication to occur, that DNA will now become hemi-methylated. 
It has previously been shown that a hemi-methylated version of a methylation 
dependent response element causes a reduction in complex formation with Zta 
(Karlsson et al., 2008a). It is also likely that any DNA binding proteins will be 
displaced by the replication machinery during replication, including Zta. When 
the double stranded genome is reformed, Zta is now free to bind to 
unmethylated, potentially lower affinity binding sites. These response elements 
may control late lytic genes, those which require replication to occur before they 
are expressed.  
Whether Zta binds to newly replicated genome, and whether it activates any 
expression, is an interesting question, which does not appear to have been 
addressed in the literature yet. Using BrdU, the newly replicated genome could 
be labelled, and then immunoprecipitated for. A Zta re-ChIP could then be 
performed to address this question. I would predict that the binding profile would 
change, with those regions containing methylation dependent ZREs losing 
signal, and those regions with non-methylation dependent ZREs gaining signal, 
shifting the distribution of Zta. However, the large number of unmethylated 
genomes may mean that the relative binding, and therefore signal, at each 
region is diluted, as only a finite amount of Zta is available to bind, unless new 
Zta is being expressed.  
Some of the gene promoters identified with only methylated dependent sites in 
their promoter regions have previously been classified as late lytic genes; why 
would these genes be activated in a methylation dependent context, and how 
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would the stable RNA products only be detected when replication was allowed 
to take place? Some reasons for this could include a requirement of the 
expression of a true late lytic gene, only expressed post-replication, which is 
needed to stabilise the RNA product. Another explanation could be that the 
chromatin structure of the particular region is such that even though the DNA is 
methylated, the response element is hidden from Zta, and therefore unavailable 
for binding, until after replication has taken place to displace the chromatin 
structure.  
Zta is the prototypic member of a family of transcription factors that interact with 
DNA in a methylation dependent manner. C/EBP alpha has recently been 
shown to share the same characteristics (Rishi et al., 2010). It has been 
suggested that the interaction between C/EBP alpha and it is methylated 
sequence elements are needed to activate tissue specific genes during 
differentiation. Although both proteins have the ability to recognize some DNA 
sequence elements only when the CpG motifs are methylated, and are both 
bZIP transcription factors, the consensus sites for methylation dependent 
binding are not the same. As shown in chapter 4 however, Zta does show some 
affinity for the C/EBPalpha site, although this interaction requires further 
investigation for full characterization. In chapter 5, it can be observed that a 
human factor has affinity for the methylated RpZRE3 site; perhaps this is C/EBP 
alpha, or another, as yet unknown, methylation dependent binding factor. To 
question this, I was interested to perform a DNA affinity pulldown, using 
biotinylated versions of the RpZRE3 oligonucleotide used in the EMSAs. The 
sample would then be prepared to send to mass spectroscopy to attempt to 
identify the proteins binding to this sequence. The conditions for this needed to 
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be optimised and a high quality sample collected to ensure a good mass 
spectroscopy reading, and therefore I did not have time to attempt this 
experiment. 
The biphasic methylation cycle is observed for several different classes of 
viruses that establish latency (Fernandez et al., 2009). Yet even KSHV, which is 
closely related to EBV, does not contain a BZLF1 homologue. Perhaps the 
recent discovery that a cellular transcription factor also has methylation 
dependent DNA binding properties (Rishi et al., 2010) implies that other viruses 
may rely on host methylation dependent transcription factors to differentially 
control the expression of their genomes during the establishment of latency or 
replication.  
The C189S mutation has been observed to be methylation dependent for some 
ZREs, but not others. However, the ability to reactivate lytic cycle was shown to 
be diminished when the C189S mutation was used (Schelcher et al., 2005). 
Perhaps this suggests an additional role for Zta in lytic reactivation than 
specifically direct DNA binding. Zta is known to interact with other proteins, both 
viral and of the host; the C189 residue may be required for one of these key 
interactions. Alternatively, the C189 residue may only be required in binding to 
the methylated CpG in RpZRE3, and is involved in competition with other 
proteins for this particular site during reactivation. EMSAs performed with rabbit 
reticulocyte lysate (RRL) and wheatgerm would contain other proteins, which 
may be involved in the observed binding status. Bacterially expressed Zta was 
used in Wang et al. (Wang et al., 2005), in which they saw very little difference 
between wildtype and C189S mutation in the methylation dependent binding to 
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RpZRE2. This concurs with the finding in Schelcher et al (Schelcher et al., 
2005) for RpZRE2. However, RpZRE3 binding was not addressed by Wang et 
al. It would be interesting to see if the reduction observed in chapter 4 in ZREs 
binding with C189S Zta in vitro translated in RRL or wheatgerm was replicated 
with bacterially expressed Zta. 
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ENSG00000072786 STK10 
ENSG00000115694 STK25 
ENSG00000054654 SYNE2 
ENSG00000171148 TADA3L 
ENSG00000135801 TAF5L 
ENSG00000162227 TAF6L 
ENSG00000178913 TAF7 
ENSG00000160551 TAOK1 
ENSG00000092607 TBX15 
ENSG00000100926 TM9SF1 
ENSG00000164124 TMEM144 
ENSG00000065600 TMEM206 
ENSG00000112697 TMEM30A 
ENSG00000156171 TMEM77 
ENSG00000163472 TMEM79 
ENSG00000164897 TMUB1 
ENSG00000168591 TMUB2 
ENSG00000185361 TNFAIP8L1 
ENSG00000077097 TOP2B 
ENSG00000167333 TRIM68 
ENSG00000206557 TRIM71 
ENSG00000144935 TRPC1 
ENSG00000163728 TTC14 
ENSG00000200368 U47924.1 
ENSG00000150991 UBA52 
ENSG00000165006 UBAP1 
ENSG00000184182 UBE2F 
ENSG00000174607 UGT8 
ENSG00000147854 UHRF2 
ENSG00000111981 ULBP1 
ENSG00000100373 UPK3A 
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ENSG00000156467 UQCRB 
ENSG00000173660 UQCRH 
ENSG00000111237 VPS29 
ENSG00000139719 VPS33A 
ENSG00000163811 WDR43 
ENSG00000206061 Z97652.9 
ENSG00000213062 Z99572.1 
ENSG00000176261 ZBTB8OS 
ENSG00000120784 ZFP30 
ENSG00000131127 ZNF141 
ENSG00000204920 ZNF155 
ENSG00000166526 ZNF3 
ENSG00000198546 ZNF511 
ENSG00000171425 ZNF581 
ENSG00000173545 ZNF622 
ENSG00000143373 ZNF687 
ENSG00000169957 ZNF768 
ENSG00000198346 ZNF813 
 
Genes which contain a RpZRE3 core element in the promoter region, defined 
as 500bp upstream of the gene start. 
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Appendix II 
Seq 
Found 
Position 
Class 
TGAGCAA 1064 Class1 
TGACACA 1539 Class1 
TGACACA 2496 Class1 
CCGCTCA 2531 Class3 
ACGCTCA 2809 Class3 
TGGCACA 3659 Class1 
TGAGCAA 3970 Class1 
TCGCTAA 4274 Class3 
TCAGCGA 4385 Class3 
TCGCCCA 4595 Class3 
TCGCGAA 4943 Class3 
TGTGCAA 5851 Class1 
TGGCACA 6496 Class1 
ACGCTCA 6994 Class3 
TCAGCGA 8055 Class3 
GCGCTCA 8097 Class2 
TGTGTAA 8114 Class1 
TGACTAA 8916 Class1 
TTAGCAA 9158 Class1 
TGTGTAA 9299 Class1 
TGTGCAA 9598 Class1 
GGAGCGA 9676 Class3 
TGAGCAA 9845 Class1 
TCGCCCA 10488 Class3 
GGAGCGA 11057 Class3 
TCGCAAA 11101 Class3 
TCGCCCA 11235 Class3 
TGGCACA 12009 Class1 
GGAGCGA 12119 Class3 
CGGGCGA 12587 Class3 
CGGGCGA 12613 Class3 
GGAGCGA 13263 Class3 
CGGGCGA 13334 Class3 
TCAGCGA 14532 Class3 
TCGCCCA 14733 Class3 
TGGCACA 15081 Class1 
GGAGCGA 15191 Class3 
CGGGCGA 15659 Class3 
CGGGCGA 15685 Class3 
GGAGCGA 16335 Class3 
CGGGCGA 16406 Class3 
TCAGCGA 17604 Class3 
TCGCCCA 17805 Class3 
TGGCACA 18153 Class1 
GGAGCGA 18263 Class3 
CGGGCGA 18731 Class3 
CGGGCGA 18757 Class3 
GGAGCGA 19407 Class3 
CGGGCGA 19478 Class3 
TCAGCGA 20676 Class3 
TCGCCCA 20877 Class3 
TGGCACA 21225 Class1 
GGAGCGA 21335 Class3 
CGGGCGA 21803 Class3 
CGGGCGA 21829 Class3 
GGAGCGA 22479 Class3 
CGGGCGA 22550 Class3 
TCAGCGA 23748 Class3 
TCGCCCA 23949 Class3 
TGGCACA 24297 Class1 
GGAGCGA 24407 Class3 
CGGGCGA 24875 Class3 
CGGGCGA 24901 Class3 
GGAGCGA 25551 Class3 
CGGGCGA 25622 Class3 
TCAGCGA 26820 Class3 
TCGCCCA 27021 Class3 
TGGCACA 27369 Class1 
GGAGCGA 27479 Class3 
CGGGCGA 27947 Class3 
CGGGCGA 27973 Class3 
GGAGCGA 28623 Class3 
CGGGCGA 28694 Class3 
TCAGCGA 29892 Class3 
TCGCCCA 30093 Class3 
TGGCACA 30441 Class1 
GGAGCGA 30551 Class3 
CGGGCGA 31019 Class3 
CGGGCGA 31045 Class3 
GGAGCGA 31695 Class3 
CGGGCGA 31766 Class3 
TCAGCGA 32964 Class3 
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TCGCCCA 33165 Class3 
TGGCACA 33513 Class1 
GGAGCGA 33623 Class3 
CGGGCGA 34091 Class3 
CGGGCGA 34117 Class3 
GGAGCGA 34767 Class3 
CGGGCGA 34838 Class3 
TCGCCCA 35355 Class3 
TGAGCCA 35627 Class1 
TGGCACA 36973 Class1 
TGAGTAA 36999 Class1 
TGGCACA 40268 Class1 
TGTGTAA 40545 Class1 
TGAGCAA 40563 Class1 
TGACACA 40601 Class1 
TGACACA 40634 Class1 
TGTGCAA 41182 Class1 
TGAGCCA 41299 Class1 
TGACACA 41341 Class1 
TGAGCAA 41446 Class1 
TGGCACA 42064 Class1 
TGAGCCA 42719 Class1 
TGACACA 42745 Class1 
TGTGTAA 42977 Class1 
AGACACA 44098 Class1 
TCGCTCA 44488 Class2 
TGGCACA 44931 Class1 
TGGCACA 45013 Class1 
TGTGTAA 45804 Class1 
TGGCACA 46136 Class1 
TGAGCCA 46229 Class1 
TGACACA 46236 Class1 
TGACACA 46649 Class1 
CGGGCGA 46830 Class3 
GTTGCAA 47938 Class1 
ACGCTCA 48106 Class3 
TCGCGAA 48276 Class3 
TGAGCCA 48874 Class1 
CCGCTCA 49180 Class3 
TGAGCCA 49865 Class1 
TGACTAA 49898 Class1 
TCGCAAA 50112 Class3 
CGTGCGA 50239 Class3 
TCAGCGA 51867 Class3 
TCGCGCA 52223 Class3 
CGTGCGA 52313 Class3 
CCGCTCA 53115 Class3 
TCGCTCA 54329 Class2 
TCGCGCA 54479 Class3 
CGGGCGA 54867 Class3 
ACGCTCA 55224 Class3 
GGAGCGA 55612 Class3 
TCGCAAA 55691 Class3 
TCGCGAA 55922 Class3 
GGAGCGA 55978 Class3 
CCGCTCA 56000 Class3 
TGACACA 56120 Class1 
AGAGCGA 56585 Class3 
TCGCAAA 56741 Class3 
AGAGCGA 57203 Class3 
GGAGCGA 57770 Class3 
TGACACA 57916 Class1 
TCGCAAA 58796 Class3 
TGAGTAA 59231 Class1 
CGTGCGA 59810 Class3 
CGGGCGA 60129 Class3 
TGTGTAA 60137 Class1 
CGGGCGA 61602 Class3 
CCGCTCA 62709 Class3 
TCGCGCA 62739 Class3 
CGGGCGA 62859 Class3 
TCAGCGA 63099 Class3 
AGAGCGA 63745 Class3 
TGAGTAA 63836 Class1 
TGTGTAA 64251 Class1 
TCGCGCA 64356 Class3 
TCAGCGA 64756 Class3 
TGGCACA 64904 Class1 
GCGCTCA 65095 Class2 
TGGCACA 65510 Class1 
CGAGCGA 65653 Class3 
ACGCACA 66022 Class3 
CCGCTCA 66379 Class3 
TGAGCAA 66453 Class1 
TCGCACA 67330 Class3 
TGGCACA 67405 Class1 
CCGCTCA 67430 Class3 
TGAGCAA 67471 Class1 
TGACTCA 67517 Class1 
TGAGCAA 67534 Class1 
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TGAGCCA 68533 Class1 
AGACACA 68865 Class1 
AGACACA 68959 Class1 
TGACACA 69642 Class1 
GCGCTCA 69772 Class2 
TGTGTAA 70425 Class1 
TGGCACA 70771 Class1 
TTAGCAA 70869 Class1 
TCGCTCA 71579 Class2 
TGACTCA 72140 Class1 
TGGCACA 72260 Class1 
TGAGCAA 72289 Class1 
TGGCACA 72331 Class1 
TCGCTCA 72357 Class2 
AGACACA 72799 Class1 
TCGCTCA 73151 Class2 
CGCGCGA 73472 Class3 
ACGCACA 73603 Class3 
GGAGCGA 73674 Class3 
TAAGCGA 73744 Class3 
ACGCACA 73772 Class3 
TGTGCAA 73895 Class1 
GCGCTCA 74228 Class2 
TCGCTCA 74259 Class2 
CGCGCGA 74278 Class3 
CCGCTCA 74313 Class3 
TGGCACA 74474 Class1 
TTAGCAA 74800 Class1 
GCGCTCA 74961 Class2 
GCGCTCA 75097 Class2 
TCGCTCA 75398 Class2 
TGGCACA 76293 Class1 
TGACTAA 76489 Class1 
CCGCTCA 77781 Class3 
TCGCAAA 78712 Class3 
TCGCCAA 78832 Class3 
TGAGCCA 79610 Class1 
TGACACA 79839 Class1 
TGACTCA 79928 Class1 
TCGCCCA 80217 Class3 
TCAGCGA 80925 Class3 
AGAGCGA 81114 Class3 
TGGCACA 81283 Class1 
TCGCTAA 81516 Class3 
CGGGCGA 81523 Class3 
TGACACA 81591 Class1 
TCGCTCA 81676 Class2 
TGAGCCA 82263 Class1 
TGACACA 82824 Class1 
TGAGCCA 83076 Class1 
TGACACA 83158 Class1 
TGAGCAA 83534 Class1 
TGACTCA 83711 Class1 
AGACACA 84759 Class1 
ACGCTCA 85520 Class3 
TGACACA 85672 Class1 
CGAGCGA 85752 Class3 
TCGCCCA 85961 Class3 
CCGCTCA 86129 Class3 
TTAGCAA 86512 Class1 
AGACACA 86563 Class1 
TCGCCAA 86656 Class3 
ACGCACA 86722 Class3 
TTAGCAA 87215 Class1 
GGAGCGA 88057 Class3 
TGTGTAA 88128 Class1 
TCGCCCA 88189 Class3 
TCGCCCA 88280 Class3 
CGTGCGA 88298 Class3 
TGACTCA 88879 Class1 
TGACACA 89176 Class1 
ACGCACA 90390 Class3 
AGACACA 90998 Class1 
TTAGCAA 91015 Class1 
TGAGCCA 91028 Class1 
TGAGCCA 91267 Class1 
TGACACA 91564 Class1 
AGAGCGA 91720 Class3 
AGAGCGA 91867 Class3 
CCGCTCA 92152 Class3 
ACGCTCA 92675 Class3 
CGGGCGA 92703 Class3 
ACGCACA 93436 Class3 
TGAGCCA 93923 Class1 
TAAGCGA 94003 Class3 
TCGCTCA 94083 Class2 
TCGCGAA 94143 Class3 
CGTGCGA 94635 Class3 
ACGCTCA 95613 Class3 
AGACACA 95714 Class1 
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GGAGCGA 96954 Class3 
GCGCTCA 97772 Class2 
TCGCTAA 97802 Class3 
TGAGCAA 97820 Class1 
TCGCAAA 98293 Class3 
CGTGCGA 98544 Class3 
CCGCTCA 98600 Class3 
TCGCTAA 98776 Class3 
AGAGCGA 99131 Class3 
TCGCGAA 100070 Class3 
TCGCCCA 100301 Class3 
ACGCTCA 100875 Class3 
TCGCGAA 101174 Class3 
AGAGCGA 101557 Class3 
CGAGCGA 102192 Class3 
TCGCACA 102206 Class3 
ACGCTCA 102328 Class3 
TCGCTCA 102515 Class2 
GGAGCGA 102573 Class3 
TGACTAA 103356 Class1 
AGACACA 104685 Class1 
AGACACA 105007 Class1 
CGGGCGA 105798 Class3 
TCGCAAA 106516 Class3 
TCGCCCA 106659 Class3 
TCGCTCA 107508 Class2 
TCGCGCA 107910 Class3 
TGAGTAA 108242 Class1 
TGAGCCA 109615 Class1 
TCGCCCA 110120 Class3 
TGACTCA 110187 Class1 
TCAGCGA 110385 Class3 
CGAGCGA 110422 Class3 
TGAGCAA 110520 Class1 
GCGCTCA 111586 Class2 
TAAGCGA 111642 Class3 
ACGCTCA 111830 Class3 
TGGCACA 112019 Class1 
TGGCACA 112041 Class1 
CGGGCGA 112601 Class3 
TGAGCCA 113412 Class1 
TGGCACA 113561 Class1 
TTAGCAA 113695 Class1 
TCGCTCA 114508 Class2 
TGAGCAA 115217 Class1 
TGGCACA 115843 Class1 
TGAGTAA 116169 Class1 
TCAGCGA 116329 Class3 
AGACACA 116442 Class1 
TGACACA 117134 Class1 
TCAGCGA 117301 Class3 
TGAGCCA 117305 Class1 
ACGCACA 117330 Class3 
TGACTCA 117482 Class1 
TGACTAA 117779 Class1 
TGAGCCA 118010 Class1 
TGGCACA 118770 Class1 
CCGCTCA 118883 Class3 
TGACTAA 119208 Class1 
AGAGCGA 119628 Class3 
TGAGCCA 119873 Class1 
CGGGCGA 121488 Class3 
TGACTAA 121678 Class1 
GCGCTCA 121732 Class2 
TCGCCCA 122177 Class3 
ACGCTCA 122582 Class3 
CGTGCGA 124443 Class3 
TGAGCAA 124867 Class1 
TGACACA 125177 Class1 
GCGCTCA 125625 Class2 
TAAGCGA 125682 Class3 
TGAGCCA 125705 Class1 
GTTGCAA 125960 Class1 
GTTGCAA 125961 Class1 
AGAGCGA 126320 Class3 
ACGCTCA 126339 Class3 
TCGCCCA 127124 Class3 
TGACACA 127692 Class1 
CGGGCGA 128065 Class3 
TCGCCAA 128124 Class3 
TGGCACA 128514 Class1 
TGGCACA 128541 Class1 
CCGCTCA 129105 Class3 
GGAGCGA 129184 Class3 
TCAGCGA 130682 Class3 
TGAGCAA 130785 Class1 
TGACTCA 131207 Class1 
CGGGCGA 131551 Class3 
TGACTCA 132419 Class1 
TAAGCGA 132656 Class3 
Appendix 
 
TGAGCAA 132865 Class1 
TGGCACA 132939 Class1 
CGTGCGA 132953 Class3 
TGAGCCA 133577 Class1 
TCGCCAA 134174 Class3 
TCGCCCA 134722 Class3 
TGAGCCA 134836 Class1 
CGTGCGA 134890 Class3 
TGAGCCA 135205 Class1 
CCGCTCA 135309 Class3 
TCGCGCA 135520 Class3 
CGCGCGA 135588 Class3 
TGTGCAA 135908 Class1 
TCGCCAA 136720 Class3 
ACGCTCA 136730 Class3 
TGAGCCA 137354 Class1 
TGACACA 137394 Class1 
TCGCAAA 137420 Class3 
TGACTCA 138228 Class1 
TCGCTAA 138488 Class3 
TGAGCCA 138537 Class1 
TGAGCAA 138615 Class1 
TTAGCAA 138682 Class1 
CGGGCGA 139408 Class3 
AGACACA 139577 Class1 
TGAGCCA 140206 Class1 
TGTGCAA 143463 Class1 
TGAGCAA 143481 Class1 
TGTGTAA 143553 Class1 
TGTGCAA 144101 Class1 
TGAGCCA 144218 Class1 
TGACACA 144260 Class1 
TGTGCAA 144875 Class1 
TGGCACA 144985 Class1 
TGAGCAA 145019 Class1 
TGTGCAA 145048 Class1 
TGAGCCA 145957 Class1 
TGGCACA 146560 Class1 
ACGCACA 147574 Class3 
GGAGCGA 147692 Class3 
AGACACA 147765 Class1 
TGGCACA 148653 Class1 
CGCGCGA 148804 Class3 
GCGCTCA 149138 Class2 
AGAGCGA 149824 Class3 
CGGGCGA 150363 Class3 
CGAGCGA 150440 Class3 
TCGCCCA 150532 Class3 
CGTGCGA 150576 Class3 
TGGCACA 150639 Class1 
TGACTCA 150945 Class1 
AGAGCGA 151198 Class3 
TCGCCCA 151207 Class3 
AGACACA 151353 Class1 
AGACACA 151359 Class1 
TGACACA 151673 Class1 
TGAGCAA 151806 Class1 
TGTGCAA 151864 Class1 
GTTGCAA 152777 Class1 
GGAGCGA 152784 Class3 
GGAGCGA 153004 Class3 
TCAGCGA 153043 Class3 
TGTGTAA 153679 Class1 
AGAGCGA 153979 Class3 
TCGCTCA 154723 Class2 
TCGCCCA 155458 Class3 
TGACACA 155644 Class1 
TGAGCAA 156452 Class1 
TCGCTCA 156537 Class2 
TGGCACA 157098 Class1 
CCGCTCA 158123 Class3 
TCGCGCA 159076 Class3 
CGAGCGA 159166 Class3 
ACGCACA 159326 Class3 
AGAGCGA 159547 Class3 
GCGCTCA 159626 Class2 
CGGGCGA 159847 Class3 
TGACTCA 159919 Class1 
TCGCCCA 160372 Class3 
ACGCTCA 160846 Class3 
TCAGCGA 161224 Class3 
TCGCCCA 161241 Class3 
TGTGCAA 161262 Class1 
TGGCACA 161974 Class1 
CCGCTCA 162449 Class3 
AGAGCGA 162946 Class3 
TCGCCCA 163069 Class3 
CGTGCGA 163432 Class3 
GGAGCGA 163832 Class3 
TGAGTAA 164363 Class1 
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TCAGCGA 164458 Class3 
TCGCAAA 164485 Class3 
TCGCCCA 164520 Class3 
TCGCTCA 165058 Class2 
TCGCTCA 165122 Class2 
TCGCCCA 165367 Class3 
ACGCTCA 165400 Class3 
TGAGCCA 165516 Class1 
GTTGCAA 166363 Class1 
TGACTCA 166416 Class1 
TCGCTCA 167108 Class2 
TGACACA 167192 Class1 
TGGCACA 167265 Class1 
TGGCACA 167602 Class1 
TGACTAA 167701 Class1 
AGAGCGA 168648 Class3 
TGAGTAA 168744 Class1 
TGACACA 169027 Class1 
TCGCACA 169590 Class3 
AGACACA 169878 Class1 
TGACACA 170114 Class1 
AGACACA 170416 Class1 
TGACACA 170652 Class1 
AGACACA 170939 Class1 
TGACACA 171175 Class1 
AGACACA 171477 Class1 
TGACACA 171713 Class1 
 
Positional predictions using ZRE32 in the EBV genome 
 
Appendix 
 
Appendix III 
cycle 
phase 
Gene name Class I Class II Class III Total 
LL BNRF1 1 0 0 0 
U EBER 1 1 1 0 2 
U EBER 2 1 1 1 3 
LL BCRF1 3 0 1 4 
L Cp 0 0 3 3 
U BWRF1 0 0 3 3 
L Wp 0 0 1 1 
EL BHLF1 4 0 0 4 
EL BHRF1 4 0 0 4 
EL BFLF2 2 0 0 2 
U BFRF1A 4 0 0 4 
EL BFLF1 4 0 0 4 
EL BFRF1 4 0 0 4 
EL BFRF2 0 0 0 0 
LL BFRF3 1 0 1 2 
L Qp 2 0 2 4 
U BPLF1 1 0 2 3 
LL BORF1 0 0 3 3 
U BOLF1 0 0 2 2 
EL BORF2 1 0 1 2 
EL BaRF1 1 0 2 3 
EL BMRF1 4 0 2 6 
LL BMRF2 1 3 0 4 
EL BSLF2/BMLF1 4 1 0 5 
EL BSLF1 2 1 0 3 
LL BSRF1 1 2 2 5 
LL BLRF1 1 0 0 1 
EL BLLF3 2 0 0 2 
LL BLRF2 2 0 0 2 
EL BLLF2 0 0 1 1 
LL BLLF1 2 0 1 3 
LL BZLF2 0 0 0 0 
EL BZLF1 4 0 0 4 
EL BRRF1 0 0 2 2 
EL BRLF1 1 1 2 4 
LL BRRF2 1 1 2 4 
LL BKRF2 0 1 1 2 
U BKRF3 1 1 1 3 
EL BKRF4 0 0 3 3 
LL BBRF1 0 1 2 3 
EL BBLF4 0 0 3 3 
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LL BBRF2 1 1 0 2 
LL BBRF3  0 0 2 2 
EL BBLF2/BBLF3 0 0 1 1 
LL BBLF1 0 2 0 2 
EL BGLF5 2 0 3 5 
EL BGLF4 0 1 1 2 
U BGLF3.5 2 0 2 4 
LL BGRF1/BDRF1 0 0 1 1 
U BGLF3 0 0 0 0 
LL BGLF2 0 1 0 1 
LL BGLF1 2 0 1 3 
EL BDLF4 1 0 0 1 
U BDLF3.5 3 0 2 5 
LL BDLF3 2 0 1 3 
LL BDLF2 0 0 0 0 
LL BDLF1 0 0 1 1 
EL BcRF1.2 2 0 0 2 
LL BcLF1 1 1 1 3 
LL BTRF1 0 1 1 2 
LL BXLF2 1 0 0 1 
LL BXRF1 1 0 1 2 
EL BXLF1 2 0 2 4 
EL BVRF1 2 0 2 4 
LL BVRF2 1 0 3 4 
U BVLF1 1 0 2 3 
LL BdRF1 1 0 0 1 
LL BILF2 4 0 1 5 
U RPMS1 2 0 1 3 
EL LF3 2 0 0 2 
U LF2 1 0 4 5 
U LF1 3 0 0 3 
U BILF1 1 0 3 4 
U A73 1 0 1 2 
EL BALF5 1 1 0 2 
LL BALF4 0 1 3 4 
U BARF0 0 0 2 2 
U BALF3  1 0 3 4 
EL BALF2 1 1 3 5 
EL BALF1 0 2 2 4 
EL BARF1 0 2 1 3 
L LMP-2A 1 0 0 1 
EL BNLF2b 2 2 0 4 
EL BNLF2a 2 1 0 3 
L LMP-1 1 1 0 2 
L LMP-2B 1 1 0 2 
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ZREs in the promoter regions of EBV genes including the positional predictions 
of the 3 AP1-like sites not included in the initial search. Changes in count of 
Class II ZREs are highlighted. 
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Abstract
Background: Epstein Barr virus (EBV) infects the majority of the human population, causing fatal diseases in a small
proportion in conjunction with environmental factors. Following primary infection, EBV remains latent in the memory B
cell population for life. Recurrent reactivation of the virus occurs, probably due to activation of the memory B-
lymphocytes, resulting in viral replication and re-infection of B-lymphocytes. Methylation of the viral DNA at CpG motifs
leads to silencing of viral gene expression during latency. Zta, the key viral protein that mediates the latency/reactivation
balance, interacts with methylated DNA. Zta is a transcription factor for both viral and host genes. A sub-set of its DNA
binding sites (ZREs) contains a CpG motif, which is recognised in its methylated form. Detailed analysis of the promoter of
the viral gene BRLF1 revealed that interaction with a methylated CpG ZRE (RpZRE3) is key to overturning the epigenetic
silencing of the gene.
Methodology and Principal Findings: Here we question whether we can use this information to identify which host genes
contain promoters with similar response elements. A computational search of human gene promoters identified 274 targets
containing the 7-nucleotide RpZRE3 core element. DNA binding analysis of Zta with 17 of these targets revealed that the
flanking context of the core element does not have a profound effect on the ability of Zta to interact with the methylated
sites. A second juxtaposed ZRE was observed for one promoter. Zta was able to interact with this site, although co-
occupancy with the RpZRE3 core element was not observed.
Conclusions/Significance: This research demonstrates 274 human promoters have the potential to be regulated by Zta to
overturn epigenetic silencing of gene expression during viral reactivation from latency.
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Introduction
Epstein Barr virus (EBV) infects and causes several diseases in
humans including Burkitt’s lymphoma, nasopharyngeal carcino-
ma, Hodgkin’s disease, post-transplant lymphoproliferative disor-
der and infectious mononucleosis (glandular fever) [1–4]. Like
other members of the gammaherpesviruses family, EBV infection
persists for life following primary infection. The virus is
maintained in a state of latency in memory B-lymphocytes and
occasional reactivation and replication is considered to maintain
the virus within individuals [5]. In EBV-induced lymphomas, EBV
is also present in a latent state. In cell lines derived from these
lymphomas, the viral genome is predominantly methylated [6–9].
The effect of silencing viral gene expression not only aids evasion
from the immune system [10], but also prevents the destruction of
tumour cells by viral replication. Indeed, reactivation of EBV from
latency has been proposed as a route to treat EBV-associated
lymphomas [11,12].
EBV latency is disrupted following physiological activation of B-
lymphocytes, through the expression of Zta (BZLF1, ZEBRA,
EB1, Z) [13–15]. Zta is a sequence-specific DNA-binding protein,
which resembles the bZIP family of transcription factors and plays
a critical role in the reactivation of viral gene expression and
replication of the genome. Through direct interaction with Zta
response elements (ZREs) in promoters, Zta regulates the
expression of viral and cellular genes. Many host and viral
promoters that have been evaluated to date contain ZREs within
the proximal five hundred nucleotides of 59 sequence. Thus far,
eight have experimentally verified binding sites for Zta in their
proximal promoter regions:
BSLF2+BMLF1 [16,17]; BRLF1 [18]; BZLF1 [17,19,20]; the
joint promoter for BHLF1 and BHRF1 [19]; the lytic EBNA1
promoter Fp [21]; BRRF1 [22]; and BMRF1 [23]. Furthermore, 6
host genes are directly regulated by Zta through ZREs in their
promoters DHRS9 [24]; EGR1 [25,26]; CIITA [27]; IL-8 [28]; IL-
10 [29]; and IL-13 [30]. Zta interacts with a diverse range of ZREs
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[31] and multiple sites exist in some Zta-responsive promoters,
sometimes in close proximity. One example is the viral promoter
for the BZLF1 gene, Zp, which contains the two functional ZIIIA
and ZIIIB ZREs within a total span of 20 nucleotides [17,19,20].
Zta has the unusual feature of interacting with a sub-set of ZREs
that contain a methylated CpG motif [32]. In some cases Zta is
able to interact with the non-methylated ZRE, while for other
ZREs the interaction with Zta is dependent on methylation
[22,26,32–34]. This has led to the classification of ZREs into three
classes: class I ZREs do not contain a CpG motif; class II ZREs
contain a CpG motif that is recognized in both the methylated and
non-methylated states; and class III ZREs contain a CpG motif
but are only recognized when methylated [35]. The ability of Zta
to interact with methylated CpG-containing ZREs allows Zta to
activate gene expression in the latent viral genome despite the
repressive methylation status and thus overturn the epigenetic
silencing of the viral genome [22,32–35].
To date, three genes with CpG-containing ZREs have been
studied: EBV BRLF1, EBV BRRF1 and human EGR1 [22,26,32–35].
Of these, investigation of the regulation of the EBV gene BRLF1
provided compelling evidence that the interaction of Zta with a
methylated ZREwas instrumental in reactivating EBV into lytic cycle
in B-lymphocytes [32–35]. The viral BRLF1 gene includes three
ZREs in the promoter proximal region [18,32]. Two of the ZREs
contain CpG motifs; RpZRE2, is a class II ZRE and the other,
RpZRE3 is a class III ZRE [35]. The ability of a single point-
mutation in Zta to differentiate between the interaction of Zta with
methylated and non-methylated RpZRE3 allowed the relevance of
the interaction of Zta with this promoter to be established [34,36,37].
The viral BRRF1 gene contains two CpG-containing ZREs, which
Zta only interacts with in their methylated states [22]. The presence
of a CpG-containing ZRE in the promoter of the human EGR1 gene,
which is recognized by Zta in its methylated form, suggests that EBV
may overturn epigenetic silencing of host genes in order to modulate
the host cell environment [26].
The RpZRE3 core element (TCGCGAA), which was clearly
shown to be required for overturning epigenetic silencing of
BRLF1 in B-lymphocytes [34,36,37], was chosen to identify all
human genes that contain an exact match to this CpG-containing
ZRE within the 2500 to +1 region of the promoter and evaluate
whether they are recognised by Zta in their natural context.
Materials and Methods
Identification of Human Promoters Containing RpZRE3-
Core Elements: Initial Sampling
Promoter regions (defined as 2500 to +1 base pairs from the
transcription start site) of a sample of human protein-coding genes
in Ensembl (49) [38] were extracted using the Biomart data
management system [39]. The sample represented 40% of the
human genome. A search was made for all occurrences of an exact
(forwards and reverse) match to identify those promoters with the
TCGCGAA RpZRE3 core element.
Identification of Human Promoters Containing RpZRE3-
Core Elements: Whole Genome Scanning
An identical screen was undertaken on the entire human
genome from Ensembl (50) [40], resulting in the identification of
274 promoters which were designated the RpZRE3-promoter-
274 data-set. The 7 nucleotides of the RpZRE3 core element,
along with 10 flanking nucleotides on each side, were extracted
from each of the 5 genes from the initial sampling. The
Transcription Factor Binding Site (TFBS) Perl modules [41]
were used to create a Position Weight Matrix (PWM) based on
the entire length of these 27-nucleotide sequences. TFBS Perl
modules were also used to search the promoter regions (2500 to
+1) of all human protein coding genes in Ensembl 50 [40] which
were extracted using Biomart [39]. Those promoters that
matched the PWM with a threshold value .80% and contained
an exact match to the RpZRE3-core element were additionally
filtered using 2 criteria (a) the presence of CpG islands and (b)
function (based on the over-representation of Gene Ontology
(GO) terms [42]). The location of CpG islands were predicted
using the EMBOSS program CpGPlot [43] with default options.
Only genes with a CpG island present in the promoter were
retained. The GO term annotations for molecular function and
biological processes were extracted from Ensembl for each gene
[40]. The number of genes in the RpZRE3 promoter dataset with
each GO term annotation was compared with the total number
of genes in Ensembl with the same GO term. The GO terms that
occurred with a significantly higher frequency (p,0.05) in the
RpZRE3 dataset, compared to entire genome, were defined as
over-represented.
DNA Binding Analysis by EMSA on RpZRE3 Containing
Promoters
Double stranded labelled DNA probes were made by labelling
6 pmol of oligonucleotide (27 nt long) at the 59 end with
[c-32P]ATP (30 mCi) using polynucleotide kinase (Roche).
12 pmol of the complementary oligonucleotide strand was added
and incubated with the labelled single strand at 95uC for 2
minutes, 65uC for 10 minutes, and 37uC for 30 minutes to anneal
the strands. The concentration of the probe was 33.3 nM. The
oligonucleotides comprised the core 7-mer sequence surrounded
by 20 nucleotides corresponding to the cognate flanking sequence
for each promoter and were synthesised. Where indicated in the
figure, the central CpG motif was methylated on both cytosines
during synthesis (Sigma).
Zta protein was in vitro translated using wheatgerm extract
(Promega). This was incubated with the labelled probe (at a final
probe concentration of 3.3 nM) for 30 minutes at room
temperature, before the sample was fractionated on an 8% native
polyacrylamide gel at 100 volts for 1 hour. Following detection of
the radio labelled DNA using a Storm phosphorimager, the
relative signals were quantitated using ImageQuant software (GE
Healthcare, UK).
Competition EMSAs were carried out with a 100X excess of a
double stranded non-labelled oligonucleotide in addition to the
standard EMSA reaction. Equal quantities of each of the
complementary oligonucleotides were annealed in the same
manner as the labelled probes and diluted to yield a solution
concentration of 3.33 mM. This was added to the EMSA reaction
at a final concentration of 333 nM (i.e. 100X excess).
Oligonucleotides
The oligonculeotides used were double strand versions of the
following sequences (59-39):
XPC GGTGCGTCACTCGCGAAGTGGAATTTG
ZC3H8 GCTTCCCGGCTCGCGAAAGGGAGGACC
HDAC2 TCCCCCACTGTCGCGAAGCTCCCGCCC
MNT CCGCGGCGTCTCGCGAAGGGAGGGGCG
Cyclin L2 GGGCGGCTCCTCGCGAAGCTCCACGGC
RpZRE3 GTTTATAGCATCGCGAATTTTGAGTGC
CAPN2 CCGGGGAGGCTCGCGAATCGCGGTCCA
CDO1 CGTCCCAGCGTCGCGAACCACAGCGGC
FALZ GGCGCGCAGCTCGCGAAATGCCCGGCG
KIF1B GCTTCGGCCCTCGCGAAACTCCGCCCG
LLGL1 TCGGCCGGGCTCGCGAAGGGACGCCCG
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LMO4 GGATCCCGGGTCGCGAAGGGCAGCCCA
MBD4 CCTCCTGCTCTTCGCGAACCGCCCCGC
PLEKHJ1 AGCCGCTCCCTCGCGAAAGTTGGCCCC
PRKD1 CTTCCTGGGGTCGCGAACTTCCCGGGC
SEC14L CGCCCGCTACTCGCGAAGCCCAGCCCG
TADA3L GCTGCGCTTCTCGCGAAAGGGCAGGCA
TOP2B CCGCGCCCCATCGCGAAGATCCGGAGC
XPCLMNTR GGTGCGTCACTCGCGAAGGGAGGGGCG
MNTLXPCR CCGCGGCGTCTCGCGAAGTGGAATTTG
XPC Mcore GGTGCGTCACCCCCTTAGTGGAATTTG
XPCLM3Mcore GGTCCGCCTCCCCCTTAGTGGAATTTG
AP1 mut GATCCACCCCTTAGAGGAAAACATACG
Prediction of Transcription Factor Binding Sites Using
Promo
The transcription factor binding site prediction program
PROMO [44] was used with the default setting of 15%
dissimilarity value, to identify potential bZIP transcription factor
binding sites within the XPC oligonucleotide.
Results
Identification of Human Promoters Containing the
RpZRE3-Core Element: Initial Sampling
The initial search for RpZRE3-core elements in a sample of
human promoters revealed 67 genes with an RpZRE3-core
element. 5 of these that are involved in gene regulation were
selected for DNA binding analysis. These 5 genes were ZC3H8
(ENSG00000144161), HDAC2 (ENSG00000196591), XPC
(ENSG00000154767), MNT (ENSG00000070444) and CyclinL2
(ENSG00000116148) and together with the RpZRE3 element
from the viral BRLF1 promoter (Rp), formed the RpZRE3-
promoter-6 data-set.
DNA-binding assays were undertaken with the methylated
forms of each of the 5 human promoters using 27mer double
strand oligonucleotides encompassing the 7-nucleotide core
element and 10-nucleotide flanking region on each side together
with RpZRE3 from Rp. Electrophoretic mobility shift assays
(EMSA) were undertaken with in vitro translated Zta protein. Zta
protein/DNA complexes formed readily with the oligonucleotides
from all six promoters (Figure 1). The specificity of the assay is
shown by the lack of complex formation with control protein. In
addition, we undertook competition experiments with an excess of
unlabelled oligonucleotides and included a version with a mutant
ZRE to further probe the specificity of the interaction. This
confirms that Zta interacts with all six RpZRE3 core elements
specifically.
Identification of Human Promoters Containing RpZRE3-
Core Elements: Whole Genome Scanning
The complete human genome was scanned for additional
RpZRE3-core elements. This resulted in a data-set of 274 genes,
denoted the RpZRE3-promoter-274 data-set (see Table S1). To
assess whether there was an influence of flanking sequence on the
interaction of Zta with these ZREs we undertook a systematic
filtering process. The RpZRE3-promoter-274 dataset was first
filtered by a Position Weight Matrix (PWM), which was generated
from the RpZRE3-promoter-6 data-set. Matches were further
filtered for genes with at least one CpG island in the promoter and
an over-represented GO term. This resulted in 12 previously
unidentified promoters and a further one that had been identified
in the initial screen (Figure 2). Together with the promoters from
the initial screen and the viral BRLF1 promoter (RpZRE3-
promoter-6 data-set), these form the RpZRE3-promoter-18 data-
set.
Oligonucleotides were designed using the same principles with
10 nucleotides of flanking sequence on each side of the RpZRE3-
core element, and the ability of Zta to interact with each site in its
methylated form was assessed. The EMSA analysis revealed that
all twelve of the newly identified methylated promoters were
recognised by Zta (Figure 3).
This analysis demonstrated that for the RpZRE3-promoter-18
data-set, the flanking sequence surrounding the methylated core 7-
mer element did not have a profound effect on the ability of Zta to
interact with promoters and therefore the core element was
sufficient to facilitate binding. This was illustrated by the
generation of a PWM using sequence from the RpZRE3-
promoter-18 data-set (Figure 4), which revealed negligible
sequence conservation outside of the core element.
Recognition of the Non-Methylated Promoters
Zta is able to recognise many response elements which do not
contain a CpG motif and therefore do not have a methylated core
element (Class I ZREs) [15,35]. In addition, Zta recognises one
CpG containing ZRE, RpZRE2, even in the absence of
methylation (Class II ZREs) [33]. The ability of Zta to recognise
the promoters in their non-methylated forms may impact on the
ability of EBV to alter their gene expression, so we investigated the
classification of ZRE for each of the 17 human promoters.
A series of DNA binding experiments with the oligonucleotides
representing the human promoters in the RpZRE3-promoter-18
data-set, were undertaken comparing non-methylated with
methylated RpZRE3-core elements. The interaction of Zta with
the sites was quantitative, as demonstrated by the reduction in
complex formation as the Zta protein concentration was titrated
on each of the methylated promoters (Figure 5). All bar one
display negligible binding to the non-methylated oligonucleotides
(at least 10-fold lower than to the methylated sites) and can
therefore be classified as class III ZREs.
Zta displayed a reproducible interaction with the non-
methylated XPC oligonucleotide; the interaction reached 50% of
the binding observed with the methylated oligonucleotide
(Figure 5). This raises the possibility that the XPC core RpZRE3
element is influenced by the flanking sequence to behave as a class
II ZRE.
Additional ZRE Juxtaposed with an RpZRE3-Core Element
in Flanking Region
To identify whether sequences conferring methylation indepen-
dent recognition was confined to a specific flank of XPC, a series
of mutant oligonucleotide probes that exchanged flanking
sequences between XPC and a class III site (MNT), that is not
recognised when non-methylated, were designed. Analysis of the
interaction with Zta by EMSA revealed that the ability to confer
Zta binding resided within the 59 sequence of XPC; the hybrid
XPCLMNTR was able to bind but MNTLXPCR was not
(Figure 6). This suggested that the 59 XPC flanking sequence of the
RpZRE3 element influenced binding. However, it was surprising
to discover that mutation of the RpZRE3 element within XPC did
not prevent interaction with Zta (Figure 6).
A further explanation for the interaction of Zta with the non-
methylated XPC promoter is that an obscure ZRE is present in
the 59 flank. To address this further we attempted to identify
putative ZREs in the XPC promoter using the transcription factor
binding site prediction program PROMO [44,45]. Although this
program contains a PWM for Zta binding sites, none were
predicted in this sequence. However, PROMO predicted the
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Figure 1. Interaction of Zta with methylated RpZRE3 core element from 5 human promoters. (a) The nucleotide sequence of one strand
of each oligonucleotide spanning the indicated ZREs is shown, with the conserved RpZRE3 core element (TCGCGAA) aligned. Double strand versions
of these sequences were used as probes in EMSA, with the 2 cytosines within the CpG core motif methylated. The RpZRE3 from EBV BRLF1 promoter
is included. (b) DNA binding between in vitro translated Zta with each probe was undertaken by EMSA. The ability of Zta (Z) to interact with the
probe was compared with an unprogrammed translation lysate (C) as a negative control. The complex was separated on an 8% gel by electrophoresis
and visualised by phosphoimaging. The excess probe can be seen at the bottom of the gel. The probe used in each experiment is indicated below
the gel. (c) Competition of each ZRE sequence (at 100X excess) against labelled RpZRE3 was determined by competition EMSAs. Data from at least 2
experiments was taken to calculate competition i.e. the percentage of labelled probe displaced by unlabelled competitor. Methylated ZREs were used
for both probe and competition. AP1 mut, an oligonucleotide previously shown not to interact with Zta [36], was used as a negative control to define
the level of non-specific binding. Error bars indicate standard error.
doi:10.1371/journal.pone.0009443.g001
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Figure 2. Identification of human promoters containing RpZRE3 core elements in the human genome. (a) The bioinformatics analysis
undertaken for the genome wide scan is represented as a flow diagram. Genetic input or output is represented by ovals, and filters by trapeziums. (b)
A Position Weight Matrix (PWM) was created using the aligned sequences of the RpZRE3-promoter-6 data-set. These sequences are shown in Fig. 1(a).
This was used to filter the genomic data from the human promoter sequences (2500 to +1). (c) Overrepresented GO terms found for the 274 genes
were identified. (d) The 13 genes identified as candidate genes, 12 previously unknown genes and 1 from the initial screen, and their associated
Ensembl accession codes.
doi:10.1371/journal.pone.0009443.g002
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presence of AP1, c-fos and c-jun binding sites within the 59 flank of
XPC (59TGCGTCA) (Figure 7). c-fos and c-jun proteins are both
members of the bZIP transcription factor family; they form AP1
DNA binding activity as either homodimers or heterodimers. It is
relevant that fos/jun dimers share some DNA recognition motifs
with Zta [15–17,31,46–49]. This led to the hypothesis that the
predicted AP1 site in the 59 flanking sequence is an additional
ZRE that is responsible for binding to the non-methylated XPC
oligonucleotide. To test the hypothesis, further mutations were
introduced into the 59 XPC flanking sequence in the predicted
AP1 site (59TCCGCCT). The ability of Zta to interact with the
double AP1/core mutant site (XPCLM3Mcore) was compared
with the core-only mutant. Dual mutation of the predicted AP1
site and the core abrogated the ability of Zta to interact with the
XPC oligonucleotide, demonstrating that binding of Zta to the
non-methylated XPC site resided with this AP1 site (Figure 7).
This analysis showed that the RpZRE3 core element is not
recognised in its non-methylated state in the context of any of the
viral or cellular promoters in the RpZRE3-promoter-18 data-set,
and that this ZRE is specifically recognised when methylated.
Discussion
A computational search revealed a set of 274 human genes with
cellular promoters containing the 7-mer RpZRE3 core element.
Flanking sequence can influence the interaction of some
transcription factors with DNA, for example, the interaction of
the E2F family with DNA is influenced by a region of at least 8
nucleotides 59 and 11 nucleotides 39 to the central nucleotide [50].
Before assigning all 274 genes as candidates for regulation by Zta,
it was important to assess whether the cognate flanking sequence
had a profound effect on binding by Zta. Consideration of the
sequences represented in the flanking sequence of this set of genes
revealed it to be diverse; all four nucleotides were represented in
55% of positions and three of the four nucleotides were
represented at the remaining positions. Indeed, the immediate
flank of the RpZRE3 core element, consisting of four nucleotides
both 59 and 39, had 100% representation of all four nucleotides. It
can therefore be concluded that the flanking sequence does not
prevent binding to the methylated RpZRE3 core, and a PWM
generated from the RpZRE3-promoter-18 data-set showed little
conservation outside the core motif. In contrast, the interaction
with the non-methylated core element initially appeared to be
influenced by flanking sequence in only 1 of the 18 promoters.
However, further analysis revealed this to be due to the presence of
a second ZRE in the flanking sequence.
These results show that the approach of undertaking a
computational pattern match search for the 7-mer RpZRE3 core
element is a fast and reliable method to identify promoters
containing ZREs that are recognized by Zta only when they are
methylated (class III ZREs).
The identification of two adjacent juxtaposed ZREs in the XPC
promoter presents an interesting problem; can both sites be
occupied at once? The natural juxtaposition of ZREs has been
previously described for a viral promoter; BZLF1 and a cellular
promoter EGR1. In the BZLF1 promoter, the elements are situated
with 12 base pairs between the central nucleotides; both can be
occupied simultaneously and both are functionally relevant
[17,19–20]. For the EGR1 promoter, the elements are immediately
adjacent with just 8 nucleotides between the central nucleotides
[25,26]. There is no evidence for simultaneous occupation by Zta
and only one element appears to be functional in vivo [26]. The
arrangement of the XPC promoter places the elements 8
nucleotides apart, identical to EGR1, and there is no evidence
from the DNA-binding experiments for simultaneous occupation
of the sites. As one ZRE is recognised in a methylation-dependent
manner and the other is recognised when non-methylated, it is
possible that the arrangement may provide a fail-safe mechanism
to ensure that the gene is regulated in both its methylated and non-
methylated states.
Figure 3. Interaction of Zta with methylated RpZRE3s found in
human promoters. EMSA analysis with in vitro translated Zta protein
(Z) or an unprogrammed translation lysate (C) with the probes indicated
to the right of each gel was carried out as described in Fig. 1.
doi:10.1371/journal.pone.0009443.g003
Figure 4. Analysis of the RpZRE3 core element flanking sequence. (a) A Position Weight Matrix (PWM), created using the probe sequences of
the dataset RpZRE3-promoter-18.
doi:10.1371/journal.pone.0009443.g004
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The simple computational approach taken to identify the
location of this methylation-dependent and novel DNA-binding
motif in human gene promoters identified 274 genes potentially
regulated by overcoming epigenetic silencing during the viral
replicative cycle. Given the known functions of Zta in reprogram-
ming viral gene expression, disrupting cell cycle control and
replicating viral DNA, it is interesting to note that the Gene
Ontology terms that are over-represented in the RpZRE3-
promoter-274 gene-set are largely involved in transcription,
chromatin re-modelling and mitosis. This strongly suggests that
Zta may activate this set of cellular genes in order to accomplish
these functions. Testing whether these genes are activated during
latency disruption in memory B-lymphocytes in vivo is technically
challenging given both the scarcity of memory B-lymphocytes in
peripheral circulation and the infrequency of latency disruption in
vivo.
The co-location of the RpZRE3 core element in 274 human
promoters is unlikely to have been driven by an evolutionary
advantage to the virus, but may reflect the involvement of a
cellular transcription factor interacting with the same element.
This would suggest that this set of genes share a common mode of
regulation during human development or differentiation. Further
Figure 5. Comparison of Zta interaction with non-methylated and methylated RpZRE3s from human promoters. DNA binding analysis
of in vitro translated Zta protein (Z) or an unprogrammed translation lysate (C) with both non-methylated and methylated versions of the probes
indicated to the right of each gel was carried out by EMSA as described in Fig. 1. A titration of Zta protein (1:2, 1:4, 1:8) was used to compare non-
methylated binding to that of the methylated equivalent. Quantitation of the complexes formed between Zta and the non-methylated and
methylated probes, from at least 2 experiments, is represented as a histogram to the right of the corresponding gel. Complex formation is shown
relative to the maximum binding for each probe. Error bars indicate standard error.
doi:10.1371/journal.pone.0009443.g005
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more, it will be interesting to question whether co-occurrence of
the RpZRE3-core element with other transcription factor binding
sites forming a co-operative cis-regulator module which may
illuminate the regulation of these host and viral genes.
Supporting Information
Table S1 RpZRE3-promoter-274 data-set: A table of genes
which contain a RpZRE3 core element in the 500 bp promoter
region.
Found at: doi:10.1371/journal.pone.0009443.s001 (0.05 MB
XLS)
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Abstract
Epstein-Barr virus (EBV) encoded transcription factor Zta (BZLF1, ZEBRA, EB1) is the prototype of a class of transcription
factor (including C/EBPalpha) that interact with CpG-containing DNA response elements in a methylation-dependent
manner. The EBV genome undergoes a biphasic methylation cycle; it is extensively methylated during viral latency but is
reset to an unmethylated state following viral lytic replication. Zta is expressed transiently following infection and again
during the switch between latency and lytic replication. The requirement for CpG-methylation at critical Zta response
elements (ZREs) has been proposed to regulate EBV replication, specifically it could aid the activation of viral lytic gene
expression from silenced promoters on the methylated genome during latency in addition to preventing full lytic
reactivation from the non-methylated EBV genome immediately following infection. We developed a computational
approach to predict the location of ZREs which we experimentally assessed using in vitro and in vivo DNA association assays.
A remarkably different binding motif is apparent for the CpG and non-CpG ZREs. Computational prediction of the location
of these binding motifs in EBV revealed that the majority of lytic cycle genes have at least one and many have multiple
copies of methylation-dependent CpG ZREs within their promoters. This suggests that the abundance of Zta protein
coupled with the methylation status of the EBV genome act together to co-ordinate the expression of lytic cycle genes at
the majority of EBV promoters.
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Introduction
Infection of human B-lymphocytes by Epstein-Barr virus results
in the establishment of a latent state in which a highly restricted set
of viral genes are expressed [1]. This is accompanied by extensive
methylation of CpG motifs in non-expressed viral genes [2,3,4]. In
response to physiological stimuli, such as engagement of the B-cell
receptor, epigenetic silencing of the viral genome is overturned,
resulting in widespread activation of viral gene expression and lytic
replication [4,5]. The expression of a subset of host genes is also
altered during this period [6,7,8,9,10,11,12,13,14].
The switch between latency and the lytic cycle is orchestrated by
the viral gene BZLF1, which encodes the protein Zta (also known
as ZEBRA, BZLF1, EB1, or Z) [15,16,17]. Zta resembles the AP1
family of bZIP transcription factors but has a unique dimerisation
domain and does not form heterodimers with cellular bZIP
proteins [18]. Three classes of Zta DNA binding sites (Zta
response elements (ZREs)) have been defined for Zta [19]. Class I
ZREs include classical AP1-like recognition elements. However,
some Zta binding sites contain a CpG motif and Zta has the
unusual property of binding preferentially to these ZREs when
they are methylated [20,21], defining class II ZREs [19].
Remarkably, some CpG-containing ZREs are only recognized in
their methylated form (class III ZREs) [19,20,21,22,23,24,25].
Methylation of the viral genome occurs during latency and has
recently been shown to be required for EBV replication [3]. The
ability of Zta to bind to methylated ZREs suggests that Zta may
have a direct role in overriding the epigenetic silencing of the viral
genome to activate expression of viral genes required for lytic
replication.
The requirement for methylation at critical ZREs may also
contribute to the establishment of latency during the immortal-
ization of infected cells. The EBV genome is not methylated when
it enters cells but the genome gradually becomes methylated
during immortalization and the establishment of viral latency
[3,4]. Zta is transiently expressed during the early period
immediately after infection and is required for efficient immortal-
ization [3]. It is therefore essential that Zta should not activate the
full lytic replication cycle at this stage. A plausible hypothesis to
explain this is that expression of key lytic cycle genes are controlled
by class III ZREs that do not function in their unmethylated form.
We developed a computational approach to identify candidate
ZREs and applied it to a genome-wide analysis of the EBV
genome that revealed many novel target loci. The implications of
these data for the ability of EBV to evade epigenetic silencing of
the host viral genome is discussed.
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Results
Prediction of ZREs core sequences bound by Zta using
PROMO
In order to predict novel ZRE core sequences, we started by
searching three well-characterized Zta-responsive promoters from
the EBV genome (BZLF1 promoter (Zp) [26,27,28,29], BRLF1
promoter (Rp) [27,29,30] and BMRF1 promoter [31] using the
PROMO algorithm [33,34] and the position frequency matrix
(PFM) for Tranfac 8.3 Zta transcription factor entry T00923
[32,33]. These 3 promoters are known to contain eight previously
verified sites: in Zp (ZREIIIA and ZREIIIB); in Rp (ZRE1, ZRE2
and ZRE3) and in BMRF1 promoter (AP1, ZRE(244) and ZRE
(2107)) (Figure 1 and Table S1) however, the PROMO algorithm
only predicted one of these sites (RpZRE1) using the PFM
T00923. In addition, 6 novel sites where predicted (Table S2).The
ability of Zta to interact with each predicted site was assessed using
electrophoretic mobility shift assays (EMSA) (Figure 1, Table S2),
although three novel sites were identified, eight known sites were
missed and three false positives were predicted indicating that the
PFM used had a low sensitivity.
Application of a novel ZRE PFM to predict CpG
containing ZREs
A new PFM was generated using the core sequences of five CpG-
containing ZREs (denoted PFMCpG5) from the promoters described
above and the BRRF1 promoter [22] (Figure 2). The accuracy of the
PFM was evaluated by searching for ZREs in the well-characterized
viral promoters (Rp, Zp and BMRF1p). PFMCpG5 identified all 5
verified CpG containing sites and predicted two novel sites; one
located in Rp, centered on 2114, and one located in the BMRF1
promoter, centered on 2148. DNA binding experiments demon-
strate that Zta interacts with both sites in a methylation-dependent
manner, characteristic of class III ZREs (Figure 3), thus the new PFM
(ZRECpG5) has a high level of sensitivity. The PFMCpG5 was then
used to predict core ZREs in the complete EBV genome. Within the
EBV genome a total of 16 novel sequence variants of CpG ZREs
were predicted (A–P) (Figure 3). EMSAs were undertaken with each
of the novel ZRE core sequences (both non-methylated and
methylated) to evaluate Zta binding (Figure 3). All but two of the
predicted ZRE sequences bound in the methylated form. Only one
sequence bound significantly in the unmethylated form. Therefore 13
out of 16 predictions are classified as Class III ZREs, 1 is classified as
Class II and 2 did not interact with Zta significantly. Combined with
previously published ZREs, this resulted in a total set of 32 distinct
sequence variants of ZREs (ZRE32) (Table 1).
Identification of ZRE core binding sequences in the EBV
genome
Global analysis of the EBV genome was then undertaken using
an exact pattern match with the 32 validated variants of the ZRE
core sequence (Figure 4). This revealed 469 locations within the
EBV genome that matched one of the ZRE core sequences (Table
S3 and http://bioinf.biochem.sussex.ac.uk/EBV).
Figure 1. Evaluation of predicted ZREs in three EBV promoters. A. Summary of the known (filled box) and predicted (open box) core ZRE
sequences within the proximal 500 nucleotides of the indicated BZLF1, BRLF1 and BMRF1 promoters. The arrows represent the transcription start sites.
Stars represent CpG ZREs. B. Double strand oligonucleotides were generated with the core ZRE sequence and at least 10 nucleotides of cognate
sequence on either side. Following radio labeling, these were incubated with in vitro translated Zta and subject to EMSA. The reactions contained no
protein, 0, control lysate, C or Zta, Z. The DNA probes are indicated above with their originating promoters. C. Double strand oligonucleotides were
generated with the core ZRE sequence and 10 nucleotides of cognate sequence on either side. Following radio labeling, these were subject to in vitro
methylation with SssI methyl transferase (+), or a mock reaction (2). Subsequently, they were incubated with in vitro translated Zta and subject to
EMSA. The reactions contained control lysate, C; or Zta, Z.
doi:10.1371/journal.pone.0025922.g001
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The occurrence of ZREs throughout the EBV genome appears
to be widespread; with 81 out of 86 (94%) EBV promoters
containing at least 1 ZRE core sequence (Table S4). This suggests
that Zta has the potential to regulate the expression of the majority
of EBV genes. Furthermore, 58 EBV promoters contained at least
1 CpG containing ZRE. These regions are methylated during
latency [3,4], suggesting that methylation-dependent Zta interac-
tion with ZREs could influence the expression of a broad range of
EBV genes once Zta is synthesized at the onset of lytic cycle.
Of particular relevance to the control of EBV gene expression
immediately after infection are 22 EBV genes that contained CpG
ZREs but have no methylation independent ZREs in their
promoters (Table 2). These genes are prime contenders to be
regulated in a strictly methylation-dependent manner by Zta.
These were originally classified as displaying early lytic, late lytic
and latent patterns of gene expression [34], but importantly,
genome wide expression studies revealed that all are up regulated
during lytic cycle in BL cells, with the majority reaching peak
levels approximately 24 hours after lytic activation [6].
Three of these promoters were chosen to question whether Zta
interacts with the novel CpG ZREs in vivo; BKRF4, BGLF4 and
BTRF1. The location of the CpG ZREs in each promoter is
indicated in Figure 5. Lytic cycle was activated in Akata cells [35]
by surface immunoglobulin ligation, undertaken in the presence of
acyclovir to inhibit genome replication. Chromatin was subjected
to Zta immunoprecipitation (ChIP) and the interaction of Zta with
these promoters was assessed by Q-PCR. The ability of this
antibody to precipitate Zta bound to chromatin is demonstrated
by western blotting in Figure 6. In addition, we show that Zta as
opposed to a control antibody specifically precipitates chromatin
from a region of oriLyt containing multiple ZREs. Using primer
sets proximal to the CpG ZREs from BKRF4, BGLF4 and BTRF1
compared to primer sets from three regions of the EBV genome
devoid of ZREs, we reveal that Zta specifically binds to all three of
these promoters that contain novel CpG ZREs in vivo (Figure 7).
Discussion
Following several iterations of a predictive and evaluative
approach, we identified a set of 32 distinct sequence variants in the
core 7-nucleotide sequence to which Zta can bind. This includes
20 variants containing a CpG motif, the majority of which (90%)
are only recognized by Zta when they are methylated.
The consensus binding sites identified for non-CpG ZREs are
similar to the binding sites originally described for Zta (Figure 8).
In contrast, the binding sites for CpG containing ZREs are
remarkably different. This sequence is dominated by an almost
invariant G 59 to the absolute prerequisite for me-CpG at positions
19 and 29 in the right-half of the core sequence.
The identification of 58 EBV promoters that harbor methyla-
tion dependent CpG ZREs, combined with the knowledge that the
EBV genome is heavily methylated during latency [3,4], suggests
that Zta plays an important role in overturning epigenetic
silencing of over half of the EBV genes during lytic replication.
Indeed, all three of the promoters tested displayed a strong
interaction with Zta in vivo in ChIP analyses. A genome-wide DNA
binding analysis was recently published identifying sequences to
which a mutant form of Zta, that is replication and transactivation
dead, can interact [3]. This report highlighted the strength of the
interaction between Zta and methylation dependent binding of
Zta to CpG ZREs in the EBV genome.
The EBV genes that contain only methylation-dependent ZREs
are of particular interest. All of these genes are heavily methylated
during viral latency yet unmethylated following replication and
immediately after infection [3,4]. Several are required for EBV
replication and include components of the helicase/primase complex
(BBLF4, BBLF2/BBLF3), the viral protein kinase (BGLF4), and
glycoproteins gL (BKRF2) and gB (BALF4). In addition, the promoters
for BBLF4 and BBLF2/BBLF3 have been validated as being targets
for Zta that are completely dependent on methylation for Zta
activation [3]. Our discovery that one in five EBV promoters contain
CpG ZREs but have no methylation independent ZREs strongly
supports the hypothesis that the unmethylated status of the EBV
genome guards against the expression of the full range of lytic genes
and therefore lytic replication during the establishment of latency.
Zta is the prototypic member of a family of transcription factors
that interact with DNA in a methylation-dependent manner. C/
EBP alpha has recently been shown to share the same
characteristics [36]. It has been suggested that the interaction
between C/EBP alpha and methylated sequence elements are
needed to activate tissue specific genes during differentiation [36].
The biphasic methylation cycle is observed for several different
classes of viruses that establish latency [4]. Yet even KSHV, which
is closely related to EBV, does not contain a functional Zta
homologue. The question arises as to how the methylated genomes
of these viruses can be reactivated. We suggest that the recent
discovery that a cellular transcription factor also has methylation
dependent DNA binding properties [36] implies that other viruses
may rely on host methylation dependent transcription factors to
differentially control the expression of their genomes during the
establishment of latency or replication.
Methods
Computational prediction of ZREs core sequences bound
by Zta
The starting point for the computational approach was the Zta
transcription factor entry T00923 in Transfac 8.3 that includes 6
experimentally verified ZRE binding sites [32,33]. The Promo
algorithm [37,38] generated a position weight matrix (PWM)
Figure 2. Position Frequency Matrix (PFM) of CpG containing
ZREs (PFMCpG5). A. The core seven nucleotide element of the CpG
containing ZREs found within the BRLF1, BRRF1, and BMRF1 (Rp, Nap and
BMRF1p) promoters are shown. B. The number of incidences of each
nucleotide at each position and the thus the frequency were calculated.
C. The consensus sequence is represented as a sequence LOGO.
doi:10.1371/journal.pone.0025922.g002
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based on the T00923 transcription factor entry, and we used it to
search 3 well-characterized Zta-responsive promoters from the
EBV genome (BZLF1 promoter (Zp) 500 bp upstream of the
published transcription start sites were included. A positive match
was taken as one with an 85% similarity rate.
DNA binding assays
Electrophoretic mobility shift assays (EMSA) were undertaken
using Zta protein generated in a wheat germ in vitro translation
system (Promega) and [32P]-radio labeled double strand oligonu-
cleotides, as described previously [39].
Figure 3. Zta recognition and methylation dependence of PFMCpG5 predicted CpG containing ZREs. A. Flow diagram illustrating the
information flow from the PFM to the predictions of novel ZREs in the EBV genome and their subsequent evaluation. B. Core heptamer sequences, in
both forward and reverse complement, of PFMCpG5 predicted CpG containing ZREs within the EBV genome. C. PFMCpG5 was used to predict the
potential for further ZREs in the EBV genome. Double strand oligonucleotides were generated. Following radio labeling, these were subject to in vitro
methylation with SssI methyl transferase (+), or a mock reaction (2). Subsequently, they were incubated with in vitro translated Zta and subject to
EMSA. The reactions contained control lysate, C; or Zta, Z.
doi:10.1371/journal.pone.0025922.g003
Methylation-Dependent Protein Transcription Factor
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Where indicated in the figure, the central CpG motif was
methylated on both cytosine residues during synthesis (Sigma) or
methylated probes were synthesized or methylated in vitro using the
CpG methyltransferase M.sssI (NEB) [23].
Zta protein (B95-8 strain) was in vitro translated using
wheatgerm extract (Promega).
Zp (296): TAAATTTAGGTGTGTCTATGAGGTA-
CA
Zp (2365): ACAGATGGACCTGAGCCACCCGCC
Zp (2662): CCTCTTTGGCTGACACACCTCTC-
GCCC
Rp (2204) & RpZRE2: CATCTTGTCCTGTGA-
TAAAATCGCTCATAAGCTTAGT
Rp (2439 & 2447): ATGACTCGGGTGTGTC-
CTTGTGTGAGGTCTCACCTG
Rp (2114): CACTCATACTTAAGCGATGCT-
GATGCA
BMRF1p (2173): TGGGGGGTGGTGTGCCATA-
CAAGGGAGC
BMRF1p (2248): CCTTGGTGGATGTGCGAGC-
CATAAAGCA
CpG5 A : AAGCGATGGCCGAGCGAT -
GACTCGTGT
CpG5 B: TCCAGATGACTGAGCGCACGGCCT-
CAA
CpG5C: AAAGATCTGGTTGGCGATCCGGTACAC
CpG5 D: TTGGAAAACATTAGCGACATT-
TACCTG
Table 1. List of core ZREs included within ZRE32.
ZRE Core Sequence Class Names
Forward Reverse
TGAGCCA TGGCTCA I Zp ZREIIIA
TGAGCCA TGGCTCA I Rp ZRE1
TGAGCCA TGGCTCA I Zp (2365)
TTAGCAA TTGCTAA I Zp ZREIIIB
TGTGTAA TTACACA I DSL ZRE1
TGAGCAA TTGCTCA I DSL ZRE2
TGAGCAA TTGCTCA I DSL ZRE7
TGAGCAA TTGCTCA I BMRF1ZRE(244)
TGAGCAA TTGCTCA I BMRF1ZRE(2107)
TGTGTCA TGACACA I DSL ZRE3
TGTGTCA TGACACA I DSL ZRE4
TGTGTCA TGACACA I DSL ZRE6
TGTGTCA TGACACA I DHRS9 ZRE1
TGTGCAA TTGCACA I DSL ZRE5
TGTGCAA TTGCACA I CIITA (221)
TGAGTCA TGACTCA I BSLF2+BMLF1
TGAGTCA TGACTCA I BMRF1 AP-1
TGAGTCA TGACTCA I IL8 AP1
TGAGTCA TGACTCA I DHRS9 (ZRE2)
TGACTAA TTAGTCA I Fp AP-1-Like Site
TGTGTCT AGACACA I Zp (296)
TGGCACA TGTGCCA I BMRF1 (2173)
TGAGTAA TTACTCA I CIITA
TGAGTAA TTACTCA I IL13
GTTGCAA TTGCAAC I IL-8 ZRE
GGAGCGA TCGCTCC III Egr1
TGAGCGA TCGCTCA II Rp ZRE2
TTCGCGA TCGCGAA III Rp ZRE3
TGTGCGA TCGCACA III BMRF1 (2248)
TGAGCGT ACGCTCA III Nap ZRE2
CGGGCGA TCGCCCG III Nap ZRE1
CGAGCGA TCGCTCG III CpG5 A
TGAGCGC GCGCTCA II CpG5 B
TTGGCGA TCGCCAA III CpG5 C
TTAGCGA TCGCTAA III CpG5 D
TGTGCGT ACGCACA III CpG5 E
TTTGCGA TCGCAAA III CpG5 F
TCAGCGA TCGCTGA III CpG5 G
CGTGCGA TCGCACG III CpG5 I
TGCGCGA TCGCGCA III CpG5 J
CGCGCGA TCGCGCG III CpG5 K
AGAGCGA TCGCTCT III CpG5 L
TGGGCGA TCGCCCA III CpG5 M
TAAGCGA TCGCTTA III CpG5 O
TGAGCGG CCGCTCA III CpG5 P
doi:10.1371/journal.pone.0025922.t001
Figure 4. Information flow for the identification of ZREs in the
EBV genome. Flow diagram illustrating the use of the pattern
matching tool (ZRE32) to identify exact sequence matches for the 32
verified ZREs in the EBV genome.
doi:10.1371/journal.pone.0025922.g004
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Table 2. EBV genes that contain CpG ZREs but have no methylation independent ZREs in their regulatory regions, with the
kinetics and extent of any change in their expression in Akata cells undergoing lytic cycle [6].
Cycle Promoter/Gene Class Sequence
Offset From
Gene Start
Peak
expression
time (hr)
fold change
expression
early lytic BALF1 II TCGCTCA 274 12 8.2
II TCGCTCA 2138
III TCGCCCA 2383
III ACGCTCA 2416
late lytic BALF4 III TCGCGCA 2164 24 15.2
III TCGCTCG 2254
III ACGCACA 2414
unknown BARF0 III CGAGCGA 45 36 7.3
III TGCGCGA 245
early lytic BARF1.2 II TGAGCGA 114 24 9.2
II TGAGCGA 50
III TGGGCGA 2488
early lytic BBLF2/BBLF3 III TCGCCCA 91 12 19.5
early lytic BBLF4 III TCGCTCG 2221 12 7.9
III TCGCACA 2235
III ACGCTCA 2357
late lytic BBRF1 III AGAGCGA 231 24 7
III TTCGCGA 2414
late lytic BBRF3 III TGGGCGA 234 24 20.5
III TTTGCGA 2177
late lytic BDLF1 III TCGCCCG 2390 24 21.5
late lytic BGLF2 II TCGCTCA 133 24 14.3
early lytic BGLF4 II GCGCTCA 2260 8 12.1
III TCGCTTA 2316
late lytic BGRF1/BDRF1 III CGGGCGA 249 24 8.3
late lytic BKRF2 II TGAGCGC 155 24 14.1
III TTAGCGA 185
early lytic BKRF4 III TTAGCGA 270 24 16.3
III TGAGCGG 2246
III CGTGCGA 2302
early lytic BLLF2 III CCGCTCA 218 24 12.4
BOLF1 III TCGCCCG 175 24 4.2
III TCGCTGA 265
late lytic BORF1 III CGGGCGA 130 24 12.4
III TGCGCGA 10
III TGAGCGG 220
early lytic BRRF1 III CGGGCGA 225 24 7
III TGAGCGT 253
late lytic BTRF1 III TGGGCGA 2292 24 8.5
unknown BWRF1 repeats III CGGGCGA 72 , ,
III CGGGCGA 46
III GGAGCGA 2422
latent Cp EBNAs III TGGGCGA 270 24–48 6–8.2
III TTTGCGA 2204
III GGAGCGA 2248
latent Wp EBNAs III TCAGCGA 180 48 6.1
doi:10.1371/journal.pone.0025922.t002
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Figure 5. ZREs in the EBV genome. The entire EBV genome was subjected to an exact pattern match search, using the ZRE32 set of core
sequences. Each site was classed by binding behaviour, and plotted by the first nucleotide of the site to form a genome wide map of ZREs. Class I
sites are indicated by blue diamonds, Class II sites are indicated by red stars, Class III sites are indicated by green triangles, and gene starts and
direction are indicated by arrows. The location of transcription start sites and their orientation are indicated by arrows.
doi:10.1371/journal.pone.0025922.g005
Figure 6. Chromatin precipitation (ChIP) analysis of Zta. Akata cells were induced or not to enter lytic cycle by the addition if anti-IgG as
indicated. 48 hours later the cross-linking agent was added and chromatin and total proteins were harvested. A. The proteins were subject to western
blot analysis for Zta expression. B. A chromatin precipitation experiment was undertaken with the Zta antibody and a control antibody. The
precipitated chromatin and input chromatin were subject to western blot analysis to detect Zta protein. C. The location of ZREs and Q-PCR amplicons
are illustrated for a region central to OriLyt left and for a region flanking OriLyt left. The genome co-ordinates are indicated. Transcription start sites
and the direction of transcription are shown by arrows. Blue diamonds represents the class I ZREs. The amplicons used for Q-PCR are indicated as
black horizontal bars. D. Association of Zta with OriLyt left was assessed using chromatin precipitation from Akata cells in lytic cycle, followed by
Q-PCR. The binding is shown relative to maximal binding to Orilyt left.
doi:10.1371/journal.pone.0025922.g006
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Figure 7. Chromatin precipitation (ChIP) analysis of Zta binding with the EBV genome. A. Five regions of the EBV genome are illustrated,
together with gene names and sequence co-ordinates. Three contain core CpG ZREs and two do not. Transcription start sites and the direction of
transcription are indicated with arrows. Green triangles represent class III CpG ZREs and the red star represents a class II ZRE. The amplicons used for
Q-PCR are indicated as black horizontal bars. F. Association of Zta with the indicated regions of the EBV genome was assessed using chromatin
precipitation from Akata cells in early lytic cycle (stalled prior to DNA replication with acyclovir), followed by Q-PCR. The binding is shown relative to
maximal binding to OriLyt left (OL5).
doi:10.1371/journal.pone.0025922.g007
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CpG5 E: TTTGGCGTCATGTGCGTCTGGAT-
GACA
CpG5 F: CAGACTCTGGTTTGCGAGGCTGG-
GCGG
CpG5 G: GCCGCCGCACTCAGCGAGGAG-
GCCTGC
CpG5 H: CGAGGAGGCCTGCGCGTGTTCCT-
CAAC
CpG5 I: CCAATGTCTGCGTGCGAGCCGGG-
CTTG
CpG5 J: CTTTGCGCTCTGCGCGAGGAC-
GAGCTC
CpG5 K: GCAGGGCCCCCGCGCGATCTAGG-
TAGG
CpG5 L: CTCATAGGTCAGAGCGACATA-
GAGGCG
CpG5 M: TTTCAAGTCGTGGGCGAATTAACT-
GAG
CpG5 N: AGCAAGGTGCTGGGCGTGGACC-
GCGCG
CpG5 O: CACTCATACTTAAGCGATGCT-
GATGCA
CpG5 P: GTCATGTAGGTGAGCGGGCAGT-
CCTTG
Chromatin Immunoprecipitation
Chromatin was prepared from Akata cells [35], following
induction with anti IgG, in the presence of 100 mM acyclovir
essentially as described in [40], except that a mixture of Protein
A and protein G were used to capture antibodies. Precipitation
was undertaken using an amino-terminal Zta antibody from
Santa Cruz.
Primers: absolute genomic position and sequence
OL5 F 41195-41216 CAGCTGACCGATGC-
TCGCCA
OL5 R 41342-41323 ATGGTGAGGCAGG-
CAAGGCG
BKRF4 F 98591-98611 CATTGCTCTCT-
GAGCGGTTA
BKRF4 R 98688-98667 ACCAGATGCTTCTTG-
GAGTTG
BGLF4 F 111611-111631 ACCGAGGCTCT-
TAGTTGCTG
BGLF4 R 111686-111666 GTTGCGGACATGGT-
GACTTA
BTRF1 F 126981-127000 AGCTACGCAATCG-
GAGTCA
BTRF1 R 127052-127034 GGAGGCGCAGTCTAG-
CAG
Region with no ZREs
OR1 F 139875-139895 CCGCATGTCCAACCAC-
CACG
OR1 R 139997-139976 ATGCTACCTAGGCCTG-
CGTCC
OL1 F 38229-38249 GCGCAACAGTGCCAC-
CAACC
OL1 R 38302-38282 CAGGACCTGGCGGTAGTG-
CAG
MID-BORF1 F 60768 -60788 TGCCTGA-
GACCTCTCGGACGG
MID-BORF1 R 60817-60792 CCACGACG-
CAGTCCTTAGGATCATG
Generation and application of ZRE PFMs
A position frequency matrix (PFMCpG5) was created using 5
CpG containing ZRE core binding sequences (Figure 3) and
used to search (a) the 3 EBV promoters using the algorithm
Matscan [41], and (b) the complete Human herpesvirus 4
(Epstein-Barr virus) Genome NC_007605 extracted from
GenBank [42]. An 85% similarity score was used to define a
positive match to the PFMCpG5. PFMs for non-CpG ZREs and
CpG ZREs were generated in a similar manner and displayed
using WEBLOGO [43].
Exact pattern matching was employed to search for each of the
32 core ZRE sequences within the EBV genome. A rolling
window of seven nucleotides was used and an exact comparison
of each of the core ZREs sequences, was made. In addition, the
reverse complement of the sequence was checked in the same
manner.
A MySQL database of the locations of the exact matches
within the EBV genome was generated and simple analyses
can be conducted using a web interface which is publically
available at URL: http://bioinf.biochem.sussex.ac.uk/EBV/.
The database uses gene annotations extracted from the
RefSeq NC_007605 entry and data from the exact match
predictions.
Figure 8. Sequence Logos CpG and non-CpG ZREs. The
sequences comprising ZRE32, were divided into those sites which do
not contain a CpG motif, class I ZREs and those that do, class II and class
III ZREs. A. A PFM was created from (PFMnon-CpG ZREs) and is displayed
using relative letter height. B. A PFM was created from (PFMCpG ZREs)
and is displayed using relative letter height.
doi:10.1371/journal.pone.0025922.g008
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Supporting Information
Table S1 The sequences of published ZREs used in this study
are shown, together with their names and references. CpG motifs
are shown in bold.
(DOCX)
Table S2 ZREs predicted using PROMO, together with the
results of their evaluation by DNA binding assays (EMSA) are
shown. CpG motifs are shown in bold.
(DOCX)
Table S3 All ZREs in the EBV genome are shown with the
position of the central nucleotide using RefSeq NC_007605.
(DOCX)
Table S4 The number of ZREs close to each EBV promoter
(between 21000 and +200 from the annotated gene start) are
shown using RefSeq NC_007605.
(DOCX)
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